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Amyotrophic Lateral Sclerosis is a globally occurring neurodegenerative disease with 
serious implications for the patient’s life as well as imposing a heavy economic burden 
both on the affected individuals and society. Due to higher exposure to risk factors and 
an increasing lifespan, total costs of Amyotrophic Lateral Sclerosis are expected to rise 
drastically in the near future. Since there are no causal treatments known and currently 
available medications only alleviate symptoms, more research in interdisciplinary fields 
of science is necessary. 
This thesis focuses on the familiar type of Amyotrophic Lateral Sclerosis, more 
specifically the disease-induced aggregation of the well-studied protein Superoxide 
Dismutase 1, whose mutations account for 10-20 % of all ALS incidents in familiar 
Amyotrophic Lateral Sclerosis. Dissociation of SOD1 into aggregation prone 
monomers is currently viewed as one of the most important triggers for neuronal death. 
It is envisaged to stabilize the homodimer structure of the protein with a small molecule 
through an affinity-based approach in order to prevent aggregation and to restore the 
catalytic activity of pathological mutants. Using in silico design, several lead structures 
are elaborated as potential lead structures for protein-ligand binding. Upon rational 
variation of these structures, a small molecular library is synthesized to verify the 
computational results with biophysical techniques. After expression and purification of 
the protein, methods such as Isothermal Titration Calorimetry, Fluorescence 
Anisotropy, Microscale Thermophoresis as well as X-Ray Diffraction of protein-ligand-
complex crystals are employed to obtain information about the biophysical properties 
of the synthesized ligands. It is demonstrated that some of the aforementioned small 
molecules show affinity-based binding to the protein of interest. Facile synthetic 
pathways to these molecules and strategies for their variation are outlined. 
The significance of this work is that it expounds a rational approach for the 
development of novel, structurally diverse small molecules that exhibit the ability to 






2.1 Amyotrophic Lateral Sclerosis  
2.1.1 Epidemiology and clinical picture 
Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease (MND) or 
Lou Gehrig`s disease is a fatal neurodegenerative disease that affects motor neurons 
in the spinal cord, the brain, and the motor cortex.[1] It was first described in the 19th 
century by CHARCOT, a French neurologist.[2] The annual incidence of ALS is 1 to 3 per 
100.000 whereas the annual prevalence amounts to 3 to 8 per 100.000, implying that 
ALS is a rare neurodegenerative disease with a late onset (56 to 58 years).[3,4] It is 
estimated that around 150.000 patients suffer from this disease, which makes ALS the 
third most common neurodegenerative disease. The gender ratio is approximately 
1.5:1 in favor of men.[5,6]  
ALS has a very complex clinical picture, especially in the early stages of the disease, 
since muscle degeneration is one of the first symptoms that can manifest itself in a 
variety of consequences. If the first motor neuron is affected, spastic atrophies such 
as gait disorder, decreased dexterity or swallowing problems can be observed.[7][8] 
Damage to the second motor neuron typically leads to muscle atrophy, cramps and 
ultimately to paralysis of arms and legs. When these symptoms start in the arms and/or 
legs, it is referred to as the “limb onset” that makes up for approx. 58-80% of all ALS 
cases. Speech and swallowing difficulties as the primary symptom are labeled as 
“bulbar onset”, which adds up to approx. 28% of all cases. The bulbar onset is 
connected to shorter median survival rates than the limb-onset.[4,6,9,10] Eventually, both 
of these pathways lead to serious impairments of patients due to them being unable to 
walk, stand or perform the most basic handwork. Weakening of the respiratory muscles 
leads to pneumonia, which is the prevailing reason for death of the affected persons. 
The median survival time is around 3 to 5 years from diagnosis, although a special 
form of ALS exists, the so-called chronically juvenile form that has a much longer 
survival time.[11] Due to the symptoms being very generic and non-specific, the 






2.1.2 Pathophysiology of ALS 
 
ALS can be divided into two major groups, sporadic ALS (sALS) and familial ALS 
(fALS) (Figure 2.1.2-1).[11–13] These two cases cannot be distinguished by molecular 
genetic techniques since their clinical picture is very similar. The exact cause for ALS 
is not known as of today, but it is generally accepted that genetic and environmental 
factors play a huge role in the course of the disease, no matter whether sALS or fALS 
is present.[7] It is worth noting that genetic factors are much better understood than 
environmental factors, the consequence being that fALS can be described much more 
precisely than sALS.  
Environmental factors that are being discussed controversially are smoking, exposure 
to air pollution, head injury, physical activity and sports as well as chronical exposure 
to certain substances such as lead, other heavy metals, or pesticides.[14] The list is not 
exhaustive, though specific personal characteristics might be as relevant as the known 
environmental factors. In case of fALS, the autosomal dominant pathway of inheritance 
mainly consists of mutations in the following genes: tardbp (5%), c9orf72(40%), vapb 
(3%), fus (5%), and sod1 (20%). A large contribution is attributed to unknown gene 
factors that could not be identified yet.[13]  
The sporadic form of ALS is significantly less explored in terms of genetic factors. Only 
11% of all cases can be attributed to known genes, the majority of them are also linked 
to fALS. The vast majority of sALS-affected genes are unknown and their investigation 
will provide much needed knowledge towards potential treatment of ALS.[13,15] 
 
Figure 2.1.2-1. Etiology of ALS and the most common genetic factors for fALS (A) and sALS (B).[13] 




The interactions between symptoms, clinical pictures, gene mutations and their 
subsequent harmful effects on eukaryotic cells form a complex picture that is not fully 
understood so far. An overview of the mentioned mutations and their consequences is 
shown in Figure 2.1.2-2.[15] 
The discussed mutations lead, amongst other things, to a pathological accumulation 
of misfolded proteins such as TDP-43, FUS or SOD1.[16–18] The protein degradation 
pathways are often malfunctional, leading to problems in proteostasis for a number of 
affected proteins.[19] Protein clearance mechanisms are commonly compromised as 
well. Furthermore, transport between the nucleus and cytoplasm of eukaryotic cells 
can be affected, mainly caused by mutations in c9orf72 and gle1 genes.[20,21] Mutations 
might also impair vesicle transport and axonal transport via disturbance of the 
cytoskeletal structure of the cell and its surrounding compartments, including 
oligodendrocytes. These mutations occur in a plethora of different genes; however, 
they are very rare and only make up for a small amount of ALS incidences. Interference 
with RNA and DNA homeostasis can occur via RNA-binding mutants, vitiation of repair 
mechanisms (especially for DNA) and altering of RNA metabolism. Moreover, 
transcription and translation processes can be disturbed. These changes in RNA/DNA 
behavior can be subsumed into one of the major factors of the ALS-related 
pathophysiological mechanism.[22] 
There are also mutations in the ubqln2-gene, attributed to the X-chromosomal 
inheritance that affect the degradation of ubiquitinated proteins leading to aggregates 
and neuronal damage.[23] Furthermore, increased oxidative stress due to mitochondrial 
dysfunctions seems to play a role in fALS as well as sALS.[24] A genetic factor that 
might be pertinent for both forms of ALS is the regulation of the glutamate homeostasis, 
which is dependent on a large number of genes, neurotransmitters and proteins.[25] A 
reduced capacity of the glutamate transporter EAAT2 leads to an altered glutamate 
concentration on the NMDA receptors (N-Methyl-D-Aspartate) and AMPA receptors 
(Amino-3-hydroxy-5-methyl-4-isoxazolpropionic acid), resulting in excitotoxicity, 
overstimulation and ultimately in an efflux of calcium ions into the neuron, which is a 
risk factor for oxidative stress. The corresponding gene mutations can be found in ALS 
patients, though not everyone is affected by them.[12,26] Mutations in SOD1 can also 
contribute to mitochondrial dysfunction; it is believed that these effects stem from 




affecting microglia, astrocytes, lymphocytes and macrophages has also been linked to 
ALS and various putative drugs are tested in clinical trials all over the world (Phase I 
to III).[28] 
 
Figure 2.1.2-2. Overview of the most abundant gene mutations in ALS, their pathology and the overall 





2.1.3 Treatment of ALS – state of the art 
As of 2021, ALS cannot be cured and complementary treatments need to be used, 
which can be divided into two groups: medicinal and non-drug therapies.  
Medicinal therapies 
There are only two approved drugs available to treat symptoms of ALS: The glutamate-
dependant sodium channel blocking-agent Riluzole, which was approved in 1995 as 
the first drug against ALS, and the antioxidant radical scavenger Edaravone, which 
was approved in the US and Japan in 2017.[29][30] 
 
Figure 2.1.3-1. Structures of Riluzole and Edaravone. 
Both of these have in common that they do not stop the progress of ALS but have the 
potential to slow it down significantly. Riluzole does that by blocking TTX-sensitive 
sodium channels, which can be associated with damage done to neurons while also 
increasing glutamate uptake, accelerating glutamate clearance from the synapse, as 
well as preventing presynaptic glutamate release.[31] Whether the sodium channel 
blocking capacity or the intervention in the glutamate homeostasis is the prevailing 
factor for the retardation of ALS is currently under investigation. The mechanism by 
which Edaravone is active in ALS patients is unknown. Edaravone is known for its 
antioxidant potential and could possibly reduce oxidative stress in ALS patients, which 
is a known factor for neuronal death. Phase III clinical trials failed in Europe while being 
successful in Japan, this might be due to genetic variations between European and 
Asian population. 
Recently a combination of two different drugs called AMX0035, consisting of sodium 
phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA) was screened in a Phase 
II clinical trial with promising results.[32] PB is a chemical chaperone, which 
accumulates misfolded or aggregated proteins, resulting in reduced neuronal stress. 
Furthermore, it is able to inhibit the histone deacetylase, resulting in an epigenetical 




death. TUDCA on the other hand is an antioxidant with neuroprotective properties that 
inhibits mitochondria apoptosis, decreases the amount of ROS and prevents neuronal 
death caused by oxidative stress.[34] It is also well known from traditional Chinese 
medicine and therefore considered a safe substance with limited side effects. 
Masitinib, an inhibitor of the tyrosine-kinase, is screened in a Phase III clinical trial for 
the treatment of ALS since 2020 after a failed Phase III clinical trial in 2017.[35] 
More than 50 different substances have been proposed as a putative drug for the 
treatment of ALS since 1995. However, no substance was able to provide a cure for 
this disease, which reemphasizes its complexity and heterogeneity in symptoms, 
pathophysiology, and genetics. 
Another approach that is discussed in the literature is a targeted gene therapy, which 
is being tested in clinical trials. The general concept of curing a neurodegenerative 
disease by means of a gene therapy was proven by the use of Zolgensma®, a viral 
vector-mediated drug against Spinal Muscular Atrophy (SMA).[36] 
Apart from the drugs already discussed, substances to relieve the typical symptoms of 
ALS are also commonly used for the treatment of patients. Muscle relaxants from the 
benzodiazepine group (diazepam, clonazepam and others) or anticonvulsants such as 
gabapentin see frequent use. Swallowing problems that are one of the earliest 
symptoms of ALS can lead to pooling of saliva, which requires tricyclic antidepressiva 




Another essential part of ALS treatment are the non-drug therapies that need to be 
started immediately after onset of the disease. Amongst them are physiotherapy, 
occupational therapies, changes in lifestyle, speech and breathing therapies and the 
usage of machines such as ventilators, wheelchairs, bracers or feeding tubes.  
The result of these drastic courses of action that need to be taken is a heavy financial 
burden that is implied on the individual patient as well as on the society as a whole. 
ALS is considered one of the most cost intensive neurological diseases, even 




Numbers for Germany were collected in a study from 2020, which implies that up to 
520.000.000 € need to be expended to fulfill the needs of ALS patients yearly.[37] Since 
the most important risk factor for ALS is the age of an individual, numbers are expected 
to rise dramatically within the near future. This means that new medications and better 
methods for non-drug therapies are necessary. 
 
2.2 Superoxide Dismutase 1 (SOD1) 
 
Mutations in the gene that encodes for the protein Superoxide Dismutase 1 have been 
found in around 20% of all fALS cases as was discussed already.[6] Since this is the 
protein of interest in this work, the different forms of humans SOD1 will be explained 
and its structure, its mutants, and importance for ALS will be depicted in this 
subchapter. 
SOD1 is an ubiquitously expressed protein of many organisms that metabolizes 
oxygen and catalyzes the disproportionation of superoxide radicals into oxygen and 
hydrogen peroxide according to the following equation: 
 
Superoxide radicals belong to the group of reactive oxygen species (ROS) and are 
often very harmful to cells; hence, the importance of SOD1 for the reduction of 
oxidative stress is highlighted.  
Three different forms of SOD exist in humans: The mitochondrial manganese-based 
SOD (Mn-SOD), the extracellular SOD (EC-SOD) and the copper/zinc-containing SOD 
(Cu/Zn-SOD), which is located in the cytosol (this specific protein is also called 
SOD1).[38][39] This protein was discovered in 1968 by McCord and Fridovich; this was 
considered a major breakthrough in the biochemistry of reactive oxygen species and 
oxygen metabolism in eukaryotic cells.[40] Different forms of SOD have since been 






The mechanism of the degradation of superoxide radicals into hydrogen peroxide and 
oxygen is also referred to as a “ping-pong mechanism” and is depicted in Figure 2.2-
1.[41,42] 
 
Figure 2.2-1. Ping-pong mechanism: The reactive center of the protein (the Cu2+ ion) is reduced to Cu+ 
under simultaneous oxidation of the superoxide radical to hydrogen peroxide and reoxidation of the 
copper ion. 
The structure of SOD1 and its most important properties are depicted in Figure 2.2-2. 
 
Figure 2.2-2: Structure of wt hSOD1. Left: metal binding sites in a SOD1 monomer with Cu2+ (grey) and 
Zn2+ (orange). Middle: Ribbon model of the SOD1 dimer. Right: Intra-monomeric disulfide bridge 
between Cys57 and Cys146. PDB-code: 2C9U. Picture taken from Niklas van den Bergh. 
The fully metallized protein has a weight of 32 kDa and consists of two monomers that 
are connected through a large dimer interface that exhibits strong hydrophobic 
interactions. Each monomer consists of a beta-barrel structure with two metal binding 
sites. The Zn2+ ion plays a major role for the structural integrity of the monomer and is 
coordinated by three histidine and one asparagine residue, whereas the Cu2+ ion is 
coordinated by four histidine residues and is responsible for the catalytic activity of the 




intramolecular disulfide bridge between Cys57 and Cys146 stabilizes the beta-sheet 
structure.[44] Due to these structural properties, SOD1 is one of the most stable proteins 
known in the literature with a melting temperature of 85 – 95 °C and a dissociation 
constant of Kd = 10 nM.[45][46] The region between AA 122 and 143 is called the 
electrostatic loop, contributing to the active center of the protein. The zinc-binding 
region between AA 49 and 84 is called the zinc-loop and enhances the catalytic activity 
through a small canal that leads to the active center of the protein. The transit of 
negatively charged molecules is favored while preventing larger structures to interfere. 
The result is a very large enzymatic activity of around 109 M-1s-1 and the kinetics can 
be described as diffusion-controlled. [47] 
More than 200 mutations – largely missense mutations, stop-codon and depletion 
mutations – are known for SOD1.[48] The most common mutations for SOD1 are A4V, 
I113T and G93A.[49] It is unclear whether every single mutation leads to ALS or whether 
a combination of mutations is required. Some of these mutations also retain their 
catalytic activity or show only a small decrease in their efficiency. This is why the loss 
of function of SOD1 is not attributed to ALS but more so a toxic gain of function, which 
could also be substantiated by animal trials in 1998.[50][51] This undesirable gain of 
function can be rationalized by looking at the complex post-translational maturation of 
SOD1 that mainly consists of the following steps: N-terminal acetylation, transient 
complex formation with hCCS, chaperone-dependent Zn and Cu insertion, formation 
of the disulfide bridge between Cys57 and Cys146 and following homodimerization. 
Mistakes at any of these steps can either lead to misfolded SOD1 or promote the 
dissociation of the stable dimer into aggregation-prone monomers.[52][53]  
Figure 2.2-3 presents an overview about the most common ALS-related mutations of 
SOD1 and the affected regions of the protein.[49] It is noteworthy that mutations can 
occur in every domain of the protein, i.e. on the dimer interface, the electrostatic loop, 
the zinc loop or in the beta-barrel structure. No correlation between the affected region 
and the consequences of different mutations can be observed, but the two most 
common mutations A4V and I133T are both located at the region of the dimer interface. 
The median onset of both mutations is comparable but the survival rate of I113T is 
more than three times higher than the survival rate of A4V. This means that A4V is one 
of the most deadly mutations of SOD1. Weakening of the dimer interface in the region 




dissociation of the homodimer into aggregation prone monomers due to weakening of 
attractive van-der-Waals interactions. Other mutations such as H46R or G37R have a 
significantly lower onset age but result in a drastically elevated survival time of around 
17 years. Some mutations also occur in the sALS type, e.g. I113T. Most of the known 
mutations decrease the structural integrity of the protein, leading to, amongst other 
things, undesired changes in conformation. This is especially true for mutations near 
the metal binding sites such as H46R or G85R, where changes in the beta-barrel 
structure can be observed without altering the catalytic activity of the protein.[54] 
 
 










The commonly discussed aggregation pathways are depicted in Figure 2.2-4.  
 
Figure 2.2-4. Aggregation pathways of SOD1. Left: Point mutations or a change in pH can lead to a 
smaller dimer interface with weaker hydrophobic interactions, leading to the dissociation of the dimer. 
Middle: Loss of metal ions due to weaker binding of the mutants through changes in complex geometry 
are believed to destabilize the quaternary structure. The resulting apo enzyme is prone to aggregation. 
Right: Reduction of the intra-monomeric disulfide bridge or mistakes in the maturation process of SOD1 
are attributed with loss of stability of the dimer. 
As was already described, aggregates seem to have a major impact in SOD1-related 
ALS. These soluble aggregates tend to form larger, insoluble amorphous (observed in 
fALS) or fibrilic structures that can interfere with a plethora of different components of 
the cell.[55–57] These structures are similar to amyloid aggregates observed in other 
neurodegenerative diseases such as Alzheimer’s disease or frontotemporal dementia. 
Point mutations are generally believed to have an influence on the overall stability of a 
protein; therefore, they might be causing the formation of aggregates. A second 
discussed pathway is the lack of zinc and copper ions, resulting in a much less stable 
apo enzyme that is prone to aggregation.[58–60] Many causes exist for the loss of metals 
such as faulty homeostasis, malfunction of chaperones or mutations in the respective 
metal binding sites. A third origin discussed for the aggregation of SOD1 is the 
reduction of the intramolecular disulfide bridge that results in a flexible zinc loop, 
significantly weakening the beta-barrel structure.[61] In turn, a larger part of the protein 
is exposed to solvents and ROS, furnishing the aggregation of mutant SOD1. Effects 





2.3 Therapeutic approaches for SOD1 related ALS  
 
As previously depicted, one of the key factors in fALS is the dissociation of the SOD1-
dimer into aggregation prone monomers that ultimately build up prion like 
structures.[56,63,64] These aggregates have the potential to interfere with a plethora of 
different processes in the cell, which can lead to apoptosis, disturbance of homeostasis 
or other gain of toxic functions. A selection of possible harmful influences is shown in 
Figure 2.3-1. 
 
Figure 2.3-1. Harmful effects of SOD1-related aggregates in the cell.[65][66][67] 
The regulation of metal levels is a critical factor in protein maturation, folding and for 
its activity. Therefore, mutations that interfere with these processes are commonly 
found in ALS (e.g. G93A) and can be partially counteracted by increased metal intake. 
This is especially true for copper ions, since several mutants show a significantly 
decreased potential to interact with the SOD1-dependant human copper chaperone 
hCCS, leading to a decreased copper level and lower activity. Recent studies and 
clinical trials found a beneficial effect of metallated ATSM (CuATSM) for mutations that 
do not interfere in the metal-binding regions (e.g. G93A or G37R).[68] Positive effects 
on the disease onset and progression were confirmed in mice and led to an increase 
in the survival rate of about 18 months compared to the placebo group.[69,70] The 
molecular mechanisms are unclear; it is assumed that CuATSM increases metalation 




BIANCI et al. used cisplatin, a common anti-cancer drug, as a tool to prevent 
aggregation and to redissolve SOD1 oligomers and aggregates. Crystal structures 
indicated that each Cys111 residue shows a high binding affinity to a cisplatin molecule, 
therefore preventing intermolecular disulfide bridges. It is noteworthy that binding of 
cisplatin at the dimer interface does not hamper the activity of the metalated protein. 
These findings could be validated by thermal shift assays, which showed a significant 
increase in the melting temperature of the protein.[71] However, it was observed that 
cisplatin and other drug-like molecules that target Cys111 covalently inhibit the 
maturation process by preventing interactions between SOD1 and its natural 
chaperone.[72] 
In 2004, LANSBURY et. al. reported that an intersubunit disulfide bridge between two 
non-natural Cys148 residues in each monomer was able to stabilize the monomer 
towards inhibition of dissociation (Figure 2.3-2). In order to realize this approach a 
valine moiety needed to be exchanged for a cysteine in both monomers by means of 
mutagenesis. The final protein was much more stable compared to wt hSOD1 in vitro 
as was shown by thermal shift studies.[63] 
 
Figure 2.3-2. Ribbon style visualization of wt hSOD1 with the introduced disulfide bridge. Ala4 is shown 
in space-filling mode and the red dot marks the original position of the AA that was mutagenized. 
Reprinted with permission from [63] © 2004 Am. Chem. Soc. 
One year later, the same group discovered a new potential target area on the protein 
for binding to small molecules and over one million structures were tested for their 
suitability in silico. 20 different structures were identified to stabilize the protein when 
exposed to aggregation inducing conditions (Figure 2.3-3). The binding cavity was 




potential to form hydrogen bonds with the surrounding AAs.[73] This was one of the first 
approaches that made use of the binding affinity of a small molecule to a specific area 
of the protein. Mutagenesis of the surrounding AAs confirmed the importance of Val7 
and Val148 in that those mutants did not benefit from the identified structures in terms 
of aggregation. Furthermore, it was deducted that the identified ligands needed to 
comprise of at least one aromatic moiety to bind to the protein in an affinity-based 
manner. Later the same group expanded their in silico studies to over 2 million 
substrates and presented an improved compound list. These molecules had higher 
binding affinities and showed an affinity for SOD1 in human blood plasma.[74] 
 
Figure 2.3-3. Left: Superposition of the backbone of three mutants (S134N, H46R, A4V), wt and apo-
wt in the region of Val148 and the best 20 hits from in silico screening. Right: Overlay of several docked 
structures showing a strong relation between the existences of an aromatic residue that resides deep 
in the cavity and a more variable, solvent exposed substructure.[73] Copyright © The authors, CC BY 
4.0 license. 
Another potential binding site near Trp32 was found by ANTONYUK et al. in 2013 when 
they tried to reproduce the findings of NOWAK et al. Crystal structure analysis revealed 
that several putative ligands (e.g. Uridine-5-monophosphate) did not bind at the 
expected Val148 cavity but instead preferred binding near Trp32.[75,76] Moreover, the 
proposed ligands isoproterenol and 5-fluorouridine were found to be ineffective in 
stabilizing A4V and I113T mutants under aggregation inducing conditions. The authors 
concluded that crystal structure studies were the gold standard in ligand design and 
that in silico studies need to be validated by biophysical assays since their uncertainty 
is rather large. The same binding site was used later by POKRISHEVSKY et al. who 




type. Additionally, the use of the anti-cancer drug 5-fluorouracil proved to be beneficial 
for the reduction of aggregation in said mutant.[77,78] 
AUCLAIR et. al. used a completely covalent approach for the stabilization of SOD1 in 
2009 by employing a maleimide structure, which was supposed to tether the Cys111 
moieties of each monomer together, thus preventing the dissociation (Figure 2.3-4). 
They were able to show that a tethering of such sort was indeed stabilizing the dimer 
and could restore the catalytic activity of the G85R mutant. They concluded that the 
aforementioned cysteine residues were a potential target for therapeutics on a peptide 
basis. Even if a mutation showed unstable monomers, i.e. that no dimer was formed 
at all, they reported that usage of their maleimide-based structure would be able to 
overcome this and would still be able to tether monomers together, forming a functional 
dimer.[79] 
 
Figure 2.3-4. Left: The small molecule DTME/TME and the predicted binding modes between it and the 
Cysteine residues of the protein. Right: Model of TME (resulting from a thiol-exchange reaction between 
the cross-linked DTME and Cys111) binding to both cysteines in each monomer.[79] Copyright © The 
authors. 
In 2018, HASNAIN et. al. introduced the cysteine-reactive molecule Ebselen for the 
maturation of SOD1 and its mutants. The selenium atom is able to form an S-Se bond 
in a disulfide reduced monomer, that is very reminiscent of a traditional disulfide bond, 




formation of a selenol compound that is oxidized back to Ebselen by H2O2 and the 
functional SOD1 monomer, which in turn folds to the functional dimer. The dimer can 
then bind two more Ebselen molecules, which stabilize the dimer against dissociation 
through a selenylsulfide bond and --interactions. The authors showed that Ebselen 
promoted the formation of the disulfide-intact dimer, folding and zinc binding of SOD1 
and its mutants. The mechanism of the Ebselen-promoted maturation of SOD1 is 
shown in Figure 2.3-5.[80] 
 
Figure 2.3-5. Mechanism of the Ebselen-promoted maturation of SOD1. The red part shows that the 
absence of Ebselen can lead aggregation of SOD1 and finally to ALS.[80] Copyright © The authors. CC 
BY 4.0 license 
In 2020, the group of HASNAIN reported variations of the Ebselen core structure to 
increase binding affinity to SOD1 through usage of several different interactions such 
as hydrogen bonds, charge--stacking or -−stacking (Figure 2.3-6, right). Many of 
the chosen ligands increased the melting temperature as could be seen in thermal shift 






Figure 2.3-6. Left: Structure of Ebselen and Ebsulfur. Middle: Binding model of the small molecules and 
SOD1 at the dimer interface. Right: Electron density map of Ebselen bound to SOD1, showing proximal 
water molecules (in red) and a possible --interaction between both covalently bound molecules.[81] 
Copyright © The authors. CC BY 4.0 license. 
 
2.4. Fluorescence Anisotropy 
 
Fluorescence Anisotropy or Fluorescence Polarization is a method used to determine 
binding constants and reaction kinetics. It is based on the change in rotational freedom 
a molecule experiences upon binding to a larger structure like a protein.[82] 
In order to gain information about the binding process, one of the binding partners, 
preferably the smaller molecule, needs to be labeled with a fluorophore or needs to 
exhibit inherent fluorescence. The irradiation of a freely moving fluorophore with 
polarized light leads to the emission of depolarized light; this is because the typical 
fluorescence lifetime is in the range of nanoseconds while the Brownian motion and 
rotation of an unbound molecule is in the picosecond range. This means that any 
polarization of the irradiated light becomes depolarized before it can be re-emitted. 
When the ligand binds to a larger structure like a protein, the rotational freedom is 
hindered, proportional to the binding affinity and binding mode of the ligand to the 
protein. When the ligand-protein complex is then irradiated with polarized light, the 
timespan of rotation and fluorescence lifetime overlaps, which leads to the re-emission 
of polarized light (Figure 2.4-1). Afterwards, the difference between the free, unbound 
state compared to the bound state can be calculated. Titration of the two binding 





Figure 2.4-1. General scheme of a Fluorescence Anisotropy Assay.[83] Copyright © The authors. CC BY 
3.0 license. 
Aside from requiring a fluorophore on one of the molecules, a few things need to be 
taken into consideration. First, the fluorophore emission spectrum must not overlap 
with the spectrum of the fluorescent amino acid tryptophan that is present in many 
proteins. Alternatively, one could use the fluorescence of said residue, but since the 
rotation of a protein is relatively small even in the unbound state, the differences 
between bound and unbound state are typically very small so that the assay becomes 
less accurate. Furthermore, the anisotropy is dependent on temperature and viscosity 
of the solvent, so a careful control of these parameters is essential. Moreover, the 
utilized fluorophore should have a fluorescence lifetime that is short compared to its 
rotational correlation time in order to allow the molecules to stay aligned during 
emission. However, if it becomes too small the changes in anisotropy might become 
too small to precisely detect them.[84] 
The requirement of having an inherent fluorescence was met by LS1 as well as LS3. 
No information about the fluorescence lifetime of the excited states could be obtained, 
since the experiments needed to obtain these (time-correlated single photon counting 
[TCSPC] or cross correlation phase fluorometry) were beyond the scope of this 
thesis.[85,86] This meant that every single result of the fluorescence anisotropy assay 
was to be taken conditionally and additional biophysical assays were absolutely 





2.5 Microscale Thermophoresis (MST) 
 
Microscale Thermophoresis is a fluorescence-based experiment that can be used to 
measure melting temperatures as well as Kd or IC50 – values of protein-ligand 
interactions.[87,88] The general principle can be explained as follows: The observed 
molecule (ligand or protein) changes its physical properties such a size, hydration shell 
or shape upon binding to another molecule.[89] These changes induce effects in 
secondary physical parameters such as the diffusion time, which can be recorded.  
The underlying principle was already established in 1856 by Ludwig and is called 
thermophoresis (thermodiffusion, thermomigration or Ludwig-Soret-effect): Molecules 
or particles in general experience different responses to a temperature gradient 
depending on their physical properties and move along this gradient to constitute a 
new equilibrium.[90] MST combines these two effects by establishing the temperature 
gradient by means of an IR-Laser that is focused to an area of approximately 25 µm 
radius. Upon experiencing this gradient, molecules start to move out of the irradiated 
area in which their velocity depends on the aforementioned properties size, shape, 
charge, and solvation shell. Either the protein or the ligand needs to be labeled with a 
fluorescent dye in order to observe changes in concentration that can be calculated 
from alterations of the fluorescence intensity inside the irradiated area. The new 
equilibrium is reached within seconds since the observed area is rather small and the 
temperature gradient is typically only a few °C.  
In order to measure the Kd-values of a protein-ligand interaction the fluorescently 
labeled protein is used in a set concentration, typically in the nM range, while the 
concentration of the ligand is varied from the mM to nM range. The thermophoresis of 
each measurement is fit into a titration curve from which biophysical parameters can 
be extracted. 





Figure 2.5-1. Top left: Basic construction of the experiment. The infrared laser constructs the 
temperature gradient while the fluorophore is excited by a second light source. Top right: MST trace of 
a single measurement and the different states of the experiment. Bottom left: Three MST traces of three 
individual measurements are plotted together. Bottom right: The MST signal plotted against the ligand 
concentration constitutes a binding curve, which gives information about binding properties.[91] Copyright 
© The authors. CC BY 4.0 license. 
 
Several differences in the fluorescence signals can be recorded during each individual 
experiment:  
1. The initial fluorescence solely depends on the concentration of the labeled 
molecule since there is no irradiation at this point; this is used to normalize the 
obtained values.  
2. When the IR irradiation starts, the temperature gradient is set almost 
immediately because the solvent molecules (most often water) rapidly absorb 
energy of this wavelength. In general, it can be assumed that the higher the 
decay of the fluorescence signal the stronger the protein-ligand interaction. 
3. Thermophoresis occurs, in which the molecules move along the temperature 




equilibrium is reached. The ratio of the initial fluorescence and the fluorescence 
at the equilibrium is typically used as the final value for each individual 
measurement. 
4. The IR irradiation stops, and the molecule diffuses back into the now non-
irradiated area. The fluorescence signal increases again since the concentration 
of the labeled molecules is increased through rediffusion.  
 
2.6 Isothermal Titration Calorimetry (ITC) 
 
Isothermal Titration Calorimetry is one of the biophysical measurements that was used 
in this thesis without the need of a fluorophore. Instead, the underlying physical 
principle is the formation or release of heat that occurs when a ligand is binding to its 
binding partner, in this case to a protein, which can be recorded. Using this data, 
several thermodynamic parameters of said interaction can be calculated.[92] 
An ITC-device consists of two identical cells that are made of inert material such as 
gold, located in an adiabatic shell (see Figure 2.6-1). The reference cell is filled with 
the same solvent that is used for the measurement, most often aqueous buffer, but in 
general, many solvents can be used. The sample cell is filled with the protein of interest 
and known quantities of the ligand are then titrated into the sample cell. Both cells are 
electrically connected in a way that the temperatures are kept consistent. Upon 
addition of ligand, the temperature of the sample cell can either increase or decrease, 
after which the heating device at the sample cell re-establishes the temperature of the 
reference cell. The ITC signal consists of the amount of energy (typically in kJ/mol) 
needed to maintain the temperature equilibrium after each addition of the ligand. These 
signals are then plotted against time, resulting in so-called “spikes”, each synonymous 
to one injection of the ligand solution. Upon integration of these signals with respect to 
time, the binding curve is obtained as the amount of total heat exchanged per injection. 
Analysis of the binding curve provides thermodynamic parameters such as Kd – values, 
affinity (1/Kd), stoichiometry of the reaction and reaction enthalpy H.[93] 
ITC is one of the most sensitive biophysical measurements available and is often only 




to the large amount of time that is required for each measurement and the generally 
high amount of protein and ligand that is needed. 
The general principle of ITC is summarized in Figure 2.6-1. 
 
Figure 2.6-1. General principle of ITC. Left: Construction of the ITC device. Right top: Raw data obtained 
in the experiment showing the characteristic “spikes”. Right bottom: Integrated binding curve with 
several biophysical parameters that can be extracted from the measurement.[94] Copyright © The 
authors. CC BY 4.0 license. 
Due to the already described restrictions of the experimental procedure, ITC 
measurements were rarely used in the scope of this thesis and no screening of entire 
lead structures could be performed. Instead, ligands were chosen selectively to either 
validate already existing biophysical properties or to test the general viability of ITC for 
a series of compounds, e.g., their solubility in the chosen buffer. All ITC measurements 







3 Aim of the work 
Up to today, no literature-known ligand could be used as a therapeutic drug either due 
to missing affinity to the protein (e.g., the DTME approach), questionable 
reproducibility or low binding affinities and problematic solubilities of the lead 
compounds (e.g., the Ebselen derivatives).  
The approach of this thesis aims to overcome the explained shortcomings by using an 
affinity-based stabilization through a small molecule that binds to the Cys111 cavity and 
prevents the formation of aggregates (Figure 3-1). Furthermore, the molecules should 
be designed in a way that their water solubility for biophysical assays is high whilst 
opening up the possibility to change the solubility towards lipophilicity.  
 
Figure 3-1. Approach of this thesis. 
In order to attain this goal, the workflow needs to be divided into several steps: 
1. In silico investigation of the Cys111 cavity and design of ligands. 
2. In silico binding studies with those ligands. 
3. Synthesis of a small library of molecules to allow for a screening of substances 
with different properties. 
4. Biophysical measurements to gain information about binding modes, Kd-values, 
aggregation properties and activity of the formed protein-ligand complexes. 




4 Results and discussion 
4.1 In silico studies and properties of the Lead Structures 
 
A substantial simplification for the process of finding a suitable ligand to bind to a 
protein can arise from the existence of a natural binding ligand. An extremely well-
studied example of this is 3,4,5-trimethoxyphenylethylamine, a naturally occurring 
phenylethylamine found in cacti. It binds to several receptors from the serotonergic 
system, e.g. to the 5-HT2A–serotonin receptor, with a binding affinity of ca. 1.4 M.[95] 
Based on the structure of this ligand, a plethora of non-natural molecules have been 
designed (see Figure 4.1-1). They found use as research chemicals, tools for 
biophysical studies (e.g. 25C-NBOMe) or recreational drugs (e.g. 2C-B).[96] 
 
Figure 4.1-1. Comparison of different antagonists for the 5-HT2A-serotonin receptor derived from the 
natural binding ligand 3,4,5-trimethoxyphenyethylamine.  
Unfortunately, no natural ligand is known for SOD 1 except for several phosphate-
binding sites near the metal ions, but those are not suitable for this project. Therefore, 
binding partners needed to be identified by a rational approach. For this, the general 
structure of the already described binding cavity needed to be further elucidated to find 
possible binding sites for small molecules. 
Upon examining the cavity discussed above, it became obvious that most of the 
affected amino acids were non-polar amino acids like leucine, isoleucine, valine, and 
alanine. This was in accordance with the expectation to find these amino acids at the 
dimer contact interface, but unfortunately, these amino acids do not really offer any 
possibility for a protein-ligand interaction except for weak and unspecific non-polar 
interactions. However, two major amino acid contributors toward ionic interactions 
could be found: Arg116 with its charged guanidine-group in the side chain and the often 
times also charged N-terminal end of the protein chain in proximity to the dimer contact 




(Figure 4.1-2). This area was defined as the binding site for possible ligands and its 
impact on the selection of ligands could be described as follows: 
1. The binding site mainly consists of non-polar amino acids, which means that the 
ligand should also be largely non-polar by its nature. At the same time, a certain 
solubility in water is desired in order to allow biophysical measurements to be 
performed without significant issues. 
2. Ionic interactions are possible with the two charged guanidino groups of the 
Arg116 as well as the charged N-terminal ends of the protein monomer. 
3. The size of the area restricts the size of the ligand to approximately 14.4 Å in 
length and 7.8 Å in width. Considering that for ionic interactions to occur, the 
distance between the ligand and the charged group should not be larger than 
4 Å and not smaller than 2 Å, a size between 12 and 15 Å is assessed as 
optimal. These values are only estimated though, since the actual orientation of 
the ligand in the binding site cannot be esteemed without in silico dockings, 
therefore it can be possible that the ligand binds in a diagonal manner (16.5 Å). 
4. Since SOD1 is a homodimer, the binding site is C2-symmetrical, which means 







Figure 4.1-2. Structure of the upper binding cavity of SOD1 from the top (left) and from the side (right). 
Cys111 in yellow, Arg116 in blue and the N-terminal end of the protein monomer in red. 
These constraints meant that the specific structure of the ligand was largely variable, 
which drastically reduced the chance to find a ligand with strong binding affinity on the 
spot. Instead, a rational approach needed to be implemented in a way to find the best 
balance between possible binding interactions of different structures and their 




First, the required non-polar nature of the ligand was addressed: Considering the size 
of the area of the binding site, three different core structures were envisaged that 
featured the correct length of the molecule, a non-polar nature, and possibilities for 
modification and for the implementation of charged groups. These core structures are 
shown in Figure 4.1-3. 
 
Figure 4.1-3. The resulting core motifs of the lead structures. 
The next interaction that was considered was the ionic interaction of the already 
described Arg116 and the N-terminal end of the protein monomer. Since both of these 
moieties were positively charged, a negatively charged group on the ligand was 
optimal. Organic acid groups offered a wide variety of properties that would allow for a 
biophysical screening in order to find the best structure. Moreover, the possibility of 
transforming the acid groups into esters would allow for the desired switch in solubility 
for in vivo experiments. 









These different acids could be distinguished by several factors. The most important 







SO3H (S) -2.8 tetrahedral 2 1 
PO3H2 (O) 1.85 pyramidal 1 2 
PO2H2 (I) 2.10 pyramidal 1 1 
CO2H (C) 4.20 trigonal 
planar 
1 1 






performed with the assumption that the acid groups were deprotonated with the only 
exception being the boronic acid. Biophysical measurements are often performed in 
aqueous buffer with a pH of around 7 to 8, in order to be as close to physiological 
conditions as possible. All of the above-mentioned acid groups possess pKa-values 
that justified the assumption of being largely deprotonated at said conditions even 
though proteins tend to have structure-specific microenvironments. 
Since binding affinity was supposed to arise from interactions between charged amino 
acid residues from Arg116 and the N-terminal end of the protein monomer, the H-bond 
properties were examined. Carboxylic acids and phosphinic acids both have one H-
bond acceptor- as well as one H-bond donor-group, even though the exact strength of 
these interactions could not be anticipated. Phosphonic acids have one more H-bond 
donor-group, whereas these values are swapped when looking at sulfonic acids. The 
only acid group without H-bond-accepting properties was the boronic acid. In screening 
these different options of interactions, one could hope to find a suitable ligand for 
binding to SOD1. 
The geometry of the structures also differed from one another, albeit no specific binding 
probabilities could be derived from this property. 
The last important factor was the G-value, obtained from the mentioned in silico 
studies. It should be noted that these values were mostly used as a guideline for 
synthesis in order to determine, which structure should be synthesized first to 
maximize efficiency. Biophysical measurements are always authoritative concerning 
the binding properties, the in silico screening can only act as the first starting point to 
any research for protein-ligand interactions. 
The G-values for the investigated ligands are given in Table 4.1-2, the corresponding 









Table 4.1-2. G-values from in silico studies (swissdock.ch and AutoDockVina were used). 
Structure G (kcal/mol) Structure G(kcal/mol) 
LS1_MCH_S -10.50 LS1_S_OH -11.03 
LS1_MCH_O -12.95 LS1_O_OH -13.73 
LS1_MCH_I -11.21 LS1_I_OH -11.83 
LS1_MCH_C -10.68 LS1_C_OH -10.78 
LS2_S -10.56 LS3_S -10.49 
LS2_O -13.53 LS3_O -13.11 
LS2_I -10.85 LS3_I -11.11 
LS2_C -10.44 LS3_C -10.75 
 
 
Figure 4.1-4. Structure depiction for Table 4.1-2.  
The following trends could be observed from docking simulations: 
1. Through all three lead structures, the phosphonic acids gave the best results in 
terms of overall docking score and the phosphinic acids always came second. 
The carboxylic acids and the sulfonic acids shared the third place. 
2. The hydroxyalkane-substituted tertiary amines gave better results than the 
cyclohexylmethyl-substituted structures. This was somewhat arbitrary since the 
surrounding amino acids in the binding site were non-polar and a non-polar 
substitution was believed to increase the docking behavior. This might be 
attributed to the fact that non-polar interactions were quite hard to simulate with 
the standard docking routine and therefore could have been underestimated. 
Hydrogen bonds might also be overrepresented by the docking simulation 
because typically used force fields simulate hydrogen bonds in a more accurate 




3. When comparing the best hits (the phosphonic acids), the following ranking of 
lead structures could be obtained: LS1 > LS2 > LS3. 
It must be pointed out that binding conformations can be simulated much better than 
binding affinities using in silico studies. Therefore, the values obtained were only used 
as a guideline for synthesis and biophysical studies. Binding conformations and their 
impact on the overall proceeding of this work will be depicted in the following chapter. 
 
4.1.1 Results for LS1 
The resulting structures needed to be investigated in depth in order to gain information 
about the potential binding mode to the protein. The resulting docking information from 
the in silico screenings were visualized with Chimera. In this thesis, a selection of 
results will be presented. 
 
Figure 4.1.1-1. Results of the in silico docking for LS1_MCH_C (left) and LS1_C_OH (right). Cys111 in 
yellow, Arg116 in blue and the N-terminal end of the protein monomer in red. 
First, LS1_MCH_C and LS1_C_OH were docked. As could be seen in Figure 4.1.1-1, 
both resulting binding modes were very similar, considering the whole protein was 
accessible as a possible binding site for the ligands. Both structures were binding at 
the desired location in the protein and the resulting interactions were very similar. The 
carboxylic acids produced two salt bridge like interactions with the N-terminal end of 
the protein monomer in case of the cyclohexylmethyl-substituted lead structure and 
one in case of LS1_C_OH, even though the distances for the latter also allowed for a 
second interaction that was not recognized by the program. In the same way, all 
carboxylic acids were also able to establish salt bridges to the Arg116 residues 
concerning the distances between the respective atoms. Again, these interactions 




N-substitution: While the alkyl moiety of LS1_MCH_C possibly gave rise to 
hydrophobic interactions, the OH-groups of the covalent approach were able to 
participate in hydrogen bonding with one of the N-terminal ends of the protein 
monomer.  
In summary, the following points could be deducted from the first docking: The 
carboxylic acids were participating in salt bridges with the N-terminal end of the protein 
monomer. Interactions with the guanidine groups of Arg116 seemed possible 
considering the distance; however, the program did not detect them. This could be 
interpreted that the size of the molecules was not perfectly aligned with the size of the 
binding site or that a second charged moiety needed to be installed to allow for more 
interactions between the ligand and the protein. The N-substitution gave the expected 
results in hydrophobic interactions for the alkyl-substituted lead structure and more 
hydrogen bonds for the hydroxyalkyl-substituted lead structure.  
Next, the other acids were visualized to compare effects on the overall binding behavior 
of the ligand to the protein (Figure 4.1.1-2 for the phosphinic acids, Figure 4.1.1-3 for 
the phosphonic acids and Figure 4.1.1-4 for the sulfonic acids). 
 
Figure 4.1.1-2. Results of the in silico docking for LS1_MCH_I (left) and LS1_I_OH (right). Cys111 in 
yellow, Arg116 in blue and the N-terminal end of the protein monomer in red. 
 
Figure 4.1.1-3. Results of the in silico docking for LS1_MCH_O (left) and LS1_O_covalent (right). Cys111 





Figure 4.1.1-4. Results of the in silico docking for LS1_MCH_S (left) and LS1_S_OH (right). Cys111 in 
yellow, Arg116 in blue and the N-terminal end of the protein monomer in red. 
As could be seen, the results were comparable to the already discussed results of the 
carboxylic acids. 
For the cyclohexylmethyl-substituted lead structures, the docking always predicted 
possible hydrophobic interactions between protein and ligand and the orientation of 
the molecules was very similar in each iteration of the acids. The different acids always 
gave rise to binding with the N-terminal end of the protein monomer whilst also being 
in the correct distance for salt bridge interactions with the Arg116 residues. Again, those 
interactions were not detected by the program. 
The hydroxyalkyl-substituted lead structures also gave rise to interactions between the 
N-terminal end of the protein monomer and the acid groups while the sulfonic acid 
showed a possible salt bridge to one of the Arg116 residues. The orientation of the 
substituent also differed significantly when comparing the phosphorous-based acids to 
the sulfonic acid, even though no new interactions arose from the different orientations 
according to the in silico results. 
The strength of each of the confirmed interactions could not be deducted from the 










4.1.2 Results for LS2 
The first thing to recognize was that the phosphinic acid was the only investigated 
structure that did not bind at the desired binding site but instead showed a preferred 
binding to the lower part of the dimer contact surface (Figure 4.1.2-1). No efforts were 
made to elucidate these results further and this particular lead structure was declared 
a negative result. 
 
Figure 4.1.2-1. Results of the in silico docking for LS2_I. 
The carboxylic acid and the sulfonic acid derivatives showed a different behavior than 
the corresponding LS1-structures: - stacking between the aromatic systems could 
be observed, giving rise to a different binding mode to the protein. Both acid groups as 
well as both alcohol groups were located at the same side of the binding site instead 
of crossing it diagonally. This resulted in one confirmed interaction for the carboxylic 
acid derivative (Figure 4.1.2-2) between a carboxylic acid and the N-terminal end of 
the protein monomer. The respective sulfonic acid showed three interactions, two 
hydrogen bonds between the two alcohol groups and the N-terminal end of the protein 
monomer and Arg116, accompanied by the typical interaction of the acid group (Figure 
4.1.2-3).  
 
Figure 4.1.2-2. Results of the in silico docking for LS2_C. Cys111 in yellow, Arg116 in blue and the N-





Figure 4.1.2-3. Results of the in silico docking for LS2_S. Cys111 in yellow, Arg116 in blue and the N-
terminal end of the protein monomer in red, confirmed interactions in green. 
The phosphonic acid showed a more similar binding mode compared to the LS1-
derived structures already explained above (Figure 4.1.2-4). The two acid groups 
showed interactions to Arg116 and the N-terminal end of the protein monomer as well 
as an unprecedented interaction between an alcohol group and a backbone amide 
moiety. 
 
Figure 4.1.2-4. Results of the in silico docking for LS2_O. Cys111 in yellow, Arg116 in blue and the N-












4.1.3 Results for LS3 
All derivatives of LS3 were expected to cross the binding cavity in a diagonal manner 
to maximize potential binding interactions. This trend could be confirmed for all 
investigated structures. 
The carboxylic acid derivative crossed the cavity from one N-terminal end of the protein 
monomer to its counterpart in the other monomer, giving rise to three confirmed 
interactions (Figure 4.1.3-1). The relative steric configuration of both carboxylic acid 
residues was not identical, indicating that further optimization might be needed. 
Unfortunately, no interactions to Arg116 and the N-terminal end of the protein monomer 
were detected for a single carboxylic acid moiety. This reinforced the assumption that 
the carboxylic acid residue was not optimal for binding purposes.  
 
Figure 4.1.3-1. Results of the in silico docking for LS3_C. Cys111 in yellow, Arg116 in blue and the N-
terminal end of the protein monomer in red. 
The phosphinic acid bridged the cavity in the same manner, therefore the general 
binding mode was very similar to the one explained for the carboxylic acid (Figure 
4.1.3-2). An important difference was the existence of two concurrent interactions 
between one acid residue and both possible binding partners. 
 
Figure 4.1.3-2. Results of the in silico docking for LS3_I. Cys111 in yellow, Arg116 in blue and the N-




The phosphonic acid derivative showed the same trend in crossing the binding cavity 
(Figure 4.1.3-3). Only one interaction could be confirmed, indicating a high affinity of 
the phosphonic acid to amines that can be explained by acid-base interplay between 
both binding partners.  
 
Figure 4.1.3-3. Results of the in silico docking for LS3_O. Cys111 in yellow, Arg116 in blue and the N-
terminal end of the protein monomer in red. 
The sulfonic acid derivative showed two confirmed interactions to the N-terminal end 
of the protein monomer while crossing the cavity in the same way as all other 
investigated structures (Figure 4.1.3-4). 
 
Figure 4.1.3-4. Results of the in silico docking for LS3_S. Cys111 in yellow, Arg116 in blue and the N-










In summary, all three lead structures studied herein showed the expected tendency of 
binding in the upper cavity near Cys111. Putative interactions between the molecules 
and the protein could be confirmed. The binding mode was different between lead 
structures and acid residues within the lead structures; in turn, no clear picture can be 
drawn in that regard. It must be noted that the number of interactions did not say 
anything about the final G-value since one would expect the phosphonic acids to be 
the worst of the aforementioned acids. In reality the opposite was true (see table  
4.1-2), which again substantiated the suspicion that the in silico docking did not 
consider all possible interactions between ligand and protein. This is because the 
distances between the acid moieties and Arg116 were small enough to allow for salt 
bridges in many cases.  
Aliphatic and hydroxyl-substituted residues showed similar binding behavior that 
cannot be further elucidated by in silico studies alone. The most straightforward way 
to verify these interactions and to optimize the ligands would start with the synthesis 
of one lead structure and subsequent screening of the acid residues in biophysical 
assays. Crystal structure analysis would then allow to either confirm or invalidate the 
in silico findings, opening up the possibility to optimize the ligands in a rational way. 
The general shortcomings of computational docking such as selection of force fields, 
selection of scoring functions, reduced flexibility of ligands, too rigid behavior of 
proteins as well as omitting the role of the solvent as potential hydrogen bond donor or 
acceptor can lead to imprecise binding predictions. This was observed in this thesis as 
well, since all investigated molecules showed the possibility of binding to other areas 
of the protein. The real binding modes, binding strengths and affinities can only be 










4.2 Synthesis of LS1 
 
Parts of this chapter have been published in “Robert H.E. Schirmacher, Daniel Rösch, 
Franziska Thomas, Hexafluoroisopropanol as solvent and promotor in the Paal-Knorr 
synthesis of N-substituted diaryl pyrroles, Tetrahedron, 2021, 83, 131985. 
4.2.1 Synthesis of the molecular library based on the carboxylic acids of 
LS1 
 
Figure 4.2.1-1. Structure of the carboxylic acid derivatives of LS1. 
The first retrosynthetic task was to identify a common precursor for the different 
iterations of R that consisted of a plethora of alkyl or aryl groups as well as to plan a 
precursor for the synthesis of carboxylic acids. This was especially important since 
carboxylic acids were polar and generally more difficult to handle as solubility in organic 
solvents is reduced and purification often tedious. The transformation of the nitrile 
group into a carboxylic acid was chosen as the method of choice because the reaction 
tends to proceed smoothly in basic media and the nitrile precursors are commercially 
available, non-polar and therefore easy to handle (Figure 4.2.1-2). 
 
Figure 4.2.1-2. Synthesis of the carboxylic acid moiety from nitrile precursors (the amides are not 
isolated). 
Having set the synthesis of the acid group, the main structural motif of LS1, the central 
2,5-bis-aryl substituted pyrrole moiety with variable organic residues at the nitrogen 
atom had to be addressed. There is a broad variety of different organic reactions for 
the synthesis of pyrroles, both aryl- or alkyl-substituted and with the possibility of N-
substitution.[97] The most widely known literature approaches to bis-aryl-substituted 
pyrroles make use of palladium catalysts and require the already N-substituted pyrrole 
and a specific aryl precursor that is frequently pre-functionalized.[97,98] The N-




strong base and alkyl halides in moderate to good yields.[99] A possible two-step 
sequence to the central motif is shown in Figure 4.2.1-3. 
 
Figure 4.2.1-3. Two-step sequence for the synthesis of a possible precursor for LS1. 
This reaction sequence has several drawbacks: First, the N-substituted precursors 
have to be synthesized for each variation of R. Each of these molecules has to be 
reacted with the appropriate aryl bromide to give rise to the desired core structural 
motif afterwards. Second, switching away from nitriles could possibly cause severe 
synthetic challenges since cross-coupling reactions of this type typically have a very 
limited functional group tolerance. Third, if the desired pyrrole precursor is supposed 
to exhibit chloride- or bromide-functionalized aromatic systems, the cross-coupling 
step itself could lead to polymerization due to double-couplings on the required 1,4-
dihalide coupling partner. 
Another literature-known approach to substituted heterocycles is the arylation of N-Boc 
protected pyrrole with in situ-generated diazonium ions (see Figure 4.2.1.-4).[100] 
Pyrrole is protected using a standard Boc-protocol and the coupling partner 
benzocaine was readily synthesized from 4-aminobenzoic acid. The diazonium ions 
were then generated by treatment of the free amine with tBuONO and MeSO3H with 
additional CaCO3 for pH control in water, followed by the addition of the protected 
pyrrole, acetone, and Cu(OAc)2. When performing this reaction, no product formation 
was observed. Therefore,  this pathway was abandoned for this project. 
 




One of the most famous and well-known strategies for the synthesis of pyrroles is the 
Paal-Knorr pyrrole synthesis. Compared to modern techniques like the ones 
mentioned before, the Paal-Knorr reaction dates back to 1884 but experiences 
increasing attention in today’s current research trends such as green chemistry or 
sustainable chemistry.[101,102] The Paal-Knorr pyrrole synthesis includes the reaction of 
a 1,4-diketone and a primary amine, typically under acid or Lewis-acid catalysis. 
Commonly used solvents range from polar protic solvents such as EtOH or MeOH over 
polar aprotic solvents such as DMF or THF to nonpolar solvents, e.g. DCM or toluene. 
Novel approaches also make use of ionic liquids or deep eutectic solvents (DES) in 
order to increase the yields, minimize side products, increase reusability, and allow 
easy separation of the products.[103,104]  
However, initial tests with the highly insoluble 4,4’-succinyldibenzonitrile (32) were 
unfavorable in terms of product quality, yield and reaction control due to the use of high 
boiling solvents like DMF or DMSO (see Table 4.2.1-1, entries 1-2). Since the solubility 
of the diketone (32) was a major problem, solvent-free conditions were investigated; 
this improved the yield to 25% (Table 4.2.1-1, entry 3). Afterwards, the ionic liquid 1-
butyl-3-methylimidazolium iodide and a deep eutectic solvent of choline chloride and 
urea were employed. Unfortunately, no conversion was observed, probably due to the 
poor solubility of 32 in those respective solvents (Table 4.2.1-1, entries 4-5). The poor 
solubility of 32 in common organic solvents can be attributed to two main factors: 
Firstly, - interactions between the electron-poor aromatic rings can lead to stacking 
in the solid phase, restricting the ability of the solvent to break these interplays. 
Secondly, the hydroxyl groups of the enol form of 32 can form hydrogen bonds with 
the nitrile moieties in an inter- or intramolecular fashion, further amplifying the structure 
of the molecule. Both of these effects result in an energy barrier the solvent needs to 
overcome in order to yield solvent-separated molecules.  
Hexafluoroisopropanol is a very potent hydrogen bond donor due to its two TFB-groups 
adjacent to the alcohol, leading to a slightly acidic OH-group with a pKa of 9.3.[105] On 
the other hand, the nucleophilicity is rather limited due to steric constraints, which 
makes HFIP a suitable solvent for Paal-Knorr reactions. This presumption was 
confirmed by achieving a yield of 74% after heating the reaction mixture at reflux for 2 




Next, the reaction between 2,5-hexandione (33) and benzyl amine was investigated, 
since 33 is a common model substrate for the optimization of reaction conditions in 
Paal-Knorr like reactions. The reaction in HFIP was completed almost instantly, giving 
quantitative yield of the desired pyrrole (Table 4.2.1-1, entry 7). Afterwards, the same 
reaction was carried out under literature known conditions (Table 4.2.1-1, entries 8-11) 
and their suitability was confirmed with excellent yields for every approach. The use of 
HFIP has several advantages though: The low boiling point meant that evaporation of 
the solvent after the reaction was feasible. In addition, the reaction was completed at 
the fastest rate compared to the other procedures.  
Table 4.2.1-1. Optimization of the reaction conditions for the synthesis of 2,5-disubstituted pyrroles. 
 
 32 / 33 34a equiv. solvent cat. t (h) T (°C) yield (%)a 
1 32 5 DMF PTSA 12 100 0 
2 32 5 DMSO PTSA 24 130 12 
3 32 neat - - 96 80 25 
4 32 2.5 [BmIm]Ib PTSA 24 100 0 
5 32 2.5 CC/Uc - 24 80 0 
6 32 1.5 HFIP - 48 59 74 
7 33 1.5 HFIP - < 0.1 r.t. 99 
8 33 1.5 H2O[106] - 0.5 100 99 
9 33 1.5 CC/Uc[104] - 12 80 98 
10 33 1.5 [BmIm]Ib[103] - 1 95 98 
11 33 1.5 None[107] - 1 100 99 
aYields refer to isolated compounds. b[BmIm]I = 1-butyl-3-methylimidazolium Iodide. cCC/U = 1:1 equimolar mixture of choline chloride and urea. 
Thereafter, a catalytic approach was tested by running the same reaction in five 
different organic solvents at room temperature. Ethanol, the only protic solvent that 
was used, gave the best results (Table 4.2.1-2, entry 5). Addition of a catalytic amount 
of HFIP increased the yield by an additional 16% (Table 4.2.1-2, entry 6). This means 
that HFIP can be used as the acid additive in Paal-Knorr reactions instead of Bronsted- 
or Lewis-acids that are widely used in organic synthesis. The reason for the rate-




hydroxyl group. It must be noted that the catalytic approach gave reduced yields 
compared to the approach in HFIP as the sole solvent; therefore, it should only be used 
as long as the solvent properties of HFIP are not required. 
Table 4.2.1-2. Optimization of the catalytic activity of HFIP. 
 
entry 34a equiv. solvent cat. yield (%)a 
1 1.5 DCM - 45 
2 1.5 EtOAc - 41 
3 1.5 Et2O - 39 
4 1.5 Toluene - 46 
5 1.5 EtOH - 56 
6 1.5 EtOH HFIP (5-mol%) 82 
aYields refer to isolated compounds. 
In summary, a protocol for the synthesis of the desired 2,5-diaryl substituted pyrrole 
motif was established by employing hexafluoroisopropanol as solvent and reaction 
promotor in a Paal-Knorr pyrrole synthesis.   
Having set out this critical reaction step, a retrosynthetic analysis of LS1 is presented 
in Figure 4.2.1-5. 
 
Figure 4.2.1-5. Retrosynthetic approach to the carboxylic acids of LS1. 
The carboxylic acids can be synthesized via nitrile hydrolysis of the dicyanide 
precursors in a mixture of organic solvent and water. The dicyanide precursors can be 
synthesized utilizing the optimized reaction conditions from Table 4.2.1-1 employing 




be conveniently prepared via Aldol reaction between a ketone and a bromoketone, 
followed by base-induced in situ nucleophilic substitution and ring opening. The 
proposed mechanism of this reaction is described in Figure 4.2.1-6. 
 
Figure 4.2.1-6. Reaction mechanism for the synthesis of 1,4-diketones utilizing zinc chloride, 
triethylamine, and ethanol. 
In the first step, ketone (37) and bromoketone (38) were reacted to the desired 1,4-
diketone structure using a condensation agent consisting of ZnCl2, EtOH and Et3N in 
toluene at room temperature for several days (Figure 4.2.1-7). Recrystallization of the 
precipitated solid afforded the general precursor (32) in 70% yield.[108]  
 
Figure 4.2.1-7. Synthesis of the 1,4-diketone precursor. 
The already described Paal-Knorr-pyrrole syntheses followed by the literature-known 
base-promoted nitrile hydrolysis afforded each final structure in two individual steps 
(Figure 4.2.1-8).  
 





The following molecules were synthesized following the procedure described above 
(Figure 4.2.1-9): 
 
Figure 4.2.1-9. Overview of the synthesized carboxylic acids. Percentages in brackets indicate the 














4.2.2 Synthesis of the molecular library based on LS1 
 
Figure 4.2.2-1. General structure of LS1. 
The first retrosynthetic task for the diversification of the LS1 based library was the 
introduction of a variety of different acid moieties to the two benzene moieties, 
preferably using only one conjoint precursor for all different acids in order to shorten 
the synthetic sequence. Fortunately, all desired moieties can be conveniently prepared 
from aryl bromides using literature known protocols. 
 
Figure 4.2.2-2. Synthesis of the acid moieties from two precursors. 
As can be seen in Figure 4.2.2-2, the bromide functionality is well suited to the 
demands of the aforementioned syntheses. The phosphinic acids could be prepared 
in a single reaction step making use of a Palladium-catalysed cross coupling.[109] 
Phosphonic acids also required a cross-coupling step, followed by the McKenna-
reaction to saponify the phosphonate ester.[109,110] Boronic acids could be synthesized 
by metalation at low temperatures, followed by quenching of the intermediate lithium 
salt with triethyl borate and subsequent acidic hydrolysis.[111] Unfortunately, sulfonic 
acids are more difficult to obtain: First, the bromide can be converted to a protected 




oxidized with H2O2 after cleavage to produce the free sulfonic acid.[112,113] However, 
the synthesis of sulfonic acids was not successful following this reaction pathway. 
All of the synthesized acids were purified by acid-base extraction and precipitation from 
water at low pH values. Column chromatography, recrystallization and HPLC were 
performed if needed. 
It should be noted that all of these reactions had to be carried out twice on the same 
molecule, which in turn drastically affected the yields. 
With this in mind, a retrosynthetic analysis for the synthesis of the LS1 derived library 
is presented (Figure 4.2.2-3). 
 
Figure 4.2.2-3. Retrosynthetic approach to LS1. 
The general approach that was used for the dibromides was identical to the one used 
for the dicyanides (see Figure 4.2.1-5). The zinc-induced coupling produced the 1,4-
diketone (50) in moderate yield (63%) after a reaction time of 7 days at room 
temperature. Followed by the already introduced Paal-Knorr pyrrole synthesis (the 
amines were also commercially available) this sequence yielded both of the two 
needed precursors in only four total steps for each alteration of R. Since three different 
alkyl residues were envisaged based on their performance in in silico screenings, eight 
individual reactions would allow the synthesis of the precursor molecules for the 
ensuing transformation into the acid moieties. Those summed up to 24 individual 
reaction steps – combination of these two sequences resulted in 32 individual reactions 





An overview about the synthesized compounds and yields is given in Table 4.2.2-1. 
Since most of the reactions were performed similarly with the only variable being the 
primary amine and consequently the N-substitution, the reactions are not noted 
individually. Reactions already described in the previous chapter will be depicted again 
to present the entirety of the LS1 – derived syntheses. 
Table 4.2.2-1. Summarized yields of the library synthesis of LS1. 












PO3H2e B(OH)2f SO3Hg 
MCH 70% 63% 42 65% 51 78% 1 88% 10 53% 13 43% 16 68% / 
DMB 70% 63% 40 56% 52 43% 2 82% 11 64% 14 52% 17 48% / 
TFB 70% 63% 41 50% 53 61% 3 73% 12 53% 15 13% 18 41% * 
Reaction conditions: a,b) 1 bromoketone, 1.5 ketone, 2 ZnCl2, 1.5  EtOH, 1.5 Et3N, toluene, rt, 7 d; c) 1 
a, 10 KOH, EtOH, H2O, T; d) 3  PhNH2H3PO2, cat. Pd2(dba)3, cat. Xantphos, 3 Et3N, 1 b, toluene, 90 
°C, 3 h; e) 2 HPO(OEt)2, 2 Et3N, cat. Pd(dppf)Cl2, 1 b, toluene, 110 °C, 12-16 h then 10 TMSBr, DCM, 
MeOH; f) 3 nBuLi, 1 b, THF, -78 °C then B(OEt)3, HCl; g) 2 DMBSH, 2 NaOtBu, cat. Pd(OAc)2, cat. CyPF-
tBu, DME, 1 b 110 °C, 3 h then 6 BBr3, 10 AcCl, toluene then 10 KOH, 10 H2O2, MeOH, H2O.  *reaction 
did not produce the desired product. 
As shown in Table 4.2.2-1, the yields vary drastically, considering the reactions of the 
same acid group were done using the exact same protocol. The observed solubilities 
of the respective acids showed a broad variance, seriously restricting a clean work-up 
using acid-base extraction and subsequent precipitation. This might explain the low 
yields especially for the boronic acids. No efforts were spent to maximize yields, since 
only a very small amount of material was required to perform the biophysical 
measurements. Furthermore, the low yields could be compensated to some extent by 
producing ample starting material (the two 1,4-diketones (32) and (50)). 
Another factor that needed to be taken into consideration was a side reaction that 
occurred during the synthesis of the sulfonic acid derivatives. Since this side reaction 
proved to make the timely synthesis of said molecules impossible, it will be explained 
shortly (see Figure 4.2.2-4): A literature-known transformation of aryl bromides to tert-
butyl protected aryl thiols by means of a cross-coupling reaction was employed to 
synthesize the corresponding di-substituted pyrrole (54) in excellent yields.[113] Lewis-
acid promoted deprotection followed by immediate in situ acetate protection provided 




a Friedel-Crafts-type acetylation at the pyrrole backbone. The obtained molecule (55) 
was unsuitable for further reactions since it would be very challenging to remove an 
aryl-acetate moiety from the pyrrole backbone. Possible reaction steps to achieve this 
transformation could be the oxidation of the ketone to an ester via a copper catalyzed 
reaction[114] followed by a decarboxylation reaction. These steps would require harsh 
reaction conditions and were not tested during this thesis. The final reaction step – a 
base catalyzed deprotection followed by in situ oxidation using potassium hydroxide 
and hydrogen peroxide – was tested and delivered the desired sulfonic acid, albeit the 
acetylated one (56). No yield was determined since the purification was only performed 
using small amounts. 
 
Figure 4.2.2-4: Pathways and side reactions concerning the synthesis of the sulfonic acids. These 
reactions were performed by DIANA MUKANOV in her master thesis. 
It should be stated that in current studies, the acetylated pyrrole (58) is synthesized by 
palladium-catalyzed cross-coupling between the dibromide (51) and potassium 
thioacetate (57) in toluene (Figure 4.2.2-5). No side reactions on the pyrrole backbone 
were observed. It is noteworthy, that the same transformation of aryl bromides to aryl 
thioacetates was also successfully performed on the 1,4-diketone stage. 
 
Figure 4.2.2-5: Alternative syntheses to the desired sulfonic acids. These reactions were performed by 




In summary, the LS1 based library of twelve different molecules was successfully 
synthesized; the resulting structures are depicted in Figure 4.2.2-6. 
 
 










4.2.3 HFIP in the Paal-Knorr synthesis of pyrroles 
After optimizing the reaction conditions for the Paal-Knorr pyrrole synthesis in HFIP, 
the scope of the reaction protocol was investigated by reacting the two introduced 
diketones 32 and 33 with a range of different primary amines.  
Generally, reactions with 33 were much faster than with 32 as expected, which is also 
reflected in much higher yields when using the alkyl over the aryl diketone. In addition, 
the reactions of 32 were run at reflux whereas 33 was reactive at room temperature 
for most of the amines. 
The reaction between 32 and aliphatic amines 34a-f gave isolated yields between 50% 
and 76%, representing average to good results for this reaction type (Table 4.2.3-1, 
entries 1-6). Aniline and its derivatives 34g-i produced lower yields in the Paal-Knorr 
pyrrole synthesis (Table 4.2.3-1, entry 7-9) due to their lower nucleophilicity. The very 
electron-poor 4-nitroaniline showed no conversion at all under the chosen reaction 
conditions (Table 4.2.3-1, entry 9). 
The reaction between 33 and aliphatic amines 34a-f resulted in almost quantitative 
yields even at room temperature, highlighting the high reactivity of both reaction 
partners (Table 4.2.3-1, entries 10-15). Reactions using the less reactive aniline 
derivatives 34g-i were conducted at reflux, giving very good yields between 88 and 















Table 4.2.3-1. Reaction Scope of Paal-Knorr-Pyrrole Synthesis with Varying Amines. 
 
entry amine 32 yield entry amine 33 yield 
1a 
 
32 35a, 74% 10b 
 
33 36a, 99% 
2a 
 
32 35b, 76% 11b 
 
33 36b, 99% 
3a 
 
32 35c, 56% 12b 
 
33 36c, 97% 
4a 
 
32 35d, 50% 13b 
 
33 36d, 94% 
5a 
 
32 35e, 65% 14b 
 
33 36e, 98% 
6a 
 
32 35f, 76% 15b 
 
33 36f, 96% 
7a 
 
32 35g, 61% 16c 
 
33 36g, 90%c 
8a 
 
32 35h, 41% 17c 
 
33 36h, 88%c 
9a 
 
32 395i, 0% 18c 
 
33 36i, 90%c 
a48 h, reflux; b5 min, room temperature; c15 min, reflux. Yields refer to isolated compounds. 
 
The next step was the application of the optimized reaction conditions to a variety of 





Table 4.2.3-2. Reaction Scope of Paal-Knorr furan synthesis with varying 1,4-diketones. 
 









































































a Reaction was performed at room temperature. Yields refer to isolated compounds. 
The use of symmetrical aromatic diketones resulted in moderate to good yields of the 
desired pyrrole after two days of heating the reaction mixture to reflux (Table 4.2.3-2, 
entries 1 and 3-6). Surprisingly, the non-substituted 59 gave lower yields than the 
substituted derivatives, even if compared to the very electron poor para-nitro 
substituted diketone 61 (Table 4.2.3-2, entries 3 and 6). Non-branched mixed 1,4-
diketones 62, 63 and 64 gave comparable results to the symmetrical diketones, the 
same was true for the sterically more demanding branched 1,4-diketones 65 to 67 
(Table 4.2.3-2, entries 10-12). It is reasonable to conclude that the electronic nature of 
the diketones plays an equally important role as the steric demand of the substrates, 
resulting in somewhat arbitrary results. The tetra-substituted Atorvastatin[115] precursor 
68 was unreactive when the optimized reaction conditions were employed. This 
problem could be overcome by increasing the temperature of the HFIP solution to 
90 °C in a pressure tube. After heating for 3 days, dilution of the concentrated HFIP 
solution with a mixture of iPrOH and acetone led to the crystallization of the product in 
34% yield without the need of further purification (Table 4.2.3-2, entry 13). 
In summary, the optimized reaction conditions employing HFIP as a solvent and 
reaction promotor were suitable for the production of the desired pyrrole precursors for 
subsequent library synthesis. Furthermore, the protocol could be expanded to a range 
of different diketones and primary amines, resulting in practically useful yields for 




4.2.4 HFIP in the Paal-Knorr synthesis of furans and thiophenes 
The use of HFIP as an acid catalyst in the synthesis of pyrroles led to the question 
whether this approach was beneficial for the synthesis of furans and thiophenes as 
well. Generally, the respective 1,4-diketone is dissolved in an appropriate solvent and 
heated under Brønsted- or Lewis-acid catalysis to give the furan compound.[116] 
Unfortunately, heating of 32 in HFIP for prolonged times did not produce any furan, 
which probably meant that the acidic properties of HFIP were not strong enough for 
being a promising catalyst. Instead, heating of 32 in HFIP with a catalytic amount of 
hydrochloric acid resulted in the formation of the respective furan compound in 88% 
yield (Table 4.2.4-1, entry 1). All other 1,4-diketones resulted in yields ranging from 
91% for the para-bromo substituted 50 to 55% for the tetra-substituted Atorvastatin 
precursor 68 (Table 4.2.4-1, entries 2-10). 
The Paal-Knorr thiophene synthesis is synthetically more challenging than the furan 
synthesis since a sulfur atom needs to be introduced into the diketone prior to the 
nucleophilic attack. This means that the corresponding furan is a typical byproduct of 
thiophene synthesis since both of these processes happen on a similar time scale. 
Lawesson`s reagent was used as the sulfur-source and was added to a solution of the 
diketone in HFIP, which was heated under reflux overnight. The diketones 46, 99 and 
100 reacted cleanly and gave good yields of the desired thiophenes (Table 4.2.4-2, 
entries 2-4), while diketones 97 and 103 gave inseparable mixtures of thiophenes and 
furans in a somewhat lower yield (Table 4.2.4-2, entries 1 and 5). 
In summary, a new protocol for the Paal-Knorr synthesis of pyrroles, furans and 
thiophenes employing HFIP as solvent and reaction promotor was presented. This 
protocol is broadly applicable to a plethora of different diketone and/or amine 
compounds. The protocol shows deficiencies when it comes to sterically demanding 
substrates and requires mineral acid catalysts for the synthesis of furans. On the other 
hand, Paal-Knorr synthesis of 1,4-diketones with electron poor aromatic systems has 
scarcely been reported, probably due to a combination of solvation issues and the 
general lower reactivity, but several of these compounds were used successfully using 






Table 4.2.4-1. Reaction scope of Paal-Knorr furan synthesis with varying 1,4-diketones. 
 


























Table 4.2.4-2. Reaction scope of Paal-Knorr thiophene synthesis with varying 1,4-diketones. 
 
entry diketone yielda 










aYields were estimated from NMR integrals. All other yields refer to isolated compounds. b90 has been purified by 















4.3 Synthesis of LS2 
 
 
Figure 4.3-1. General structure of LS2. The amine can be mono- or disubstituted with an alkyl group, 
leading to two different variants of this backbone.  
The retrosynthesis of LS2 offered a more complex pattern of possible pathways 
compared to that of LS1 since more than one structure was possible. In this chapter, 
the synthesis of the mono-N-substituted ligand is depicted. The synthesis of the di-N-
substituted structure will be explained in a separate part of this thesis.  
The alkyl residues R2 and R3 were designed to enable covalent binding to the protein 
if desired. To achieve this, the alcohol groups would be replaced with thiol groups, 
which could then form disulfide bridges with Cys111 of the protein, tethering both 
monomers together. 
It should be noted that the already established methods of synthesizing the acid groups 
from the respective bromides and/or nitriles were also valid for LS2, therefore no new 
synthetic pathways were needed to be explored in that regard. The retrosynthetic 
approach for the synthesis of LS2 is shown in Figure 4.3-2.  
 
Figure 4.3-2. Retrosynthetic approach to LS2. 
The conversion to the acid moieties can be conducted according to Figure 4.3-2 from 




moiety through reductive amination to give the primary amine, followed by a 
nucleophilic substitution. The ketone precursor can be synthesized via two different 
sequences: Sequence 1 starts with the ketone moiety already installed and introduces 
the halogen at the benzene moieties. Sequence 2 starts with a phenylacetic acid 
derivative, pre-functionalized with a halogen or nitrile. Both sequences are combined 
at the ketone stage. 
 
4.3.1 Sequence 1 
The first approach started with the backbone already set up by the commercially 
available 1,3-diphenylacetone and aimed to introduce the acid groups by brominating 
the benzene moieties followed by subsequent conversion to the acid groups.  
First, different bromination methods, chosen from comprehensive arrays of literature 
known methods, were tested. Two reactions were selected: The NBS-mediated 
bromination in HFIP and the AlBr3 catalyzed bromination with elemental bromine.[117] 
Unfortunately, none of the reactions produced the desired product; also, no 
bromination in -position to the ketone was observed (see Figure 4.3.1-1).  
 
Figure 4.3.1-1. Failed bromination of 1,3-diphenylacetone. 
The next reaction that was examined was the reductive amination since it would also 
be required if Sequence 2 was chosen. Once more, a plethora of different literature-
known reactions was available to choose from: The reductive amination in TFE using 
NaBH4 as a reducing agent as well as a sodium triacetoxyborohydride mediated 
process were tested.[118,119] Further trials were performed by undergraduate students; 
however, all efforts to use secondary amines in this kind of reaction were unsuccessful. 
This was probably due to two factors: Firstly, the enol form of the ketone would result 
in a conjugated system, favoring it over the ketone form, reducing the reactivity in 
condensation reactions with amines. Secondly, the steric bulk by the two aromatic 




Thus, the strategy needed to be split up in two parts: First, the synthesis of a free 
primary amine was performed, which was followed by a nucleophilic substitution to 
obtain the desired mono- and disubstituted products. The synthesis of the free primary 
amine is depicted in Figure 4.3.1-2. 
 
Figure 4.3.1-2. Reductive amination of 1,3-diphenylacetone. 
The first reductive amination method that was tested was a two-step sequence: The 
ketoxime was synthesized by the reaction of the ketone with hydroxylamin-
hydrochloride in the presence of triethylamine in good yields. However, the complete 
reduction with lithium aluminum hydride in refluxing THF only yielded a complex 
mixture of the ketoxime, hydroxylamine and free amine that was impossible to purify. 
Instead, the amine (100) was successfully obtained by the reaction of the ketone (95) 
with a large excess of ammonium acetate and sodium cyanoborohydride in a mixture 
of MeOH and THF in 61%. The resulting product was converted to the hydrochloride 
salt and recrystallized from iPrOH. 
In summary, Sequence 1 did not produce the desired product, but a reductive 
amination strategy was established, including a purification method for the 
hydrochloride salts of similar products that would be beneficial for Sequence 2. 
 
4.3.2 Sequence 2 
Sequence 2 started from commercially available phenylacetic acid derivatives, 
functionalized with either a nitrile or a bromide moiety (96 and 97). Not many methods 
are known to produce 1,3-diaryl substituted acetones: One pathway is a Dakin-West 
like approach, starting from phenylacetic acid using NaOAc and Ac2O under reflux, 
followed by distillation.[120] Another approach makes use of a strong base to induce a 
Claisen condensation of a phenylacetic acid ester to produce a--keto ester which 
undergoes acidic saponification and subsequent decarboxylation.[121] None of these 
reactions seemed to be suitable to generate large amounts of the precursor material, 




phenylacetic acid derivative was self-condensed in the presence of 0.6 equiv. of DCC 
and 0.3 equiv. of DMAP in anhydrous DCM, which produced the desired products (98 
and 99) in moderate yields.[122] This reaction path, reminiscent of Steglich-like 
reactions, is shown in Figure 4.3.2-1. 
 
Figure 4.3.2-1. Steglich-like condensation of phenylacetic acid derivatives. 
Once the ketone was synthesized, the reductive amination was performed as 
described for sequence 1 (Figure 4.3.2-2). 
 
Figure 4.3.2-2. Primary amine synthesis by reductive amination as shown for Sequence 1. 
The nitrile-substituted ketone derivative (99) did not undergo reductive amination but 
instead produced a complex mixture of products probably due to dimerization reactions 
between intermediate imides and nitriles. The bromide-substituted ketone derivative 
(98) was transformed to the insoluble hydrochloride salt (101) with moderate to good 
yields (ca. 60-80%). This presented a problem since there would be the need for a way 
to produce carboxylic acids from aryl bromides instead of using nitriles as a precursor. 
A reasonable reaction using metal-halogen exchange followed by quenching with CO2 
was proposed for this purpose (Figure 4.3.2-3)[123]: 
 




The next step in Sequence 2 was a nucleophilic substitution with a suitable O-protected 
bromide, which led to the mono-substituted secondary amine (103) in moderate yields 
by refluxing the reaction mixture in MeCN in the presence of K2CO3 (Figure 4.3.2-4). 
The disubstituted, tertiary amine unexpectedly did not form during this reaction, even 
though secondary amines are usually more nucleophilic than primary amines. Steric 
bulk from the two 4-bromophenyl moieties might have been the reason for this outcome 
and changing the reaction conditions to higher boiling solvents such as toluene, 
stronger bases such as Cs2CO3 or increased amounts of reactants did not change the 
result. 
 
Figure 4.3.2-4. Nucleophilic substitution towards the mono-substituted precursor.  
This precursor was now ready for the implementation of the different acid groups in the 
manner already described in the previous chapter. The only acid that was synthesized 
was the carboxylic acid using the conditions from Figure 4.3.2-3. The complete 
reaction sequence for the synthesis of LS2 is shown in Figure 4.3.2-5.  
 
Figure 4.3.2-5. Synthetic pathway to the monosubstituted LS2.  
The yield of the final carboxylic acid (104) was very low due to the harsh reaction 
conditions that had to be used as well as tedious purification processes and 
inconvenient solubility properties. Furthermore, only a small amount of residue was 




In summary, the pathway shown in Figure 4.3.2-5 was identified as a plausible 
sequence, in which the desired organic residues could be synthesized except for the 
carboxylic acids. As explained above, this is because the nitrile precursor amine could 
not be synthesized successfully (see Figure 4.3.2-2), and the final conversion of aryl 
bromides to aryl carboxylic acids gave mediocre results at best. 
To overcome this issue, a different pathway to the carboxylic acids was proposed 
(Figure 4.3.2-6):  
 
Figure 4.3.2-6. Alternative reaction sequence to the monosubstituted carboxylic acid derivatives of LS2. 
Starting from the commercially available 4-cyanobenzyl cyanide (105), a three-step 
sequence was necessary to obtain the desired phenylacetic acid derivative (108) since 
a direct esterification of the nitriles (e.g., the Pinner reaction) produced large amounts 
of oligomers when more than one nitrile is present on the starting material. 
Consequently, the nitriles were hydrolyzed to carboxylic acids (106) in strongly alkaline 
media in quantitative yield, which subsequently were transformed to the ethyl esters 
by means of Fischer esterification (107). The crude product was directly submitted to 
saponification under very mild conditions with lithium hydroxide, leading to the 
selective cleavage of the alkyl ester over the aryl ester in good yield.  
This precursor was now subjected to the same reaction sequence that was already 
described in detail. Noteworthy, the reductive amination to the primary amine 
proceeded with very poor yield; this is most likely due to unfavorable solubility of the 




suitable for the isolation of the pure compound since a large amount of product was 
soluble in the organic phase (EtOAc) as well was in the aqueous phase and was lost 
this way.  
Prior to the nucleophilic substitution, the esters had to be cleaved to prevent amide 
formation via intra- or intermolecular mechanisms under the utilized reaction conditions 
(heat, base, polar aprotic solvents). To achieve this, basic hydrolysis was performed 
in 50% yield and the final molecule (111) was obtained as the hydrochloride salt in high 
purity. Due to time restrictions and the absence of commercially available reaction 
partners for nucleophilic substitution, this specific reaction was not performed during 
the course of this thesis. Still, this reaction route represents a suitable route for the 



















4.3.3 Direct approach for the disubstitution of LS2 
Since the reductive amination was not successful with secondary amines and 
nucleophilic substitution only gave secondary amines, it was not possible to obtain the 
disubstituted LS2 using these procedures. Instead, a different pathway was envisaged: 
 
Figure 4.3.3-1. Synthetic pathway to the disubstituted LS2. 
The commercially available 4-chlorobenzylmagnesium chloride (112) was reacted with 
the also commercially available di-N,O-acetale (113) in refluxing diethyl ether by 
means of a Grignard reaction (Figure 4.3.3-1).[124] This afforded the full core structure 
(114) of the disubstituted LS2 in one reaction step with 56% yield. Since both reagents 
were very expensive and very difficult to synthesize, only a very small amount of 
product could be produced. Furthermore, the purity of the product was only moderate 
even after column chromatography. Transformation into the hydrochloride salt (or other 
salts, e.g., sulfate or tartrate salts) and subsequent recrystallization could prove 
beneficial for the purification. Nevertheless, this method could potentially prove to be 












4.3.4 Synthesis towards a colorimetric assay for binding observation 
between LS2 and SOD1 
Another long-term goal was the functionalization of the mono- or disubstituted structure 
with a dye that would allow following the binding properties of LS2 via UV/VIS-
spectroscopy. To achieve this goal, the already described covalent approaches 
needed to be addressed (see Figure 4.3.2-5 and/or 4.3.3-1). In order to render the lead 
structure cysteine-reactive, the alcohol moieties had to be converted to thiol groups. 
Afterwards the functionalization with a dye could be carried out, a suitable one being 
the cysteine-reactive molecule 5,5'-disulfanediylbis(2-nitrobenzoic acid), also known 
as Ellmanns reagent or DTNB.[125] This approach is summarized in Figure 4.3.4-1. 
 
Figure 4.3.4-1. Synthetic scheme for the functionalization of LS2 with a dye and release of the 
spectroscopically detectable TNB dye upon binding to SOD1. 
As can be seen, the alcohol could be converted to a thiol following a literature known 
approach by chlorinating said alcohol with thionyl chloride in refluxing chloroform.[126] 
The chloride could then be replaced by a protected thiol via nucleophilic substitution, 
which could be cleaved under acidic conditions to afford the free thiol. Formation of a 
disulfide bridge in aqueous buffer medium with DTNB would then afford the desired 
functionalized structure. Thiols in biomolecules, such as the free cysteines in SOD1, 
are able to react with the DTNB-functionalized structure, giving rise to the covalently 
tethered SOD1 and the TNB dye that is deprotonated twice under moderately alkaline 




coefficients would then allow for the quantification of released TNB and consequently 
of the binding of the lead structure to the protein. 
It must be noted that certain requirements need to be fulfilled in order to gain reliable 
results: Preferably there must be only one possible reaction side for the functionalized 
molecule in order to ensure that the binding site on the protein remains identical. 
Furthermore, the functionalized molecule must have a similar affinity to the protein 
compared to the unfunctionalized molecule; else, no comparison can be made. The 
binding should be reasonably fast, otherwise photobleaching could diminish the 
amount of detectable free TNB and lead to false data. 
No tests on the core motif of LS2 were performed. Instead, a model system was used 
to mimic the reactivity of the dithiol handle and to investigate the reaction conditions 
(Figure 4.3.4-2). 
 
Figure 4.3.4-2. Synthesis of a model system for the DTNB-functionalized LS2. 
The commercially available bis(2-chloroethyl)ammonium chloride (115) was treated 
with TrtSH in DMF in the presence of DBU to afford the protected dithiol (116) in 71% 
yield. Deprotection with TFA and Et3SiH in DCM yielded the free dithiol in the form of 
the hydrochloride salt and small amounts of the disulfide-bridged product (117). 
Functionalization with DTNB under acidic or basic conditions failed to deliver the 
desired product, therefore, neutral conditions under buffer control seemed to be the 
most suitable conditions for this test. The optimization of this reaction was not 







4.3.5 Summary of the advances towards LS2 
In summary, LS2 could not be synthesized completely, even though several important 
advances toward the synthesis could be realized (Figure 4.3.5-1): 
For the monosubstituted structure, a reasonable approach was found to deliver the 
bromide precursor (103) in multi-gram quantities, ready for the implementation of the 
acid groups, in three steps with an overall yield of 13% starting from commercially 
available compounds. 
For the disubstituted structure, a promising although expensive method could be 
established affording the chloride precursor (114) in multi-gram quantities, ready for 
the implementation of the acid groups. 
Reaction conditions for the dye-functionalization of either the mono- or the 
disubstituted lead structure were investigated and a reliable protocol for the conversion 
of the primary alcohol to the corresponding thiol could be presented. 
 
Figure 4.3.5-1. Synthesized precursors and the free thiol as a model reaction. 
The synthesis of LS2 related compounds was very tedious and many different 
approaches had to be tested. On the contrary, the synthesis of the LS1 and LS3 
derived structures was more straightforward. Therefore, no optimization of the 











4.4 Synthesis of the molecular library based on LS3 
 
LS3 consisted of a biphenyl motif that was symmetrically substituted with methyl 
groups carrying the respective acid residues. The biphenyl core itself could either be 
fluorinated or non-fluorinated (Figure 4.4-1). 
 
Figure 4.4-1. The two substructures of LS3. 
The fluorinated structure was chosen as potential candidate to investigate the 
possibility of a covalent bond with the two Cys111 of SOD1 via nucleophilic aromatic 
substitution (Figure 4.4-2) while the protonated structure was used for comparison. 
 
Figure 4.4-2. Mechanism of the intended nucleophilic aromatic substitution. 
 
4.4.1 The fluorinated LS3 
The retrosynthetic analysis of LS3 showed a large similarity to the structures 
mentioned before since the acid groups were to be implemented analogically. The only 
difference was the fact that for LS3 one would need to introduce those acid groups 
starting from alkyl bromides instead of aryl bromides. Other than that, the retrosynthetic 





Figure 4.4.1-1. A: Retrosynthetic analysis of LS3. B: Adjusted synthesis of the different acid 
moieties.[113,127,128] 
Any acid required can be synthesized from a bromide precursor following the reactions 
depicted in Figure 4.4.1-1-B. The syntheses are largely similar to the acid syntheses 
used for LS1. The bromide precursor is accessible via bromination of the methylated 







As shown in Figure 4.4.1-1-A, the synthesis started from the commercially available 
decafluorbiphenyl (119). Methylation of this compound would give the required 
dimethyl compound (120) and was achieved by nucleophilic aromatic substitution with 
methyllithium at low temperatures in Et2O and THF. This reaction proceeded with a 
yield of 39%. Bromination was performed according to a literature protocol using NBS 
in refluxing CCl4 without the addition of a catalyst or radical starter and yielded the 
dibromide precursor in 70% yield (121).[129] The syntheses of the acids were performed 
according to Figure 4.4.1-1. 
Reacting the dibromide (121) with sodium cyanide in DMSO gave rise to the dinitrile 
compound (122), which was used without further purification. Unfortunately, all efforts 
to hydrolyze the nitriles to carboxylic acids (123) were unsuccessful (see Figure 4.4.1-
2). It is assumed that the benzylic position was too reactive under strongly alkaline 
reaction conditions due to the very strong electron withdrawing effects of the 
perfluorinated aromatic system, leading to SNX-like side reactions. 
 
Figure 4.4.1-2. Unsuccessful synthesis of the fluorinated carboxylic acid. 
The synthesis of the phosphinic acid was conducted by heating HMDS and ammonium 
hypophosphite for 2 h in an atmosphere of argon, followed by the addition of the 
dibromide precursor (121) (Figure 4.4.1-3).[127] The product was obtained after acid-
base extraction, but the purity was insufficient for biophysical assays. Unfortunately, 
all efforts to purify the product via HPLC failed, even though the molecule was identified 
with mass spectrometry and NMR, the synthesis was deemed unsuccessful. 
 





The phosphonic acid was synthesized in a two-step sequence. First, the dibromide 
precursor (121) was subjected to typical Arbusow conditions employing P(OEt)3 with 
heating. The resulting diphosphonate ester (125) was then cleaved with TMSBr under 
McKenna conditions.[110] Precipitation from acidic media gave rise to the desired  
product (19) in 32% combined yield (Figure 4.4.1-4). 
 
Figure 4.4.1-4. Synthesis of the fluorinated phosphonic acid. 
The synthesis of alkyl boronic acids was synthetically challenging and one literature 
protocol was tested. The dibromide (121) was submitted to a palladium-catalyzed 
cross coupling with B2pin2 as the coupling partner in tBuOH with the addition of several 
additives, but the starting material was reisolated (Figure 4.4.1-5).[128] The different 
solubility properties of the dibromide precursor and the salt-additives could explain the 
failure of this reaction since neither was soluble enough in the alcoholic reaction 
medium. Changes to the solvent may prove beneficial to this synthesis, fluorinated 
solvents may prove to be especially suited to solubilize fluorinated structures. 
 
Figure 4.4.1-5. Unsuccessful synthesis of the fluorinated boronic acid. 
The sulfonic acid of the fluorinated structure was successfully synthesized by reacting 
the dibromide (121) with sodium sulfite in a solvent mixture of acetone and water with 
heating. The product (20) was obtained after precipitation from strongly acidic water in 






Figure 4.4.1-6. Synthesis of the fluorinated sulfonic acid. 
 
4.4.2 The non-fluorinated LS3 
The retrosynthetic analysis for the non-fluorinated structure of LS3 was largely the 
same as for the fluorinated structure since the synthesis of the acid moieties was 
untouched by the change in the biphenyl core. The acids were synthesized according 
to Figure 4.4.1-1-B from the non-fluorinated dibromide precursor. The dibromide was 
accessible through bromination of the diol starting material (127) (Figure 4.4.2-1). 
 
Figure 4.4.2-1. Retrosynthetic analysis of the protonated LS3. 
The commercially available 4,4’-bis(hydroxymethyl)biphenyl (127) was brominated 
using PBr3 and a catalytic amount of pyridine in diethyl ether (Figure 4.4.2-2). The 
product (128) was obtained in 85% yield after liquid extraction and recrystallization 
from a mixture of methanol and diethyl ether. 
 
Figure 4.4.2-2. Synthesis of the dibromide precursor (128). 
Other than that, the reactions were done using the exact same protocols as described. 





The following LS3 related molecules were synthesized during this thesis (Figure 4.4.2-
3). 
 
Figure 4.4.2-3. Overview of the synthesized LS3 related molecules. 
 
The yields of all syntheses related to LS3 are given in table 4.4.2-1.  
Table 4.4.2-1. Overview of the LS3 related syntheses. 
Structure Conditions Yield (%) 
120 119, 2.5 MeLi, THF, Et2O, -78 °C 39 
121 120, 2 NBS, CCl4, T 73 
123 121, 3 NaCN, DMF, T then KOH, H2O, EtOH, T / 
124 121, NH4H2PO2, HMDS, cat. Pd2dba3, cat. XantPhos, DCM, 
T 
/ 
19 121, P(OEt)3, T then 10 TMSBr, DCM then MeOH, T 32 
126 121, 2.5 B2pin2, cat. Pd2dba3, cat. DMBMe2P*HBF4, 4 K3PO4, 
20 H2O, DMBOH, T then 20% HCl, T 
/ 
20 121, 2.5 Na2SO, acetone, H2O, T. 29 
128 127, 2.5 PBr3, Et2O, 0.1 pyridine, T 78 
129 128, 3 NaCN, DMF, T then KOH, H2O, EtOH, T * 
22 128, 3 NH4H2PO2, 3 HMDS, cat. Pd2dba3, cat. XantPhos, 
DCM, T 
17 
23 128, excess P(OEt)3, T then 10 TMSBr, DCM then excess 
MeOH, T 
68 
130 128, 2.5 B2pin2, cat. Pd2dba3, cat. DMBMe2P*HBF4, 4 K3PO4, 
20 H2O, DMBOH, T then 20% HCl, T 
/ 
24 1 a, 2.5 Na2SO, acetone, H2O, T 88 




As can be seen from Table 4.4.2-1, the synthesis of some acid moieties varied 
drastically in terms of yield when comparing the non-fluorinated and the fluorinated 
structure. The non-fluorinated sulfonic acid (24) was synthesized in 88% yield whereas 
the fluorinated sulfonic acid (19) could only be synthesized in 32% yield. This was 
attributed to different solubilities in water because both acids were precipitated from 
highly acidic solutions and were not purified further due to their highly polar nature. A 
similar picture emerges when comparing the phosphinic acids. The non-fluorinated 
phosphinic acid (22) was synthesized in 17% yield while the fluorinated structure (124) 
could not be synthesized at all. This was due to significant amounts of byproducts that 





















4.5 UV/VIS- and fluorescence properties of the Lead Structures 
 
The UV/VIS and fluorescence properties of the lead structures were important because 
they determined what biophysical assay could be utilized. Fluorescence Anisotropy 
required a fluorescent molecule and an unlabeled protein. Microscale Thermophoresis 
did require labeling of the protein and potential fluorescence emissions should not 
overlap with the emission of the ligand that was used. 
Table 4.5-1. UV/Vis and Fluorescence data of the synthesized compounds. Abs = Absorption, Em = 









1 330/440 2 327/445 
2 328/440 3 328/440 
3 329/440 4 332/445 
4 332/444 10 323/409 
5 329/439 11 317/409 
6 326/432 12 320/409 
7 331/437 13 314/407 
8 328/432 14 309/403 
9 330/440 15 311/400 
  16* 327/412 
  17* 322/411 
  18* 323/409 
  19 245/320 
  20 241/324 
  21 260/321 
  22 263/323 
  23 264/324 
  24 262/318 
 
* 20% DMSO was included in the buffer. a: HEPES (100 mM), NaCl (150 mM), pH 7.4  
b: 50 mM sodium phosphate, pH 7.4 
As can be seen from Table 4.5-1, LS1 and LS3 were fluorescent. In the following 





4.5.1 Optical properties of LS1 
 
Figure 4.5.1-1. A: Absorption spectra for the synthesized carboxylic acids in HEPES buffer (100 mM 
HEPES, 150 mM NaCl, pH 7.4). The kink at 340 nm results from a light source switch during the 
measurement. B: Emission spectra for the synthesized carboxylic acids in HEPES buffer (100 mM 
HEPES, 150 mM NaCl, pH 7.4) 
Initially, the carboxylic acids were characterized in terms of their optical properties. As 
can be seen in Figure 4.5.1-1-A, all synthesized carboxylic acids showed similar 
absorption maxima which were between 326 nm and 332 nm. However, the observed 
absorbance varied significantly between the different variants. Meanwhile, no 
regularity between the N-substitution-residues could be observed, which is evident in 
that both the highest (3, TFB) and the lowest (2, DMB) absorbance result from alkyl 
residues. It must be noted that the carboxylic acids could not be easily dissolved in 
HEPES buffer, which might have resulted in inaccurate stock solutions. The final 
concentrations might not have been precisely the same for every acid, which could 
explain some of the drastic differences observed in absorbance intensity.  
The emission spectra for LS1_C confirmed that the synthesized carboxylic acids were 
fluorescent (Figure 4.5.1-1-B). The emission maxima were relatively similar and 
between 432 nm and 444 nm. The emission intensity showed no regularity just as was 
observed for the absorbance intensity of the investigated carboxylic acids. As most of 
our studies were carried out in sodium phosphate buffer, the most promising ligand 







Figure 4.5.1-2. A: Absorption spectra of LS1_MCH in sodium phosphate buffer (50 mM sodium 
phosphate, pH 7.4). B: Emission spectra of LS1_MCH in sodium phosphate buffer (50 mM sodium 
phosphate, pH 7.4). 
As can be seen in Figure 4.5.1-2-A, for MCH-substituted LS1 variants a similar 
absorption maximum between 340 and 350 nm could be observed. The boronic acid 
structure (16) showed a significantly smaller absorption peak than the other three acid 
residues, whose intensities were comparable. This was not reflected in the emission 
data since the emission intensity of the carboxylic acid structure was noticeably lower 
compared to the other structures (Figure 4.5.1-2-B, compare with Figure 4.5.1-1-B). 
The replacement of the carbon atom of the carboxylic acid residue with different 
heteroatoms (P and B) could possibly influence the electron density in a way that the 
resulting emission bands were distinctly shifted. The fact that both phosphorous-based 
acids (10) and (13) also showed a difference of approximately 30% in terms of intensity 
confirmed this hypothesis. The emission maxima of the heteroatom-acids were within 
10 nm from one another, whereas the emission maximum of the carboxylic acid was 







Figure 4.5.1-3. A: Absorption spectra of LS1_DMB in sodium phosphate buffer (50 mM sodium 
phosphate, pH 7.4). B: Emission spectra of LS1_DMB in sodium phosphate buffer (50 mM sodium 
phosphate, pH 7.4). 
The general trend that could be observed for LS1_MCH was also seen for LS1_DMB 
in that the boronic acid (17) showed the lowest absorption maximum  
(Figure 4.5.1-3-A). However, the intensities of the peaks were much more comparable. 
Again, all four absorption maxima were similar and in the range of 317 – 323 nm. 
The emission spectra for the 3,3`-dimethylbutyl-substituted lead structures confirmed 
the observed trend: All heteroatom-acids showed intensive emission, whereas the 
carboxylic acid showed very weak emission while experiencing a shift in maximum of 
approx. 25 nm (Figure 4.5.1-3-B). This meant that the differences in optical properties 









Figure 4.5.1-4. A: Absorption spectra for LS1_TFB in sodium phosphate buffer (50 mM sodium 
phosphate, pH 7.4). B: Emission spectra for LS1_TFB in sodium phosphate buffer (50 mM sodium 
phosphate, pH 7.4). 
The 4,4,4-trifluorobutyl-substituted structure showed similar reults compared to the two 
structures already discussed. The absorption spectra had maxima in the range of 309 
to 314 nm, the only noticeable difference was that the boronic acid (18) showed a more 
intensive absorbance than the corresponding phosphonic acid (15) (Figure 4.5.1-4-A). 
The same was observed for the emission, the boronic acid showed a higher intensity 
than the phosphonic acid, while the carboxylic acid showed a significantly decreased 
intensity and shift towards higher wavelengths (Figure 4.5.1-4-B).  
In summary, LS1 showed fluorescence for all acid moieties. The carboxylic acids 
showed the highest absorbances and the lowest emission intensities, resulting in a 
weak overall fluorescence. All other three acids showed comparable absorbance and 












4.5.2 Optical properties of LS3 
LS3 variants were characterized in terms of their optical properties using sodium 
phosphate buffer. The following curves were obtained: 
 
Figure 4.5.2-1. A: Absorption spectra for LS3 in sodium phosphate buffer (50 mM sodium phosphate, 
pH 7.4). B: Emission spectra for LS3 in sodium phosphate buffer (50 mM sodium phosphate, pH 7.4). 
As can be seen in Figure 4.5.2-1-A, the absorption maxima of all investigated 
structures were in a rather narrow wavelength range of approx. 23 nm. The fluorination 
seemed to play a larger role on the absorbance than the nature of the acid moiety. This 
can clearly be seen when comparing the non-fluorinated sulfonic acid (24) and the 
fluorinated sulfonic acid (20): The intensities of the absorbance were roughly similar 
but the wavelengths were shifted by 21 nm, the fluorinated structure was red-shifted 
compared to the non-fluorinated structure. The same was true for phosphonic acids 
(23) and (19). 
The emission spectra of LS3 revealed a large difference between the non-fluorinated 
and the fluorinated structures in terms of fluorescence properties (Figure 4.5.2-1-B): 
The non-fluorinated structures (21-24) showed a far greater intensity than the 
fluorinated structures (19 and 20), the difference roughly equaled to a factor of 20. This 
phenomenon can be explained by the very electron-withdrawing nature of the fluorine 
atoms that leads to a very low electron density in the aromatic rings. Excitation by light 
leads to an excited electronic state, this photoexcitation can be quenched almost 
immediately by delocalisation onto the eight fluorine atoms. None of the four non-
fluorinated structures showed the same effect, in fact, their curves were similar in terms 




similar spectrum as the other acids. This is a clear difference to all investigated 
structures from LS1, where the carboxylic acid structures showed significantly weaker 
emission (compare Figures 4.5.1-1-B, 4.5.1-2-B, 4-5.1-3-B and 4.5.1-4-B). This meant 
that heteroatom-substitution did not seem to play a major role for fluorescence in LS3. 
In summary, LS3 showed fluorescence for all presented non-fluorinated acids. The 
fluorinated structures showed only weak emission while having comparable absorption 
properties, which meant that their overall fluorescence could be regarded as low. All 
non-fluorinated structures exhibited strong fluorescence with comparable absorption 





















4.6 Protein Expression 
 
The protein expression was performed under the supervision of Lisa-Marie Funk in the 
group of Prof. Kai Tittmann. Using the expression protocol from the group of Prof. 
Samar Hasnain who generously donated the plasmid vector, hSOD1 wt and the mutant 
A4V could be acquired. The plasmid vector pET303C-hSOD1wt was replicated in E. 
Coli, subtype BL21 StarTM (DE3). Transcription of the lac-operon was induced by IPTG 
and the expression of the desired protein was carried out by the T7-RNA-polymerase. 
In order to determine the optimal harvesting time, samples were drawn each hour and 
the optical density was determined at 600 nm. The cells were harvested after an 
incubation time of 20 hours, yielding approximately 32 g of cells from 6 L of culture. 
SDS-page analysis of the hSOD1 wt expression is shown in Figure 4.6-1. 
 





Afterwards the cells were disrupted and purified; the general procedures are given in 
the experimental section of this thesis. The resulting SDS-pages showed that the 
obtained protein was sufficiently pure for its use in later stages. In addition, no great 
loss of protein in the cell pellets could be observed. 
 
Figure 4.6-2. 15% SDS-page of the hSOD1 wt purification. S: Supernatant. P: Pellets. Load and 
Elution: TMAE chromatography purification fractions. 
As can be seen from Figure 4.6-2, the amount of protein lost during loading steps was 
negligible. No perfect separation of protein factions could be achieved, as early elution 
fractions contained considerable amounts of undesired side products with a molar 
weight between 40 and 60 kDa. These fractions were discarded and only the pure 
fractions that were obtained in later stages of the chromatography were used for further 
purification. The yield of the purification was approximately 60 mg of pure protein from 
1 g of cells. Afterwards, both cofactors (Cu, Zn) were reconstituted, yielding 17-20 mg 
of pure hSOD1 wt from 1 g of cells (the protocol that was used for the reconstitution of 
both cofactors is given in the experimental section). 
Following the outlined expression and purification protocol, the A4V mutant could be 
obtained in comparable yields after a similar number of steps. As expected, the stability 
of this mutant was smaller compared to that of the wildtype, especially before both 
cofactors were introduced. This might have resulted from a literature-known deficiency 
in the affinity for zinc ions, which could also explain the lower yield (85% of the wt 
yield).[130] In summary, hSOD1 wt and its A4V mutant could be expressed, purified and 






4.7 Activity analysis 
 
The activity of a protein is usually a good indicator for its successful expression or 
stability and can be measured by activity assays. Prior to activity analysis, the 
existence of a stable protein dimer had to be confirmed, since the activity of the dimer 
was used as a baseline for comparison. Thus, multi angle light scattering was 
employed to determine the molar mass of the protein in question, and a tight dimer 
with a mass of approximately 28 kDa could be identified (Figure 4.7-1, left). Afterwards, 
size exclusion chromatography was used to analyze the protein further; the data was 
in very good agreement with the MALS-data (Figure 4.7-1, right) 
 
Figure 4.7-1. Left: MALS data for hSOD1 wt. Right: SEC data for hSOD1 wt (orange), Biorad standard 
(blue). Biorad standard curve is depicted in the appendix. Pictures provided by Viktoria Mrđen Debono. 
Additional SEC experiments also confirmed a high tendency to aggregate for the A4V 
mutant when compared to the hSOD1 wt. As expected, the A4V apo variant in 







Figure 4.7-2. Left: SEC of hSOD1 wt. Right: SEC of A4V apo (orange) and holo (blue). Pictures provided 
by Franziska Otto. 
In this thesis an indirect assay based on Xanthine Oxidase, commercially available as 
a SOD test kit, was used to measure the activity of the wild type SOD1 as well as for 
the A4V mutant. The underlying catalytic cycle is described in Figure 4.7-3. 
 
Figure 4.7-3. Catalytic cycle of the commercially available SOD assay kit. 
Xanthine Oxidase catalyzes the reaction of xanthine to uric acid in the presence of 
oxygen, producing hydrogen peroxide as a side product. In a second, connected cycle, 
superoxide radicals are being produced from free oxygen, which in turn react with a 
molecule called WST-1. The product of this reaction is a formazan dye whose 
absorbance can be measured between 420 and 480 nm.[131] Upon addition of the 




inhibited. This is because SOD1 catalyzes the disproportionation of superoxide 
radicals into oxygen and hydrogen peroxide; therefore, they cannot participate in the 
xanthine oxidase cycle. The assay is indirect because instead of measuring the 
reaction rate of the disproportionation reaction (catalyzed by SOD1) the inhibition of a 
second reaction is measured. Nevertheless, quantitative values can be obtained in this 
manner. 
The catalytic activity of the fully reconstituted hSOD1 wt could be confirmed by means 
of this assay (see Figure 4.7-4). Furthermore, copper-deficient hSOD1 showed a 
significantly lower activity that was comparable to that of bovine SOD1. This again 
proved the point that copper is essential for the catalytic activity of the protein whereas 
zinc increases the overall structural integrity of SOD1.[132,133] Since all target structures 
were generally well soluble in aqueous buffer solutions, no experiments were 
performed investigating the effects of co-solvents like DMSO, PEG or glycerol on the 
activity assay.  
 
Figure 4.7-4. Activity assay of hDSOD1 wt. Left: Time-dependent absorption curve of the assay. Right: 
Slope diagram of the time-dependent measurement. Pictures provided by Lisa-Marie Funk. 
Furthermore, a significantly reduced activity of hSOD1 A4V holo/apo could be 
confirmed with the activity assay (Figure 4.7-5). The wild type showed a reaction 
inhibition that was approx. 15 times higher than the reaction inhibition observed for 
A4V. The differences between apo- and holo-enzyme of the respective types were 
negligible concerning the large relative errors. Measurements at higher concentrations 





Figure 4.7-5. Acitivity of hSOD1 wt and hSOD1 A4V shown as the reaction inhibition in phosphate buffer 
(50 mM sodium phosphate, pH 7.4). Raw data was obtained from Viktoria Mrđen Debono and Franziska 
Otto. 
 
4.8 Binding studies of LS1 and LS3 to SOD1  
4.8.1 Fluorescence Anisotropy of the LS1_C library 
The first lead structures that were synthesized were from the library of different N-
substituted carboxylic acids derived from LS1. A fluorescence anisotropy screening of 
these structures was performed by dissolving the ligand in an appropriate buffer (50 
mM sodium phosphate buffer) with a concentration of 40 µM and the protein in a 
concentration of 250 µM. The resulting mixture was incubated for 2.5 h and afterwards 
the anisotropy was recorded and compared to the anisotropy of the free ligand (40 µM 
in the same buffer). The anisotropy was recorded against a “single point”, which was 
defined through the absorption and emission wavelengths that were obtained before 
under the same solvent conditions (50 mM sodium phosphate buffer). In this way, the 
temperature and all other parameters were kept constant throughout the experiments; 
specific protocols can be found in the experimental section. 





Figure 4.8.1-1. Fluorescence anisotropy of LS1_C. The obtained values and the corresponding errors 
are given. The Benzyl-substituted structure show no error due to two negative results out of three 
triplicates. 
As can be seen from Figure 4.8.1-1, the overall  Anisotropy did not have a large value; 
this can be explained by the following hypotheses: 
1. The incubation time might have been too low in order to achieve binding to the 
protein. After measuring one of the samples on the next day, no significant 
change could be observed. This meant that the explanation was either wrong 
or that the binding was weak in general. 
2. The concentration of the ligand might have been not high enough in order to 
achieve binding of any meaningful quantity. Even though this was a plausible 
hypothesis it would mean that even a 6.25-fold excess of the protein was not 
enough to show binding of the ligand to the protein which again would justify 
calling the interaction weak binding. 
3. The fluorescence lifetime of the excited state was too short compared to its 




addition, the overall  Anisotropy does not say anything about the strength of 
the binding on its own. 
The results from this assay were utilized in determining the substituents that were best 
suited for following synthesis. This was because synthesizing each organic acid with 
all 10 residues would have been beyond the scope of this thesis. The following three 
























4.8.2 MST binding studies of LS1 and LS3 
Microscale Thermophoresis was the most important biophysical assay during this 
thesis due to several factors: First, the amount of protein necessary is lower compared 
to other techniques such as Anisotropy or ITC. Second, multiple measurements can 
be carried out in a short time. Third, the assay requires a labelled protein that was 
already prepared in our working group and was provided by Viktoria Mrđen Debono. It 
was used in all MST measurements of all compounds. Furthermore, the results 
obtained had significantly smaller errors compared to those obtained by other 
biophysical techniques. The general procedure that was used for MST measurements 
is depicted in the Experimental Section of this work. 
 
4.8.2.1 MST results for LS1 
As discussed in chapter 4.5.1, LS1 variants were fluorescent, and the emission 
wavelength made us suspect a potential influence on the dye for the protein labelling. 
It turned out that the highest concentrations in each measurement showed 
photobleaching, these values were probably the result of an interference of the ligand 
and the dye. It was concluded that the photobleaching was induced either by the ligand 
binding to the protein or by fluorescence interference. Therefore, the highest 
concentrations and the respective MST signals were ignored and taken out of 
consideration when scanning for a Kd–value, since at lower concentrations no 
bleaching or quenching could be observed. This procedure ensured that the results 
were not influenced by either ligand induced photobleaching or fluorescence 
interference, as was confirmed by the NANOTEMPER software that does not allow 
determination of a Kd-value when unknown factors signal photobleaching.  
The phosphorus-based structures were examined first, since in silco studies showed 









Figure 4.8.2.1-1. MST binding curve for LS1_MCH_O. Kd = 47 ± 17 µM. 
LS1_MCH_O gave a Kd-value in the medium µM-range, which was in accordance to 
the in silico screening (Figure 4.8.2.1-1). The S/N ratio was sufficiently high with a 
value of 10.33 and the response amplitude was 8.03.  
 
Figure 4.8.2.1-2. MST binding curve for LS1_DMB_O. Kd = 43 ± 18 µM. 
Similarly, LS1_DMB_O gave a Kd-value in the medium µM range, which was expected 
due to the similar chemical structure (Figure 4.8.2.1-2). The S/N ratio of 8.00 was lower 
as well as the response amplitude of 3.50, but since these values were still well over 
the threshold, the obtained Kd-value had a high probability of being valid. This ligand 
also showed the least amount of photobleaching, which resulted in only one full data 






Figure 4.8.2.1-3. MST binding curve for LS1_TFB_O. Kd = 107 ± 62 µM. 
LS1_TFB_O also showed moderate binding to the protein, but it had the worst Kd-value 
of all phosphonic acid derivatives (Figure 4.8.2.1-3). This was explainable considering 
the trifluoromethyl group could be considered a large deviation from the purely alkyl-
substituted structures that were examined before. It also had the largest error relative 
to the binding strength, the lowest S/N ratio of only 6.29 and the lowest response 
amplitude of only 1.87. The fluorination did not seem to improve the binding to the 
protein, even though more hydrogen bonds would be formed compared to the alkyl 
substitution units discussed before. This could be a hint that hydrophobic interactions 
play a major role in the binding to the cavity of Cys111 as could be expected due to its 
proximity to the dimer interface, which is largely influenced by those interactions. 
 





The phosphinic acids generally gave higher Kd-values than the phosphonic acids. The 
first measured phosphinic acid showed very weak binding to the protein and saturation 
was not achieved (Figure 4.8.2.1-4). Therefore, the response amplitude and the S/N 
ratio had very high values since the software assumed a very high Kd-value. The S/N 
ratio was 29.33 and the response amplitude was 24.20. This result was unexpected 
because the structure of the phosphinic acid moiety is almost identical to that of the 
phosphonic acid, which gave respectable binding properties. Nevertheless, unknown 
factors such as binding modes, binding locations or self-clustering of the ligand could 
have played a role in the results observed. 
 
Figure 4.8.2.1-5. MST binding curve for LS1_TFB_I. Kd = 207 ± 64 µM. 
In contrast, the 4,4’,4’’-trifluorobutyl-substituted phosphinic acid showed much stronger 
binding to the protein than the aforementioned derivative, the S/N ratio was 13.01 and 
the response amplitude was a low 3.76 (Figure 4.8.2.1-5). This meant that these results 
were most likely valid and proved that the phosphinic acid moiety can be used in order 
to enable binding to the protein. The Kd-value was still almost two-fold worse compared 
to its phosphonic acid counterpart, which again reemphasizes the superiority of the 
phosphonic acid moiety over the phosphinic acid moiety. This was even more so 
demonstrated by the fact that the 3,3’-dimethylbutyl-substituted phosphinic acid did not 
show any binding to the protein and exhibited excessive photobleaching, that rendered 
evaluation of the obtained data impossible. 
The carboxylic acid structures of LS1 were also measured with MST, but no binding to 




tedious compared to the phosphorous-based ligands due to lower solubility and a 
tendency to aggregate or to show adsorption to the cuvette. 
In summary, the phosphorus-based structures of LS1 were successfully measured by 
means of MST and showed binding in the middle µM range for all phosphonic acid 
derivatives regardless of N-substitution and weak or no binding for the phosphinic acid 
derivatives.  
 
4.8.2.2 MST results for LS2 
The synthesis of a final structure was not successful; therefore, no ligands could be 
measured. Nevertheless, in order to evaluate the overall fluorescence properties and 
the suitability of the core structure for MST, LS2_NH2_C was measured. 
 
Figure 4.8.2.2-1. MST binding curve for LS2_NH2_C. Kd = 10.2 ± 1.1 mM. 
As can be seen, no saturation of the curve could be achieved (Figure 4.8.2.2-1). This 
was partly because the solubility of the investigated structure was surprisingly bad in 
aqueous buffer and low concentrations had to be used. A very weak binding could be 
observed, the corresponding S/N ratio was 13.8 and the response amplitude was 10.9. 
It must be emphasized that binding of such magnitude was expected, since the 
structure was not the final ligand and the free, basic amine could potentially engage in 
a variety of unwanted binding modes or interferences with the protein. The general 




or quenching upon binding could be observed. This was also expected since no 
fluorescence of LS2 could be observed. 
4.8.2.3 MST results for LS3 
As discussed in chapter 4.5.2, LS3 variants were fluorescent, and the emission 
wavelength did not overlap with the fluorophore in the relevant wavelength range. 
The following binding curves and corresponding Kd – values were obtained: 
 
Figure 4.8.2.3-1. MST binding curve for LS3_H_O. Blue: 10% MST power. Red: 40% MST power. 
Kd = 3.3 ± 1.6 mM (blue), 2.5 ± 2.0 mM (red). 
The first ligand that was examined was the phosphonic acid derivative of the non-
fluorinated lead structure, because phosphonic acids gave the best docking score, the 
synthesis was straightforward, and the molecule could be obtained in large quantities 
(Figure 4.8.2.3-1). In addition, the solubility was the best among all of the acid residues; 
therefore, the general handling of MST probes was optimized using this ligand. 
Variation of the incubation time did not show a significant change in the results as was 
already established in the working group before (data not shown). The same batch of 
ligand was measured with the same batch of labeled protein at two different days using 
MST powers of 10% (red curve) and 40% (blue curve) respectively. The corresponding 
S/N ratios were 13.1 and 6.89, the corresponding response amplitudes were 3.15 and 
2.14. It was concluded that using lower MST power led to better results in terms of 
data significance whilst giving similar Kd-values. Therefore, the MST power was always 
chosen as low as possible. In general, the error range was very large; this was mainly 




was soluble in the chosen sodium phosphate buffer. Unfortunately, the use of a co-
solvent like DMSO or methanol led to a decrease in solubility. In our case, this 
preliminary result was sufficient, because it proved weak binding between the 
phosphonic acid residues of the ligand structure and the protein and opened the 
possibility of observing a general trend between different ligands. 
 
Figure 4.8.2.3-2. MST binding curve for LS3_F_O. Kd = 1.95 ± 1.18 mM. 
Comparably, the fluorinated phosphonic acid was shown to bind weakly with a Kd of 
1.95 ± 1.18 mM (Figure 4.8.2.3-2). The S/N ratio of 5.99 and the response amplitude 
of 4.74 did not allow for clean data evaluation and the resulting binding curve was 
noisy. This was mainly attributed to the lower solubility of the fluorinated structure. The 
obtained Kd-value was in the mM range, comparable to the non-fluorinated structure. 
 




The fluorinated sulfonic acid did not show stronger binding, and a Kd of  
1.13 ± 0.75 mM was recorded (Figure 4.8.2.3-3). The S/N ratio of 7.98 was sufficiently 
high; unfortunately, the response amplitude of 2.78 was rather low and led to large 
uncertainties. For the same reasons as mentioned above, this result was considered 
sufficient to observe a general trend. Interestingly, the non-fluorinated derivative 
showed no binding at all, even though it was more soluble in the buffer and allowed for 
a greater spectrum of concentrations in the assay. Up to this point, the reason for the 
different behavior is unknown. 
 
Figure 4.8.2.3-4. MST binding curve for LS3_H_I. Kd = 151 ± 93 µM. 
The best results for LS3 were achieved for the non-fluorinated phosphinic acid, which 
showed moderate binding in the µM range, the S/N ratio was 5.81 and the response 
amplitude was 5.65 (Figure 4.8.2.3-4). Saturation appeared to be sufficient; 
unfortunately, no comparison with the fluorinated structure could be made because it 
was impossible to synthesize it. The phosphinic acids gave the second best docking 
results next to the phosphonic acids, therefore it was concluded that phosphorous-
based structures were most likely the best for an affinity based ligand-protein complex. 
It also meant that there was a high probability that the in silico results were valid 
It needs to be noted that aggregation as well as adsorption were major issues during 
measurements even though precautions were taken to avoid these literature-known 
mistakes (low binding tips, low binding tubes, premium capillaries).[134] This 
unfortunately resulted in somewhat large error bars for some of the MST signals 
obtained. This could be overcome by measuring more triplicates with subsequent 




in the scope of this thesis. Instead, the general concept of binding to SOD1 with the 
help of symmetrically aligned acid residues was proven by these measurements. It 
should be noted that no information about stoichiometry or binding mode, i.e., the 
location where the binding event occurred, could be obtained with the MST assay. 
 
4.8.3 Results of ITC measurements 
As was already described before, ITC was used sparingly in this thesis. LS1_MCH_I 
was chosen as a model system to answer three different questions: 
First, the water solubility of the pyrrole-based LS1 was expected to vary drastically 
from the well-soluble library of LS3, this could have limited its suitability for ITC. The 
result of this test was positive; LS1_MCH_I confirmed the general suitability of the core 
structure for ITC since it was soluble in sufficient amounts in aqueous buffer. 
Secondly, the already described MST measurements of this substance needed to be 
confirmed with a second method. Since Fluorescence Anisotropy failed to deliver a 
positive result, ITC was the method of choice and it was possible to show potential 
binding to the protein in a similar magnitude of strength.  
Lastly, ITC measurements performed at early stages of the project showed a potential 
problem for the entirety of the pyrrole based LS1, because self-assembling of the 
aromatic systems was a possibility. This could in turn mask the ITC signal since 
aromatic interactions tend to be rather strong. In order to test whether this was a 
general problem, the methylcyclohexyl-substituted pyrrole was chosen as a model 










Table 4.8.3-1. ITC results for LS1_MCH_I. 
LS1_MCH_I N (sites) 
(set to 1) 
Kd (mM) H (kcal/mol) G (kcal/mol) -TS (kcal/mol) 
20mM RSLS1 
300µM hSOD1 
1 8.41 ± 0.88 2.79 ± 0.22 2.83 - 0.04 
20mM RSLS1 
175µM hSOD1 
1 4.09 ± 0.27 1.31 ± 0.06 3.26 - 1.95 
10mM RSLS1 
175µM hSOD1 
1 4.29 ± 0.794 1.34 ± 0.191 3.23 - 1.89 
10mM RSLS1_I_MeCY 
Time (min)
















S: 10mM RSLS1 C: 250µM hSOD1 wt
S: 10mM RSLS1 C: Buffer M
S: Buffer M C: 250µM hSOD1 wt
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S: 20mM RSLS1 C: Buffer M
S: 20mM RSLS1 C: 300µM hSOD1 wt
S: Buffer M C: 175µM hSOD1 wt
S: 20mM RSLS1 C: 175µM hSOD1 wt
 
Figure 4.8.3-1 Left: Raw data spectrum for 10 mM ligand. Right: Raw data spectrum for 20 mM ligand. 
Spectra were obtained by Lisa-Marie Funk. 
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S: 20mM RSLS1 C: 300µM hSOD1 wt
S: 20mM RSLS1 C: 175µM hSOD1 wt
S: 10mM RSLS1 C: 175µM hSOD1 wt
 





As can be seen from Table 4.8.3-1 and Figure 4.8.3-2, the data obtained could be 
evaluated and provided significant results. The observed binding strength was in the 
mM range, therefore the binding between the ligand and the protein was very weak. In 
addition, no clear saturation of the resulting binding curves could be achieved. This 
meant that the data was unreliable, and measurements needed to be executed again 
to obtain more data points. When comparing the Kd-values with the already discussed 
MST results of LS1_MCH_I (Figure 4.8.2.1-4) it became evident that the data obtained 
are all in the medium mM range. This means that the ITC measurements confirm the 
viability of the MST assay for measuring Kd-values. However, since a lot of protein and 
ligand were needed for ITC measurements, combined with the high time expenditure 
for this assay, no further ITC measurements were performed. 
 
4.9 Protein crystallization 
 
As was described earlier, the biophysical techniques that were used during this thesis 
could not be used to identify binding sites or binding modes, instead, X-Ray 
crystallography is the method of choice for identifying the nature of a protein-ligand 
complex. Several literature-known procedures for the crystallization of hSOD1 wt were 
tested, but they could not be reproduced successfully.[76,135] 
Because of that, an automated screen was performed by Elham Paknia from the 
working group of Prof. Holger Stark (structural dynamics) at the Max Planck Institute 
for Biophysical Chemistry Göttingen. The exact protocol is given in the experimental 
section. The best conditions from the automated screen were used to manually 
perform crystallization with the sitting-drop method and the hanging-drop method, an 





Figure 4.9-1. Crystals of hSOD1 wt. Buffer: 0.1 M MES, 0.2 M ammonium sulfate, pH 6.5, 20% 
PEG8000. Left: after three days. Right: After 10 days. 
Soaking experiments were undertaken with two ligands that were introduced in this 
thesis (LS1_MCH_I and LS1_DMB_B). Unfortunately, until today, no crystal structure 
of the protein-ligand complex could be obtained. This could be mainly attributed to 
three factors: 
1. The crystal quality itself was sufficient, but improvements need to be made. The 
corresponding resolutions were in the range between 2 and 3 Å while typical 
literature-known crystal structures result from crystals with resolutions around 1 
to 1.5 Å. 
2. The stability of the crystals needs to be increased. Small environmental 
changes such as pH, temperature, pressure, local solvent gradients or 
vibrational stress are able to destroy crystals or seriously damage them within 
seconds. In addition, the use of co-solvents in the cryoprotectant buffer needs 
to be optimized in a way that the resolution is not hampered. 
3. The soaking itself needs optimization since only very small soaking times could 
be realized because the soaking solutions quickly damaged the crystals. 
Published crystal structures of protein-ligand complexes usually have soaking 
times anywhere between 2 and 24 h. In our case, soaking times of a few 
minutes were possible, afterwards, the potential harmful effects of the soaking 
solution were deemed too large to continue the soaking process. 
Nevertheless, it was possible to obtain a refined crystal structure of hSOD1 wt by Lisa-






Figure 4.9-2. Refined structure of hSOD1 wt, derived from the crystals obtained by the experiments 

















5 Summary and outlook 
 
ALS is a fatal neurodegenerative disease with limited therapeutic options and no 
available cure. Mutations in the sod1 gene are responsible for ca. 10-20 % of all familiar 
ALS cases worldwide. Aggregation of mutated SOD1 protein is a recurring observation 
and plays a major role in the development of ALS in patients. Several aggregation 
pathways are discussed in the literature, but the dissociation of the homodimer 
structure into aggregation prone monomers seems to be one of the critical steps. 
The aim of the presented work was to synthesize small organic molecules with an 
affinity for the SOD1 protein that bear the potential to stabilize the dimer against 
dissociation or aggregation in ALS. Lead structures were identified through in silico 
screening that followed a structural analysis of the protein cavity around Cys111. The 
resulting structures were then ranked according to their putative binding energy, which 
was calculated by the open source platform swissdock.ch. Three chemically diverse 
lead structures were obtained, and their synthesis was envisaged (Figure 5-1). 
 
Figure 5-1. Chemical structures of LS1, LS2 and LS3. 
For LS1, a small library of molecules could be obtained that varied by the organic acid 
residue as well as by the N-substitution of the main pyrrole moiety. All desired 
molecules could be synthesized in amounts necessary for biophysical studies. The 
overall synthetic scheme for LS1 is shown in Figure 5-2. 
For LS2, the library synthesis was not successful, even though a large number of 
different methods and synthetic pathways were tried. A reasonable one-step procedure 
towards a possible chlorinated precursor for subsequent acid synthesis was presented, 
with the drawback of very expensive starting materials. Further optimization of the 





Figure 5-2. Synthetic approach for the library synthesis of LS1. 12 different molecules were synthesized. 
For LS3, another small library of molecules could be obtained that varied by the organic 
acid residue as well as the substitution of the core biphenyl structure. The fluorinated 
structures were to be tested in nucleophilic aromatic substitution reactions in order to 
investigate their potential to engage in covalent binding to the protein via the thiol 
moiety of Cys111. Up to this point, no reactivity towards nucleophilic aromatic 
substitution could be observed. The non-fluorinated structures served as a comparison 
to the fluorinated structure. The synthesis was performed according to Figure 5-3. 
 
Figure 5-3. A: Reactivity test for nucleophilic aromatic substitution. B: Synthesis of the protonated 





The next step was the expression and purification of hSOD1 wt and hSOD1 A4V 
proteins using standard protocols (see Experimental section for details). Both variants 
could be isolated in high purity, the A4V mutant showed significantly lower yields 
compared to the wild type, as was expected. In addition, the stability of the mutant was 
lower compared to the stability of the wild type, indicated by high molar mass 
aggregates after purification via anion exchange chromatography. Activity analysis 
showed a sharp loss in activity, which is in accordance with the literature. In summary, 
the wild type and one mutant could be isolated after expression and reconstitution; 
both showed the expected behavior in terms of activity and stability. 
Afterwards, binding studies were conducted using several different assays that were 
needed to confirm the in silico results. All ligands except for the boronic acid derivatives 
showed a sufficient solubility in water (up to 40 mM). The use of a co-solvent like 
DMSO or PEG4000 had a negative impact on the overall solubility of the ligands; 
therefore, the solubility was still the limiting factor for biophysical measurements. 
Fluorescence anisotropy was employed to screen the carboxylic acid based library of 
LS1 for the N-substituents that gave the highest binding (compare Figure 4.8-1). 
Afterwards, a microscale thermophoresis assay was developed and the resulting 
libraries of LS1 and LS3 were investigated in terms of their binding affinity. Aggregation 
and adsorption of samples, pipetting errors and the general sensitivity of the method 
were important factors to consider when the data was analyzed. Substantial errors and 
varying S/N ratios and/or response amplitudes between measurements of the same 
substance complicated the evaluation; nevertheless, a general trend could be 
observed regardless. The resulting structures that showed binding in the µM range are 


































































The obtained results show a correlation between the predicted binding energies from 
in silico studies and the MST assay in that the phosphonic acid residue was the best 
binding partners for SOD1, followed by phosphinic acid derivatives. The influence of 
the alkyl residue seemed to be less important than the impact of the acid moiety. 
Isothermal Titration Calorimetry was used to confirm already existing biophysical data, 
since it can be considered the gold standard of protein-ligand complex analysis.[136] 
The necessity of using large amounts of protein as well as the complicated procedure 
involved in measuring Kd-values prevented the use of ITC as a screening assay for the 
entire library. The Kd-value of LS1_MCH_I that was measured by means of MST could 
be confirmed by ITC. This meant that both methods could be used as complementary 







The next steps to improve the binding of potential ligands to the protein need to involve 
the crystal structure of the protein-ligand complex. Knowledge about binding sites and 
the exact nature of the interactions between both binding partners is mandatory in 
order to optimize lead structures. Molecular dynamics simulations could also help to 
identify and improve ligands for SOD1.  
The solubility of the ligands could also be improved by the addition of more polar 
groups to the aromatic systems of the lead structures. Another possibility would be the 
synthesis of the furan analogues of the LS1 derived pyrrole structures since the 
differences between the different N-substituents seemed largely negligible and their 
impact was impossible to predict with the utilized docking programs. Furthermore, 
omitting the very hydrophobic substituents would potentially increase the solubility of 
the resulting ligands. A possible synthetic pathway could make use of the dibromide 
precursor (120) that was already synthesized during the scope of this thesis (see 
Figure 5-4). 
 
Figure 5-4. Possible synthesis of furan analogues of LS1. 
In addition, the lead structures could also be extended by a methylene unit that would 
connect the acid moietiy to the benzene ring. Thereby the flexibility of the lead 
structures would be improved and the steric fit to the binding cavity could be improved. 






Figure 5-5. Possible synthesis of elongated analogues of LS1. 
On the protein side, more mutants should be expressed with the help of PCR 
techniques so that the biophysical assays can be expanded on to a broader range of 
ALS-associated proteins. Mutations that appear far from the dimer interface could 
potentially be used to gain information about the binding sites of ligands, since their 
binding modes could vary drastically between different mutants. Thereby it could be 
proven that the designed ligands show affinity to a variety of mutants instead of 
showing affinity to the wild type only. 
The development of improved conditions for biophysical assays (especially ITC 
techniques) deserves special attention since more than one assay has to be utilized in 














6. Experimental part 
 
This chapter covers all experiments, measurements and applied methods that were 
used to obtain the already mentioned results. The first part will depict organic synthesis 
and the corresponding analytical data. The second part will cover protein expression 
and all biophysical techniques that were performed in close collaboration with Lisa-
Marie Funk from the Schwann-Schleiden Forschungszentrum für molekulare 
Enzymologie, University of Göttingen. 
 
6.1 Ligand synthesis  
6.1.1 Analytics 
a) NMR spectroscopy 
NMR spectra were recorded on a BRUKER Avance III 300 or BRUKER Avance III HD 
500 device at the Institute for Organic and Biomolecular Chemistry, University 
Göttingen. Coupling constants are given in Hertz (Hz). Multiplicities are abbreviated 
as: singlet (s), broad singlet (br s), doublet (d), triplet (t), quartet (q), quintet (quint), 
doublet of doublets (dd). The internal standard for 1H- and 13C-spectroscopy was the 
solvent residue signal. Used solvents: CDCl3 (7.26 ppm, 77.16 ppm), MeOD-d4 
(3.33 ppm, 49.00 ppm), DMSO-d6 (2.50 ppm, 39.52 ppm), CD2Cl2 (5.32 ppm, 53.84 
ppm), THF-d8 (3.58 ppm + 1.72 ppm, 67.21 ppm + 25.31 ppm), D2O (4.79 ppm). 
b) Mass spectrometry 
Mass spectra were recorded on a BRUKER microTOF (ESI) or JEOL AccuTOF (EI) 
device. Applied ionization techniques were Electron Ionization (EI) or Electrospray 
Ionization (ESI). All shown data is given in m/z. 
c) UV/Vis-spectroscopy 
UV spectra were recorded on JASCO V-750 spectrometer using the associated 
software. Black quartz glass cuvettes from HELLMA ANALYTICS 104 and a light path 




substrate. The temperature was set to 25 °C, the scanning speed was typically 
200 nm/m, and the associated bandwidth was 2.0 nm.  
d) IR-spectroscopy 
IR spectra were recorded on a JASCO FT/IR 4100 A spectrometer. The substrates 
were used as solids or oils without any special treatment or capsuling in a matrix. 
Wavenumbers are given in cm-1. 
e) Melting point  
Melting points were measured with a KRÜSS melting point meter (M5000) and the 
associated capillaries. Note that the standard deviation for all melting points given in 
this thesis is ± 0.2 °C. 
f) Chemicals 
All commercially available chemicals for synthesis or analytical purposes were used 
without further purification if not stated otherwise. Anhydrous solvents were supplied 
by AcrosOrganics (Thermo Fischer scientific brand) and were stored in the original 
















6.1.2 Synthesis procedures 
6.1.2.1 Synthesis of the final ligands 1 – 24 
 
General procedure for the syntheses of the carboxylic acids 1-9: The N-substituted 
2,5-bis(4-cyanophenyl)pyrroles were taken up in a mixture of EtOH and H2O (1:1) and 
a large excess of KOH (usually around 15 equiv.) was added. The mixture was stirred 
and heated to reflux until all solids had dissolved; heating at reflux was then continued 
for the indicated amount of time. After cooling to room temperature, all volatiles were 
removed, and the residue was taken up in water. After filtration, the pH was adjusted 
to 1 with dilute HCl. The resulting precipitate was filtered, washed with water until acid 
free and dried in air. The crude products were either pure enough to use them directly 




















Synthesis of 4,4'-(1-propyl-1H-pyrrole-2,5-diyl)dibenzoic acid (1) 
 
4,4'-(1-propyl-1H-pyrrole-2,5-diyl)dibenzonitrile (39) (200 mg, 0.64 mmol, 1 equiv.) 
was dissolved in a mixture of EtOH and H2O (1:1, 20 mL) and a large excess of  
KOH (550 mg) was added to the reaction mixture. The reaction was refluxed for 2 days 
and was worked-up according to the general procedure. The product was obtained as 
a yellow solid (95 mg, 0.27 mmol, 42% yield). 
m.p.: 295 °C. 
1H-NMR (300 MHz, CD3OD):  (ppm) = 8.11 (d, 4H, J = 7.80 Hz, 8-H, 8’-H), 7.60 (d, 
4H, J = 7.80 Hz, 7-H, 7’-H), 6.38 (s, 2H, 3-H, 4’-H), 4.21 (t, 2H, J = 6.9 Hz, 11-H), 1.20 
(sex, 2H, J = 6.9 Hz, J = 7.4 Hz, 12-H), 0.41 (t, 3H, J = 7.4 Hz, 13-H).  
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 167.55 (C-10), 137.96 (C-2, C-5), 137.07 (C-
6, C-6’), 130.21 (C-8, C-8’), 129.36 (C-9, C-9’), 128.46 (C-7, C-7’), 47.38 (C-11), 23.90 
(C-12), 10.84 (C-13). 
FT-IR (solid): ṽ (cm-1) = 2970, 1738, 1672, 1601, 1421, 1365, 1228, 1217, 860, 762. 













Synthesis of 4,4'-(1-(3,3-dimethylbutyl)-1H-pyrrole-2,5-diyl)dibenzoic acid (2) 
 
4,4'-(1-(3,3-dimethylbutyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (40) (605 mg, 1.71 mmol, 
1 equiv.) was dissolved in a mixture of EtOH and H2O (1:1, 30 mL) and a large excess 
of KOH (1.41 g) was added to the reaction mixture. The reaction was refluxed for 2 
days and was worked-up according to the general procedure. The product was 
obtained as yellow crystals (189 mg, 0.48 mmol, 28% yield).  
m.p.: 300 °C 
1H-NMR (300 MHz, CD3OD):  (ppm) = 12.99 (s, 2H, CO2H), 8.02 (d, 4H, J = 8.30 Hz, 
3-H, 3’-H), 7.63 (d, 4H, J = 8.30 Hz, 4-H, 4’-H), 6.39 (s, 2H, 7-H, 7’-H), 4.19 (m, 2H, 8-
H), 0.99 (m, 2H, 9-H), 0.52 (s, 9H, 11-H, 11’-H, 11’’-H).  
13C-NMR (75 MHz, CD3OD):  (ppm) = 176.56 (C-1, C-1’), 137.87 (C-6, C-6’), 136.34 
(C-5, C-5’), 130.10 (C-3, C-3’), 129.43 (C-2, C-2’), 128.68 (C-4, C-4’), 111.58 (C-7, C-
7’), 43.98 (C-8), 42.35 (C-9), 29.71 (C-10), 28.96 (C-11, C-11’, C-11’’).  
FT-IR (solid): ṽ (cm-1) = 2970, 1739, 1678, 1602, 1419, 1366, 1229, 1217, 861, 763. 













Synthesis of 4,4'-(1-(4,4,4-trifluorobutyl)-1H-pyrrole-2,5-diyl)dibenzoic acid (3) 
 
4,4'-(1-(4,4,4-trifluorbutyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (41) (133 mg, 0.35 mmol, 
1 equiv.) was dissolved in a mixture of EtOH and H2O (1:1, 20 mL) and a large excess 
of KOH (290 mg) was added to the reaction mixture. The reaction was refluxed for 2 
days and was worked-up according to the general procedure. The product was 
obtained as an orange solid (90 mg, 0.19 mmol, 54% yield.  
m.p.: 292 °C. 
1H-NMR (300 MHz, CD3OD):  (ppm) = 8.13 (d, 4H, J = 8.30 Hz, 3-H, 3’-H), 7.63 (d, 
4H, J = 8.30 Hz, 4-H, 4’-H), 6.44 (s, 2H, 7-H, 7’-H), 4.34 (t, 2H, J = 6.6 Hz, 8-H), 1.60-
1.29 (m, 6H, 9-H, 10-H).  
13C-NMR (75 MHz, CD3OD):  (ppm) = 168.18 (C-1), 137.85 (C-6, C-6‘), 137.38 (C-5, 
C-5‘), 129.90 (C-3, C-3‘), 129.05 (C-2, C-2‘), 127.91 (C-4, C-4‘), 111.40 (C-7, C-7‘), 
44.21 (C-8), 29.73 (C-9), 29.34 (C-10), 22.80 (C-11).  
FT-IR (solid): ṽ (cm-1) = 2969, 1740, 1422, 1220. 













Synthesis of 4,4'-(1-(cyclohexylmethyl)-1H-pyrrole-2,5-diyl)dibenzoic acid (4) 
 
4,4'-(1-(methylcyclohexyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (42) (158 mg, 0.43 mmol, 
1 equiv.) was dissolved in a mixture of EtOH and H2O (1:1, 20 mL) and a large excess 
of KOH (355 mg) was added to the reaction mixture. The reaction was refluxed for 2 
days and was worked-up according to the general procedure. The product was 
obtained as a slightly yellow powder (155 mg, 0.38 mmol, 88% yield).  
m.p.: 183 °C. 
1H-NMR (300 MHz, CD3OD):  (ppm) = 8.11 (d, 4H, J = 8.30 Hz, 8-H, 8’-H), 7.61 (d, 
4H, J = 8.30 Hz, 7-H, 7’-H), 6.39 (s, 2H, 3-H, 4-H), 4.10 (d, 2H, J = 7.3 Hz, 11-H), 1.47-
1.35 (m, 3H, 12-H, 13-H, 13-H), 1.22-1.01 (m, 3H, 14-H, 14-H, 15-H), 0.94-0.76 (m, 
3H, 13’-H, 13’-H, 15-H), 0.53-0.33 (m, 2H, 14’-H, 14’-H). 
13C-NMR (75 MHz, CD3OD):  (ppm) = 168.32 (C-10, C-10’), 138.59 (C-2, C-5), 137.84 
(C-6, C-6’), 129.75 (C-8, C-8’), 128.64 (C-9, C-9’), 127.88 (C-7, C-7’), 110.83 (C-3, C-
4), 51.88 (C-11), 39.15 (C-12), 29.79 (C-13, C-13’), 25.76 (C-15), 25.06 (C-14, C-14’).  
FT-IR (solid): ṽ (cm-1) = 2970, 1739, 1676, 1604, 1422, 1274, 1230, 1216, 860, 771, 
705. 











Synthesis of 4,4'-(1-benzyl-1H-pyrrole-2,5-diyl)dibenzoic acid (5) 
 
4,4'-(1-(benzyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (43) (703 mg, 1.96 mmol, 1 equiv.) 
was dissolved in a mixture of EtOH and H2O (1:1, 40 mL) and a large excess of KOH 
(1.62 g) was added to the reaction mixture. The reaction was refluxed for 2 days and 
was worked-up according to the general procedure. The product was obtained as a 
slightly yellow solid (746 mg, 1.88 mmol, 96% yield). 
m.p.: 273 °C. 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 12.91 (s, 2H, CO2H), 7.92 (d, 4H, J = 
8.55 Hz, 8-H, 8’-H), 7.56 (d, 4H J = 8.55 Hz, 7-H, 7’-H), 7.13-7.01 (m, 3H, 14-H, 14’-H, 
15-H), 6.56-6.47 (m, 4H, 3-H, 4-H, 13-H, 13’-H), 5.38 (s, 2H, 11-H).  
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 167.49 (C-10, C-10’), 138.94 (C-13), 137.44 
(C-2, C-5), 137.37 (C-6, C-6’), 130.05 (C-8, C-8‘), 129.50 (C-9, C-9‘), 128.75 (C-14, C-
14‘), 128.58 (C-7, C-7‘), 127.37 (C-15), 125.82 (C-13, C-13‘), 112.05 (C-3, C-4), 49.19 
(C-11).  
FT-IR (solid): ṽ (cm-1) = 3130-2020, 2969, 1698, 1604, 1422, 1278, 915, 866, 776, 
701.  











Synthesis of 4,4'-(1-(2-(diethylamino)ethyl)-1H-pyrrole-2,5-diyl)dibenzoic acid (6) 
 
4,4'-(1-(2-(Diethylamino)ethyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (44) (194 mg, 
0.53 mmol, 1 equiv.) was dissolved in a mixture of EtOH and H2O (1:1, 20 mL) and a 
large excess of KOH (440 mg) was added to the reaction mixture. The reaction was 
refluxed for 2 days and was worked-up according to the general procedure and with 
RP-column chromatography (20% MeOH in H2O). The product was obtained as a light 
brown, sticky solid (40 mg, 0.1 mmol, 19% yield).  
m.p.: 286 (decomp.). 
1H-NMR (300 MHz, DMSO-d6):  = 7.95 (d, 4H, J = 8.17 Hz, 8-H, 8’-H), 7.48 (d, 4H, J 
= 8.17 Hz, 7-H, 4’-H), 6.27 (2, 2H, 3-H, 4-H), 2.05 (m, 6H, 12-H, 13-H, 13’-H), 0.51 (t, 
6H, J = 7.05 Hz, 11-H, 14-H, 14’-H).  
13C-NMR could not be measured due to its low solubility in common organic solvents. 













Synthesis of 4,4'-(1-(3,4,5-trimethoxybenzyl)-1H-pyrrole-2,5-diyl)dibenzoic acid 
(7) 
 
4,4'-(1-(3,4,5-trimethoxybenzyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (45) (112 mg, 
0.25 mmol, 1 equiv.) was dissolved in a mixture of EtOH and H2O (1:1, 20 mL) and a 
large excess of KOH (206 mg) was added to the reaction mixture. The reaction was 
refluxed for 3 days and was worked-up according to the general procedure. The 
product was obtained as a light yellow solid (23.5 mg, 0.05 mmol, 20% yield). 
m.p.: 260 °C (decomp.). 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 7.95 (m, 4H, -H, 8’-H), 7.58 (m, 4H, 7-H, 7’-
H), 6.49 (m, 2H, 13-H, 13’-H), 5.74 (s, 2H, 3-H, 4-H), 5.28 (2, 2H, 11-H), 3.51 (s, 3H, 
17-H), 3.47 (s, 6H, 16-H).  
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 167.49 (C-10, C-10’), 153.03 (C-14, C-14’), 
137.60 (C-2, C-5), 136.57 (C-15), 134.52 (C-6, C-6’), 130.15 (C-8, C-8’), 129.54 (C-9, 
C-9’), 128.79 (C-7, C-7’), 112.07 (C-3, C-4), 103.36 (C-13, C-13’), 60.32 (C-17), 55.86 
(C-16, C-16’), 49.13 (C-11). 
FT-IR (solid): ṽ (cm-1) = 1693, 1603, 1421, 1260, 1122, 768. 











diyl)dibenzoic acid (8) 
 
4,4'-(1-(benzo[d][1,3]dioxol-5-ylmethyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (46) (68 mg, 
0.17 mmol, 1 equiv.) was dissolved in a mixture of EtOH and H2O (1:1, 20 mL) and a 
large excess of KOH (141 mg) was added to the reaction mixture. The reaction was 
refluxed for 3 days and was worked-up according to the general procedure. The 
product was obtained as a light brown solid (71 mg, 0.16 mmol, 95% yield).  
m.p.: 262 °C (decomp.) 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 12.95 (s, 2H, CO2H), 7.96 (d, 4H, J = 8.40 Hz, 
8-H, 8’-H), 7.58 (d, 4H, J = 8.40 Hz, 7-H, 7’-H), 6.62 (d, 1H, J = 7.95 Hz, 13-H), 6.51 
(s, 2H, 3-H, 4-H), 6.04-5.95 (m, 2H, 16-H, 17-H), 5.87 (s, 2H, 18-H), 5.29 (s, 2H, 11-
H).  
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 167.47 (C-10), 147.68 (C-14), 146.47 (C-16), 
137.42 (C-2, C-5), 137.32 (C-9, C-9‘), 132.70 (C-6, C-6‘), 130.10 (C-8, C-8‘), 129.46 
(C-12), 128.57 (C-7, C-7‘), 119.08 (C-13), 112.10 (C-15), 108.46 (C-3, C-4), 106.23 
(C-13), 101.30 (C-17), 30.89 (C-11).  
FT-IR (solid): ṽ (cm-1) = 1679, 1605, 1420, 1245, 1176, 1038, 932, 863, 766, 697. 











diyl)dibenzoic acid (9) 
 
4,4'-(1-(2-((3,4,5-trimethoxybenzyl)amino)ethyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (47) 
(101 mg, 0.21 mmol, 1 equiv.) was dissolved in a mixture of EtOH and H2O (1:1, 
20 mL) and a large excess of KOH (173 mg) was added to the reaction mixture. The 
reaction was refluxed for 3 days and was worked-up according to the general 
procedure and with RP-column chromatography. The product was obtained as an 
orange semi solid (83 mg, 0.16 mmol, 78% yield).  
m.p.: 278 °C (decomp.). 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 7.88 (d, 4H, J = 8.10 Hz, 8-H, 8’-H), 7.34 (d, 
4H, J = 8.10 Hz, 7-H, 7’-H), 6.32 (s, 2H, 3-H, 4-H), 6.18 (s, 2H, 15-H, 15’-H), 4.23 (m, 
2H, 11-H), 3.67 (s, 6H, 18-H), 3.59 (s, 3H, 19-H), 3.15 (m, 2H, 13-H), 2.24 (m, 2H, 12-
H).  
13C-NMR could not be measured due to its low solubility in common organic solvents. 
FT-IR (solid): ṽ (cm-1) = 3354, 2969, 1738, 1584, 1541, 1374, 1228, 1216, 994, 767. 











Synthesis of ((1-(cyclohexylmethyl)-1H-pyrrole-2,5-diyl)bis(4,1 
phenylene))bis(phosphinic acid) (10) 
 
2,5-bis(4-bromophenyl)-1-(cyclohexylmethyl)-1H-pyrrole (51) (400 mg, 0.85 mmol, 
1 equiv.), Pd2(dba)3 (61 mg, 0.024 mmol, 8 mol%) and Xantphos (66 mg, 0.11 mmol, 
13 mol%) were dissolved in anhydrous toluene (15 mL) under an atmosphere of argon. 
Triethylamine (0.88 mL, 0.520 g, 5.11 mmol, 6 equiv.) and anilinium hypophosphite 
(255 mg, 1.69 mmol, 2.2 equiv.) were added to the reaction mixture and it was refluxed 
for 3 h. After cooling to room temperature, the reaction mixture was diluted with 
1 M NaOH (until pH > 12) and MTBE (50 mL). After 20 minutes of stirring the non-
soluble solids were removed by filtration through Celite. The resulting organic phase 
was extracted with 1 M NaOH (2 x 40 mL) and the combined aqueous phases were 
washed with DCM (2 x 50 mL) and filtered again. The pH value of the aqueous phase 
was adjusted to pH < 2 with conc. HCl and the resulting precipitate was filtered off. The 
product was obtained as a pale yellow solid (200 mg, 0.45 mmol, 53% yield). 
m.p.: 249.1 °C. 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 7.84-7.71 (m, 4H, 8-H, 8‘-H), 7.66 (dd, 4H,  
J = 8.01 Hz, 4JP-H = 2.64 Hz, 7-H, 7‘-H), 7.54 (d, 2H, 1JP-H = 549 Hz, PH), 6.38 (s, 2H, 
3-H, 4-H), 4.05 (d, 2H, J = 6.87 Hz, 10-H), 1.41-1.23 (m, 3H, 13-H, 13-H, 14-H), 1.07-
0.89 (m, 3H, 11-H, 12‘-H, 12‘-H), 0.85-0.62 (m, 3H, 13‘-H, 13‘-H, 14‘-H), 0.44-0.24 (m, 
2H, 12-H, 12-H).  
13C-NMR could not be measured due to its low solubility in common organic solvents.  
31P-NMR (25.8 MHz, DMSO-d6):  (ppm) = 16.06 (s, P) 
FT-IR (solid): ṽ (cm-1) = 2925, 2845, 1598, 1140, 1090, 963, 832, 779, 746. 






phenylene))bis(phosphinic acid) (11) 
 
2,5-bis(4-bromophenyl)-1-(3,3-dimethylbutyl)-1H-pyrrole (52) (200 mg, 0.44 mmol, 
1 equiv.), Pd2(dba)3 (23 mg, 0.01 mmol, 3 mol%) and Xantphos (26 mg, 0.04 mmol, 
9 mol%) were dissolved in anhydrous toluene (12 mL) under an atmosphere of argon. 
Triethylamine (0.31 mL, 0.178 g, 1.74 mmol, 4 equiv.) and anilinium hypophosphite 
(135 mg, 0.90 mmol, 2.1 equiv.) were added to the reaction mixture and it was refluxed 
for 3 h. After cooling to room temperature, the reaction mixture was diluted with 1 M 
NaOH (until pH > 12) and MTBE (50 mL). After 20 minutes of stirring the non-soluble 
solids were removed by filtration through Celite. The resulting organic phase was 
extracted with 1 M NaOH (2 x 40 mL) and the combined aqueous phases were washed 
with DCM (2 x 50 mL) and filtered again. The pH value of the aqueous phase was 
adjusted to pH < 2 with conc. HCl and the resulting precipitate was filtered off. The 
product was obtained as a pale brownish solid (120 mg, 0.28 mmol, 64% yield). 
m.p.: 193.2 °C. 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 7.78-7.67 (m, 4H, 8-H, 8‘-H), 7.66-7.55 (dd, 
4H, J = 8.01 Hz, 4JP-H = 2.46 Hz, 7-H, 7‘-H), 7.49 (d, 2H, 1JP-H = 537 Hz, PH), 6.34 (s, 
2H, 3-H, 4-H), 4.15 (m, 2H, 10-H), 0.99 (m, 2H, 11-H), 0.51 (s, 9H, 13-H).  
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 136.82 (C-6, C-6‘), 136.28 (C-2, C-5), 133.74 
(C-9, C-9‘), 130.93 (C-8, C-8‘), 128.52 (C-7, C-7‘), 111.38 (C-3, C-4), 43.96 (C-11), 
42.27 (C-10), 29.71 (C-12), 29.01 (C-13).  
31P-NMR (25.8 MHz, DMSO-d6):  (ppm) = 14.22 (s, P). 
FT-IR (solid): ṽ (cm-1) = 2951.2362.1596.1131.950.833.782.742. 






phenylene))bis(phosphinic acid) (12) 
 
2,5-bis(4-bromophenyl)-1-(4,4,4-trifluorobutyl)-1H-pyrrole (53) (200 mg, 0.41 mmol, 
1 equiv.), Pd2(dba)3 (25 mg, 0.01 mmol, 3 mol%) and Xantphos (32 mg, 0.05 mmol, 
10 mol%) were dissolved in anhydrous toluene (12 mL) under an atmosphere of argon. 
Triethylamine (0.3 mL, 0.172 g, 1.72 mmol, 4.2 equiv.) and anilinium hypophosphite 
(176 mg, 1.12 mmol, 2.7 equiv.) were added to the reaction mixture and it was refluxed 
for 3 h. After cooling to room temperature, the reaction mixture was diluted with 1 M 
NaOH (until pH > 12) and MTBE (50 mL). After 20 minutes of stirring the non-soluble 
solids were removed by filtration through Celite. The resulting organic phase was 
extracted with 1 M NaOH (2 x 40 mL) and the combined aqueous phases were washed 
with DCM (2 x 50 mL) and filtered again. The pH value of the aqueous phase was 
adjusted to pH < 2 with conc. HCl and the resulting precipitate was filtered off. The 
product was obtained as a pale brownish solid (100 mg, 0.22 mmol, 53% yield). 
m.p.: 215.0 °C. 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 7.85-7.73 (m, 4H, 8-H, 8‘-H), 7.72-7.61 (dd, 
4H, J = 7.82 Hz, 4JP-H = 2.45 Hz, 7-H, 7‘-H), 7.53 (d, 2H, 1JP-H = 546 Hz, PH), 6.43 (s, 
2H, 3-H, 4-H), 4.27 (m, 2H, 10-H), 1.71-1.50 (m, 2H, 12-H), 1.37-1.21 (m, 2H, 11-H).  
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 136.99 (C-6, C6’), 133.58 (C-9, C-9’), 131.87 
(C-2, C-5), 131.12 (C-8, C-8’), 128.42 (C-7, C-7’), 111.95 (C-3, C-4), 44.50 (C-10), 
29.33 (C-13), 25.95 (C-12), 23.08 (C-11).  
19F-NMR (400 MHz, DMSO-d6):  (ppm) = - 65.04 (s, CF3). 
31P-NMR (25.8 MHz, DMSO-d6):  (ppm) = 15.89 (s, P). 
































phenylene))bis(phosphonic acid) (13) 
 
2,5-bis(4-bromophenyl)-1-(cyclohexylmethyl)-1H-pyrrole (50) (250 mg, 0.53 mmol, 
1 equiv.) and Pd(dppf)Cl2 (41 mg, 0.063 mmol, 12 mol%) were suspended in 
anhydrous toluene (15 mL) under an atmosphere of argon. Triethylamine (0.25 mL, 
0.196 mg, 1.78 mmol, 3.4 equiv.) and diethyl phosphite (180 mg, 1.31 mmol, 
2.5 equiv.) were added sequentially and the reaction mixture was refluxed overnight. 
After cooling to room temperature, the reaction mixture was diluted with toluene 
(10 mL) and DCM (20 mL) to obtain a clear solution. Silica gel (ca. 10 g) was added, 
and the solvents were removed under reduced pressure. Purification by column 
chromatography (2.5% MeOH in DCM, Rf = 0.91) afforded the phosphonate ester as 
a slightly purple oil that was contaminated with diethyl phosphite. The crude product 
was dissolved in DCM (20 mL) and TMSBr (2.56 g, > 20 equiv.) was added dropwise 
to the reaction mixture which was stirred overnight. Afterwards, it was diluted with 
MeOH (20 mL) and stirred for 1 h, then, the solvents were removed under reduced 
pressure. The residue was coevaporated with MeOH (20 mL) twice, yielding a brown 
residue which was dissolved in 1 M NaOH (until no solids were left, pH > 12). The 
aqueous phase was washed with MTBE (2 x 20 mL) and was then acidified with conc. 
HCl until pH < 2. The precipitated solid was filtered and washed with water until the 
washings were acid-free. The solid was dried under reduced pressure and the product 
was obtained as an off-white solid (110 mg, 0.23 mmol, 43% yield).  
m.p.: > 235 °C (decomposition). 
1H-NMR (300 MHz, D2O):  (ppm) = 7.60-7.48 (dd, 4H, 3JP-H = 11.34 Hz, J = 8.1 Hz, 8-
H, 8‘-H), 7.31-7.21 (dd, 4H, J = 8.13 Hz, 4JP-H = 2.52 Hz, 7-H, 7‘-H), 6.12 (s, 2H, 3-H, 
4-H), 3.82 (d, 2H, J = 7.17 Hz, 10-H), 1.19-1.02 (m, 3H, 13-H, 13-H, 14-H), 0.91-0.67 
(m, 3H, 11-H, 12‘-H, 12‘-H), 0.64-0.47 (m, 3H, 13‘-H, 13‘-H, 14‘-H), 0.29-0.05 (m, 2H, 




13C-NMR (75 MHz, D2O):  (ppm) = 139.19 (C-9, C-9‘), 137.77 (C-2, C-5), 133.66 (C-
6, C-6‘), 130.39 (C-8, C-8‘), 127.62 (C-7, C-7‘), 108.93 (C-3, C-4), 51.51 (C-10), 38.44 
(C-11), 29.49 (C-12), 25.56 (C-14), 24.73 (C-13).  
31P-NMR (25.8 MHz, D2O):  (ppm) = 11.15 (s, P).  
FT-IR (solid): ṽ (cm-1) = 2922, 2362, 2341, 1599, 1136, 920, 833, 776, 746, 730. 























phenylene))bis(phosphonic acid) (14) 
 
2,5-bis(4-bromophenyl)-1-(3,3-dimethylbutyl)-1H-pyrrole (52) (250 mg, 0.54 mmol, 
1 equiv.) and Pd(dppf)Cl2 (39 mg, 0.060 mmol, 11 mol%) were suspended in 
anhydrous toluene (15 mL) under an atmosphere of argon. Triethylamine (0.25 mL, 
0.196 mg, 1.78 mmol, 3.4 equiv.) and diethyl phosphite (187 mg, 1.35 mmol, 
2.6 equiv.) were added sequentially and the reaction mixture was refluxed overnight. 
After cooling to room temperature, the reaction mixture was diluted with toluene 
(20 mL) and DCM (30 mL) to obtain a clear solution. Silica gel (ca. 12 g) was added, 
and the solvents were removed under reduced pressure. Purification by column 
chromatography (2.5% MeOH in DCM, Rf = 0.86) afforded the phosphonate ester as 
a slightly purple oil that was contaminated with diethyl phosphite. The crude product 
was dissolved in DCM (20 mL) and TMSBr (2.3 g, > 20 equiv.) was added dropwise to 
the reaction mixture which was stirred overnight. Afterwards, it was diluted with MeOH 
(20 mL) and stirred for 1 h, then, the solvents were removed under vacuum. The 
residue was coevaporated with MeOH (20 mL) twice, yielding a brown residue which 
was dissolved in 1 M NaOH (until no solids were left, pH > 12). The aqueous phase 
was washed with MTBE (2 x 20 mL) and was then acidified with conc. HCl until pH < 
2. The precipitated solid was filtered and washed with water until the washings were 
acid-free. The solid was dried under vacuum and the product was obtained as a brown 
solid (130 mg, 0.28 mmol, 52% yield).  
m.p.: > 190 °C (decomposition). 
1H-NMR (300 MHz, D2O):  (ppm) = 7.65-7.52 (dd, 4H, 3JP-H = 11.34 Hz, J = 8.1 Hz, 8-
H, 8‘-H), 7.35-7.26 (dd, 4H, J = 8.1 Hz, 4JP-H = 2.49 Hz, 7-H, 7‘-H), 6.17 (s, 2H, 3-H, 4-
H), 4.07-3.89 (m, 2H, 10-H), 0.91-0.77 (m, 2H, 11-H), 0.34 (s, 9H, 13-H). 
13C-NMR could not be measured due to its low solubility in common organic solvents.  
31P-NMR (25.8 MHz, D2O):  (ppm) = 11.11 (s, P).  






































phenylene))bis(phosphonic acid) (15) 
 
2,5-bis(4-bromophenyl)-1-(4,4,4-trifluorobutyl)-1H-pyrrole (53) (250 mg, 0.52 mmol, 
1 equiv.) and Pd(dppf)Cl2 (39 mg, 0.060 mmol, 11 mol%) were suspended in 
anhydrous toluene (12 mL) under an atmosphere of argon. Triethylamine (0.29 mL, 
0.277 mg, 2.1 mmol, 4.0 equiv.) and diethyl phosphite (172 mg, 1.24 mmol, 2.4 equiv.) 
were added sequentially and the reaction mixture was refluxed overnight. After cooling 
to room temperature, the reaction mixture was diluted with toluene (10 mL) and DCM 
(50 mL) to obtain a clear solution. Silica gel (ca. 12 g) was added, and the solvents 
were removed under reduced pressure. Purification by column chromatography (2.5% 
MeOH in DCM, Rf = 0.80) afforded the phosphonate ester as a slightly purple oil that 
was contaminated with diethyl phosphite (yield > 100%). The crude product was 
dissolved in DCM (40 mL) and TMSBr (2.5 g, > 20 equiv.) was added dropwise to the 
reaction mixture which was stirred overnight. Afterwards, it was diluted with MeOH (20 
mL) and stirred for 1 h, then, the solvents were removed under vacuum. The residue 
was coevaporated with MeOH (20 mL) twice, yielding a brown residue which was 
dissolved in 1 M NaOH (until no solids were left, pH > 12). The aqueous phase was 
washed with EtOAc (2 x 25 mL) and was then acidified with conc. HCl until pH < 2. 
The precipitated solid was filtered and washed with water until the washings were acid-
free. The solid was dried under reduced pressure and the product was obtained as a 
yellow solid (34 mg, 0.07 mmol, 13% yield).  
m.p.: > 190 °C (decomposition). 
1H-NMR (300 MHz, D2O):  (ppm) = 7.54-7.43 (dd, 4H, 3JP-H = 11.36 Hz, J = 8.0 Hz, 8-
H, 8‘-H), 7.26-7.11 (dd, 4H, J = 8.1 Hz, 4JP-H = 2.49 Hz, 7-H, 7‘-H), 6.11 (s, 2H, 3-H, 4-
H), 4.00 (m, 2H, 10-H), 1.38-1.24 (m, 2H, 12-H), 1.15-1.03 (m, 2H, 11-H). 
13C-NMR could not be measured due to its low solubility in common organic solvents. 
31P-NMR (25.8 MHz, D2O):  (ppm) = 1.40 (s, P).  




FT-IR (solid): ṽ (cm-1) = 2359, 2340, 1736, 1218, 927, 838, 761, 668. 




























phenylene))diboronic acid (16) 
 
2,5-bis(4-bromophenyl)-1-(cyclohexylmethyl)-1H-pyrrole (51) (270 mg, 0.57 mmol, 
1 equiv.) was dissolved in anhydrous THF (12 mL) under an atmosphere of argon. The 
reaction mixture was cooled to -78 °C and nBuLi (1.6 M in hexane, 1.1 mL, 3 equiv.) 
was added dropwise to the reaction mixture. Afterwards it was stirred for 45 minutes 
at -78 °C and then triethyl borate (0.33 g, 2.3 mmol, 4 equiv.) was added at once. The 
reaction mixture was then allowed to warm to room temperature overnight, after which 
it was diluted with 4 M HCl until pH < 3. Then, DCM (50 mL) and water (50 mL) were 
added and the aqueous phase was isolated and washed with DCM (20 mL). The 
combined organic phases were extracted with 2 M NaOH (2 x 25 mL) and the resulting 
aqueous phase was washed with DCM (20 mL). The aqueous phase was acidified with 
conc. HCl until pH < 2. The precipitated solid was filtered and washed with water until 
the washings were acid-free. The solid was dried under reduced pressure and the 
product was obtained as an off-white solid (161 mg, 0.4 mmol, 68% yield). 
m.p.: > 200 °C (decomposition). 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 8.07 (s, 4H, OH), 7.85 (d, 4H, J = 7.88 Hz, 
8-H, 8‘-H), 7.44 (d, 4H, J = 7.88 Hz, 7-H, 7‘-H), 6.24 (s, 2H, 3-H, 4-H), 4.02 (m, 2H, 10-
H), 1.41-1.22 (m, 3H, 13-H, 13-H, 14-H), 1.09-0.90 (m, 3H, 11-H, 12‘-H, 12‘-H), 0.82-
0.58 (m, 3H, 13‘-H, 13‘-H, 14-H), 0.41-0.19 (m, 2H, 12-H, 12-H).  
11B-NMR could not be measured due to its low solubility in common organic solvents.  
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 137.89 (C-2, C-5), 135.73 (C-6, C-6’), 134.93 
(C-8, C-8’), 127.41 (C-7, C-7’), 110.28 (C-3, C-4), 51.85 (C-10), 30.00 (C-11), 26.03 
(C-12), 25.39 (C-13). 
































phenylene))diboronic acid (17) 
 
2,5-bis(4-bromophenyl)-1-(3,3-dimethylbutyl)-1H-pyrrole (52) (400 mg, 0.87 mmol, 
1 equiv.) was dissolved in anhydrous THF (15 mL) under an atmosphere of argon. The 
reaction mixture was cooled to -78 °C and nBuLi (1.6 M in hexane, 1.7 mL, 3.1 equiv.) 
was added dropwise to the reaction mixture. Afterwards it was stirred for 45 minutes 
at -78 °C and then triethyl borate (0.395 g, 2.3 mmol, 4.1 equiv.) was added at once. 
The reaction mixture was then allowed to warm to room temperature overnight, after 
which it was diluted with 4 M HCl until pH < 3. Then, DCM (50 mL) and water (50 mL) 
were added and the aqueous phase was isolated and washed with DCM (20 mL). The 
combined organic phases were extracted with 2 M NaOH (2 x 25 mL) and the resulting 
aqueous phase was washed with DCM (20 mL). The aqueous phase was acidified with 
conc. HCl until pH < 2. The precipitated solid was filtered and washed with water until 
the washings were acid-free. The solid was dried under reduced pressure and the 
product was obtained as an off-white solid (165 mg, 0.42 mmol, 48% yield). 
m.p.: 277.5 °C. 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 8.07 (s, 4H, OH), 7.85 (d, 4H, J = 7.95 Hz, 
8-H, 8‘-H), 7.43 (d, 4H, J = 7.95 Hz, 7-H, 7‘-H), 6.22 (s, 2H, 3-H, 4-H), 4.15 (m, 2H, 10-
H), 1.00 (m, 2H, 11-H), 0.51 (s, 9H, 12-H). 
11B-NMR could not be measured due to its low solubility in common organic solvents.  
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 136.41 (C-2, C-5), 135.49 (C-6, C-6‘), 134.82 
(C-8, C-8‘), 127.77 (C-7, C-7‘), 110.17 (C-3, C-4), 44.03 (C-11), 41.96 (C-10), 29.69 
(C-12), 29.05 (C-13).  
FT-IR (solid): ṽ (cm-1) = 3349, 2947, 2358, 2341, 1606, 1336, 1107, 1101, 834, 742. 





phenylene))diboronic acid (18) 
 
2,5-bis(4-bromophenyl)-1-(3,3-dimethylbutyl)-1H-pyrrole (53) (157 mg, 0.32 mmol, 
1 equiv.) was dissolved in anhydrous THF (6 mL) under an atmosphere of argon. The 
reaction mixture was cooled to -78 °C and nBuLi (1.6 M in hexane, 0.7 mL, 3.5 equiv.) 
was added dropwise to the reaction mixture. Afterwards it was stirred for 45 minutes 
at -78 °C and then triethyl borate (0.200 g, 1.15 mmol, 3.6 equiv.) was added at once. 
The reaction mixture was then allowed to warm to room temperature overnight, after 
which it was diluted with 4 M HCl until pH < 3. Then, DCM (50 mL) and water (50 mL) 
were added and the aqueous phase was isolated and washed with DCM (20 mL). The 
combined organic phases were extracted with 2 M NaOH (2 x 25 mL) and the resulting 
aqueous phase was washed with DCM (20 mL). The aqueous phase was acidified with 
conc. HCl until pH < 2. The precipitated solid was filtered and washed with water until 
the washings were acid-free. The solid was dried under reduced pressure and the 
product was obtained as an off-white solid (53 mg, 0.13 mmol, 41% yield). 
m.p.: 282 °C. 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 7.87 (d, 4H, J = 7.79 Hz, 7-H, 7‘-H), 7.46 (d, 
4H, J = 7.79 Hz, 8-H, 8‘-H), 6.30 (s, 2H, 3-H, 4-H), 4.24 (m, 2H, 10-H), 1.70-1.47 (m, 
2H, 12-H), 1.40-1.18 (m, 2H, 11-H). 
11B-NMR could not be measured due to its low solubility in common organic solvents.  
13C-NMR (75 MHz, DMSO-d6):  (ppm) =  137.30 (C-2, C-5), 135.13 (C-6, C-6’), 135.01 
(C-8, C-8’), 127.49 (C-7, C-7’), 110.68 (C-3, C-4), 49.19 (C-10), 44.27 (C-12), 27.30 
(C-11). 
19F-NMR (400 MHz, DMSO-d6):  (ppm) = -65.09 (s, CF3). 





































Synthesis of ((Perfluoro-[1,1'-biphenyl]-4,4'-diyl)bis(methylene))bis(phosphonic 
acid) (19) 
 
Di-para-bibromomethyl-octafluoro-1,1’-biphenyl (121) (660 mg, 1.3 mmol, 1 equiv.) 
and P(OEt)3 were heated to 156 °C under an atmosphere of argon. Afterwards, excess 
reagent was removed by distillation under reduced pressure. The residue was purified 
by column chromatography (hexane/EtOAc 2:1, Rf = 0.55) and the intermediate 
product was obtained as a slightly yellow oil, contaminated with several phosphorus 
species. This crude product was directly used for the next step without further 
purification.  
The crude product was dissolved in THF (10 mL) and TMSBr (6.43 g, 42.0 mmol, 
30.9 equiv.) was added slowly to the reaction mixture. It was stirred for 3 days at room 
temperature and then MeOH (10 mL) and water (10 mL) were added to the reaction 
mixture. After stirring for 1 h, all solvents were removed under reduced pressure. The 
residue was dissolved in 1 M KOH-solution (15 mL) and the aqueous phase was 
washed with DCM (2 x 15 mL). Afterwards, it was acidified to pH 1 with conc. HCl and 
the precipitated solid was isolated by filtration. The product was obtained as a white 
solid (212 mg, 0.43 mmol, 32% yield). 
m.p.: > 250 °C (decomposition). 
1H-NMR (300 MHz, D2O):  (ppm) = 2.84 (d, 4H, J = 19.05 Hz, 1-H, 1’-H). 
19F-NMR (282.4 MHz, D2O):  (ppm) = -141.74 (m, 4F, 3-F, 3’-F), -142.91 (m, 4F, 4-F, 
4’-F). 
31P-NMR (25.8 MHz, D2O):  (ppm) = 14.14 (s, 2P, PO3H2). 
FT-IR (solid): ṽ (cm-1) = 2359, 1458, 1247, 1191, 1010, 952, 930, 728, 716. 




Synthesis of (Perfluoro-[1,1'-biphenyl]-4,4'-diyl)dimethanesulfonic acid (20) 
 
Di-para-bibromomethyl-octafluoro-1,1’-biphenyl (121) (209 mg, 0.4 mmol, 1 equiv.) 
was dissolved in a mixture of acetone and water (2:1, 30 mL) and afterwards Na2SO3 
(140 mg, 1.1 mmol, 2.8 equiv.) was added to the reaction mixture. It was refluxed for 
24 h and then acetone was removed under reduced pressure. The resulting aqueous 
phase was basified to pH 13 with 1 M NaOH, washed with DCM (3 x 15 mL) and 
acidified to pH 1 with conc. H2SO4. The solvent was removed and the residue was 
purified by RP-column chromatography. The product was obtained as a white, 
crystalline solid (61 mg, 0.13 mmol, 29% yield). 
m.p.: > 250 °C (decomposition). 
1H-NMR (300 MHz, D2O):  (ppm) = 4.48 (s, 4H, 1-H, 1’-H). 
19F-NMR (282.4 MHz, D2O):  (ppm) = -139.40 (m, 4F, 3-F, 3’-F), -142.33 (m, 4F, 4-F, 
4’-F). 
FT-IR (solid): ṽ (cm-1) = 2359, 1469, 1203, 1175, 1046, 979, 732. 












Synthesis of ([1,1'-biphenyl]-4,4'-diylbis(methylene))bis(phosphinic acid) (22) 
 
Ammoniumhypophosphite (0.967 g, 11.9 mmol, 6.1 equiv.) and HMDS (1.83 g, 
11.3 mmol, 5.8 equiv.) were heated under an atmosphere of argon at 120 °C for 2 h. 
Afterwards, anhydrous DCM (30 mL) was added and after all solid particles had 
dissolved di-para-bibromomethyl-octafluoro-1,1’-biphenyl (128) (0.67 g, 2.00 mmol, 
1 equiv.) was added to the reaction mixture, which was stirred for 1 h. MeOH (5 mL) 
was added and the resulting mixture was stirred for 1 h, then all solvents were removed 
under reduced pressure. The residue was taken up in 1 M KOH-solution and the 
aqueous phase was washed with DCM (2 x 15 mL) and then acidified to pH 1 with 
conc. HCl. The precipitated solid was isolated by filtration. 
This crude product (370 mg) was dissolved in DMSO (10 mL) and adamantan-1-amine 
(302 mg, 4 mmol, 2 equiv.) were added to the reaction mixture. The precipitated salt 
was isolated by filtration, washed with Et2O and dried under vacuum. It was then 
suspended in 1 M NaOH-solution and the resulting aqueous phase was washed with 
DCM (2 x 15 mL). Afterwards it was acidified to pH 1 with conc. HCl and the solid was 
isolated by filtration. The product was obtained as a white solid (0.11 g, 0.34 mmol, 
17% yield). 
m.p.: > 250 °C (decomposition). 
1H-NMR (300 MHz, D2O):  (ppm) = 7.63 (d, 4H, J = 8.04 Hz, 4-H, 4’-H), 7.32 (dd, 4H, 
J = 8.04 Hz, J = 2.21 Hz, 3-H, 3’-H), 6.91 (d, 2H, J = 517 Hz, PHOH), 2.97 (d, 4H, J = 
17.97 Hz, 1-H, 1’-H). 
13C-NMR (75 MHz, D2O):  (ppm) = 137.76 (C-5, C-5‘), 132.51 (C-2, C-2‘), 129.92 (C-
3, C-3‘), 126.65 (C-4, C-4‘), 39.19 (C-1, C-1‘). 




FT-IR (solid): ṽ (cm-1) = 2358, 1689, 1496, 1254, 1203, 1091, 974, 827, 709. 
































Synthesis of ([1,1'-biphenyl]-4,4'-diylbis(methylene))bis(phosphonic acid) (23) 
 
Tetraethyl ([1,1'-biphenyl]-4,4'-diylbis(methylene))bis(phosphonate) (23a) (504 mg, 
1.27 mmol, 1 equiv.) was dissolved in anhydrous THF (10 mL) under an atmosphere 
of argon. TMSBr (1.72 g, 11.24 mmol, 8.9 equiv.) was added dropwise to the reaction 
mixture that was stirred at room temperature for three days. Afterwards, MeOH (10 mL) 
was added and the reaction mixture was stirred for 1 h. The solvents were removed 
under reduced pressure and the residue was dissolved in 1 M KOH-solution (15 mL). 
The aqueous phase was washed with DCM (2 x 15 mL) and the pH was adjusted to 1 
with conc. HCl. The precipitated solid was isolated by filtration. The product was 
obtained as a white powder (0.29 g, 0.84 mmol, 68% yield). 
m.p.: > 250 °C (decomposition). 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 7.55 (d, 4H, J = 8.01 Hz, 4-H, 4’-H), 7.32 
(dd, 4H, J = 8.01 Hz, J = 1.92 Hz, 3-H, 3’-H), 2.98 (d, 4H, J = 21.42 Hz, 1-H, 1’-H). 
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 138.22 (C-5, C-5’), 133.85 (C-2, C-2’), 130.77 
(C-3, C-3’), 126.58 (C-4, C-4’), 35.49 (C-1, C-1’). 
31P-NMR (25.8 MHz, DMSO-d6):  (ppm) = 21.08 (s, PO3H2). 
FT-IR (solid): ṽ (cm-1) = 2358, 2332, 1090, 1011, 949, 827. 








Synthesis of [1,1'-biphenyl]-4,4'-diyldimethanesulfonic acid (24) 
 
4,4'-Bis(bromomethyl)-1,1'-biphenyl (121) (0.986 g, 2.90 mmol, 1 equiv.) was 
dissolved in a mixture of acetone and water (1:1, 20 mL). Na2SO3 (1.08 g, 8.7 mmol, 
3 equiv.) was added to the reaction mixture and it was refluxed for 30 hours. 
Afterwards, acetone was removed under reduced pressure and 1 M NaOH-solution 
was added until the pH was 12. The aqueous phase was washed with DCM (3 x 20 mL) 
and then it was acidified with conc. H2SO4 and cooled to 0 °C. The precipitated solid 
was isolated by filtration. The product was obtained as a white powder (1.12 g, 
2.50 mmol, 88% yield). 
m.p.: > 250 °C (decomposition). 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 7.52 (d, 4H, J = 8.22 Hz, 3-H, 3’-H), 7.37 (d, 
4H, J = 8.22 Hz, 4-h, 4’-H), 3.75 (s, 4H, 1-H, 1’-H). 
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 138.71 (C-5, C-5’), 134.86 (C-2, C-2’), 
131.19 (C-3, C-3’), 126.19 (C-4, C-4’), 57.64 (C-1, C-1’). 
FT-IR (solid): ṽ (cm-1) =  










6.1.2.2 Syntheses for chapter 4.2 
 
Synthesis of 4,4'-Succinyldibenzonitrile (32) 
 
ZnCl2 (5.92 g, 43.4 mmol, 2 equiv.), Et3N (4.6 mL, 32.6 mmol, 1.5 equiv) and absolute 
ethanol (2.0 mL, 32.6 mmol, 1.5 equiv.) were suspended in anhydrous toluene (50 mL) 
under an atmosphere of argon. The reaction mixture was stirred for 60 minutes. Then, 
4-acetylbenzonitrile (37) (4.73 g, 32.6 mmol, 1.5 equiv.) and 4-(2-
bromoacetyl)benzonitrile (38) (4.84 g, 21.7 mmol, 1 equiv.) were added and the 
suspension was stirred at room temperature for 7 days. The resulting yellow precipitate 
was filtered off, dissolved in hot DMF (150 mL, 80 °C) and crystallized by slow addition 
of methanol (20 mL). After storing at 0 °C for 12 hours, the crystals were filtered off 
and dried in air. The product was obtained as a slightly yellow, microcrystalline powder 
(3.75 g, 13.0 mmol, 70% yield).  
m.p.: 261 °C. 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 8.16 (d, 4 H, J = 8.61 Hz, 3-H, 3’-H), 8.02 (d, 
4 H, J = 8.61 Hz, 4-H, 4’-H), 3.47 (s, 4 H, 7-H, 7’-H).  
13C-NMR could not be measured due to its low solubility in common organic solvents. 
FT-IR (solid): ṽ (cm-1) = 2225, 1680, 1402, 1319, 1304, 1381, 1191, 1172, 1010, 860, 
840, 783, 713, 694. 







General procedure for the synthesis of 1,2,5-substituted Pyrroles: The respective 1,4-
diketone (1 equiv.) was dissolved in hexafluoroisopropanol (4-10 mL) at ambient 
temperature. The respective amine (1.5 equiv.) was added slowly, and the mixture was 
stirred for the indicated time either at room temperature or under reflux conditions. The 
reaction mixture was allowed to cool to room temperature and the solvent was removed 
under reduced pressure. The residue was dissolved in dichloromethane and washed 
with 4 M HCl to remove excess amine. The organic phase was dried over MgSO4 and 
the solvent was removed under reduced pressure. The products were mostly pure; 
however, in some cases column chromatography was necessary using hexane/EtOAc 



















Synthesis of 4,4'-(1-benzyl-1H-pyrrole-2,5-diyl)dibenzonitrile (35a) (43) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification, column chromatography (n-hexane/EtOAc 4:1, Rf = 0.40) 
was performed. The product was obtained as yellow crystals (338 mg, 0.94 mmol, 74% 
yield).  
m.p.: 168 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.58 (d, 4H, J = 6.2 Hz, 8-H, 8’-H), 7.42 (d, 4H, J = 
6.2 Hz, 7-H, 7’-H), 7.17-7.12 (m, 3H, 13-H, 13’-H, 15-H), 6.66-6.60 (m, 2H, 14-H, 14’-
H), 6.47 (s, 2H, 3-H, 4-H), 5.21 (s, 2H, 11-H). 
13C-NMR (75 MHz, CD2Cl2): δ = 137.9 (C-2, C-5), 137.3 (C-6, C-6’), 136.6 (C-12), 
132.2 (C-8, C-8’), 128.8 (C-7, C-7’), 128.7 (C-14, C-14’), 127.5 (C-15), 125.5 (C-13, C-
13’), 118.7 (C-10, C-10’), 112.1 (C-9, C-9’), 110.6 (C-3, C-4), 49.4 (C-11). 
FT-IR (solid): ṽ (cm-1) = 2922, 2221, 1599, 1178, 796, 706. 














Synthesis of 1-benzyl-2,5-dimethyl-1H-pyrrole (36a) 
 
The reaction mixture was stirred at room temperature for 5 minutes and worked-up 
according to the general procedure. The product was obtained as a slightly brown solid 
(363 mg, 1.97 mmol, 99% yield).  
m.p.: 48 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.35-7.19 (m, 3H, 10-H, 10’-H, 11-H), 6.91 (d, 
2H, J = 8.43 Hz, 9-H, 9’-H), 5.81 (s, 2H, 3-H, 4-H), 5.03 (2, 2H, 7-H), 2.14 (s, 6H, 6-H, 
6’-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 138.9 (C-8), 128.6 (C-11), 127.7 (C-2, C-5), 
126.9 (C-10, C-10’), 125.7 (C-9, C-9’), 105.4 (C-3, C-4), 46.6 (C-7), 12.2 (C-6, C-6’).  
FT-IR (solid):  ṽ (cm-1): 2918, 1652, 1493, 1408, 1355, 1303, 754, 725, 701, 689. 















Synthesis of 4,4'-(1-propyl-1H-pyrrole-2,5-diyl)dibenzonitrile (35b) (39) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (hexane/EtOAc 4:1, Rf = 0.57) was 
performed. The product was obtained as yellow crystals (432 mg, 1.31 mmol, 76% 
yield). 
m.p.: 144 °C. 
1H-NMR (300 MHz, CDCl3):  (ppm) = 7.72 (d, 4H, J = 6.2 Hz, 8-H, 8’-H), 7.55 (d, 4H, 
J = 6.2 Hz, 7-H, 7’-H), 6.38 (s, 2H, 3-H, 4-H), 4.06 (7, 2H, J = 7.1 Hz, 11-H), 1.18 (sex, 
2H, J = 7.2 Hz, 12-H), 0.43 (t, 3H, J = 7.4 Hz, 13-H).  
13C-NMR (75 MHz, CDCl3):  (ppm) = 137.97 (C-2, C-5), 136.73 (C-6, C-6’), 132.50 
(C-8, C-8’), 128.84 (C-7, C-7’), 118.84 (C-10, C-10’), 112.11 (C-9, C-9’), 110.54 (C-3, 
C-4), 47.51 (C-11), 24.07 (C-12), 10.60 (C-13).  
FT-IR (solid): ṽ (cm-1) = 2922, 2358, 2341, 2220, 1600, 834, 777.  














Synthesis of 2,5-dimethyl-1-propyl-1H-pyrrole (36b) 
 
The reaction mixture was stirred at room temperature for 5 minutes and worked-up 
according to the general procedure. The product was obtained as a brown oil (269 mg, 
1.97 mmol, 99% yield).  
m.p.: 192 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 5.68 (s, 2H, 3-H, 4-H), 3.69 (t, 2H, J = 7.5 Hz, 
7-H), 2.20 (s, 6 H, 6-H, 6’-H), 1.63 (m, 2 H, J = 7.5 Hz, 8-H), 0.94 (t, 3H, J = 7.5 Hz, 9-
H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 127.0 (C-2, C-5), 104.9 (C-3, C-4), 45.1 (C-7), 
24.3 (C-8), 12.2 (C-6, C-6’), 11.0 (C-9). 
FT-IR (solid): ṽ (cm-1) = 2962, 1660, 1518, 1406, 1298, 1018, 892, 742. 














Synthesis of 4,4'-(1-(3,3-dimethylbutyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (35c) 
(40) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (hexane/EtOAc 4:1, Rf = 0.73) was 
performed. The product was obtained as yellow crystals (378 mg, 1.07 mmol, 56% 
yield). 
m.p.: 192 °C. 
1H-NMR (300 MHz, CDCl3):  (ppm) = 7.73 (d, 4H, J = 6.2 Hz, 8-H, 8’-H), 7.56 (d, 4H, 
J = 6.2 Hz, 7-H, 7’-H), 6.38 (s, 2H, 3-H, 4-H), 4.07 (t, 2H, J = 7.0 Hz, 11-H), 1.02 (t, 
2H, J = 7.0 Hz, 12-H), 0.56 (s, 9H, 14-H, 14’-H, 14’’-H).  
13C-NMR (75 MHz, CDCl3):  (ppm) = 137.87 (C-2, C-5), 136.10 (C-6, C-6’), 132.40 
(C-8, C-8’), 129.02 (C-7, C-7’), 118.82 (C-10, C-10’), 112.06 (C-9, C-9’), 110.65 (C-3, 
C-4), 43.98 (C-12), 42.46 (C-11), 29.56 (C-13), 28.73 (C-14).  
FT-IR (solid): ṽ (cm-1) = 2959, 2222, 1602, 1491, 1476, 1332, 1268, 1249, 1234, 
1178, 1113, 1062, 850, 839, 769, 677.  












Synthesis of 1-(3,3-dimethylbutyl)-2,5-dimethyl-1H-pyrrole (36c) 
 
The reaction mixture was stirred at room temperature for 5 minutes and worked-up 
according to the general procedure. The product was obtained as a red-brown solid, 
(341 mg, 1.91 mmol, 97% yield).  
m.p.: 49 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 5.67 (s, 2H, 3-H, 4-H), 3.74 (m, 2H, J = 4.56 
Hz, 7-H), 2.19 (s, 6H, 6-H, 6’-H), 1.46 (m, 2H, J = 4.56 Hz, 8-H), 1.01 (s, 9H, 10-H, 10’-
H, 10’’-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 126.7 (C-2, C-5), 104.9 (C-3, C-4), 44.5 (C-8), 
39.8 (C-7), 29.7 (C-9), 28.9 (C-10, C-10’, C-10’’), 12.0 (C-6, C-6’). 
FT-IR (solid): ṽ (cm-1) = 2954, 1515, 1464, 1442, 1410, 1636, 1296, 1247, 1216, 1179, 
1015, 975, 740. 













Synthesis of 4,4'-(1-(4,4,4-trifluorobutyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (35d) 
(41) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (hexane/EtOAc 2:1, Rf = 0.79) was 
performed. The product was obtained as yellow crystals (338 mg, 0.89 mmol, 50% 
yield). 
m.p.: 136 °C. 
1H-NMR (300 MHz, CD2Cl2):  (ppm) = 7.75 (d, 4H, J = 6.2 Hz, 8-H, 8’-H), 7.58 (d, 
4H, J = 6.2 Hz, 7-H, 7’-H), 6.44 (s, 2H, 3-H, 4-H), 4.20 (m, 2H, 11-H), 1.56-1.29 (m, 
4H, 12-H, 13-H). 
13C-NMR (75 MHz, CD2Cl2):  (ppm) = 137.33 (C-2, C-5), 136.97 (C-6, C-6’), 132.67 
(C-8, C-8’), 128.72 (C-7, C-7’), 118.67 (C-10, C-10’), 112.58 (C-9, C-9’), 110.81 (C-3, 
C-4), 44.53 (C-11), 29.95 (q, C-13), 23.03 (d, C-12).  
19F-NMR (282 MHz):  = -66.90.  
FT-IR (solid): ṽ (cm-1) = 2224, 1599, 1492, 1250, 1244, 1151, 1019, 1010, 841, 774, 
677.  











Synthesis of 2,5-dimethyl-1-(4,4,4-trifluorobutyl)-1H-pyrrole (36d) 
 
The reaction mixture was stirred at room temperature for 5 minutes and worked-up 
according to the general procedure. The product was obtained as a red solid (386 mg, 
1.88 mmol, 94% yield). 
m.p.: 51 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 5.71 (s, 2H, 3-H, 4-H), 3.81 (t, 2H, J = 5.22 
Hz, 7-H), 2.20 (s, 6H, 6-H, 6’-H), 2.18-2.03 (m, 2H, 8-H), 1.93-1.81 (m, 2H, 9-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 127.2 (q, C-10), 127.0 (C-2, C-5), 105.5 (C-3, 
C-4), 42.0 (C-7), 30. 9 (q, C-8), 23.4 (C-8), 12.1 (C-6, C-6’). 
19F-NMR (282 MHz): δ = -66.52.  
FT-IR (solid): ṽ (cm-1) = 2939, 1402, 1380, 1290, 1251, 1135, 1032, 751;  














Synthesis of 4,4'-(1-(cyclohexylmethyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (35e) 
(42) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (hexane/EtOAc 4:1, Rf = 0.75) was 
performed. The product was obtained as yellow crystals (436 mg, 1.19 mmol, 65% 
yield).  
m.p.: 161 °C. 
1H-NMR (300 MHz, CD2Cl2):  (ppm) = 7.70 (d, 4H, J = 6.2 Hz, 8-H, 8’-H), 7.53 (d, 4H, 
J = 6.2 Hz, 7-H, 7’-H), 6.35 (s, 2H, 3-H, 4-H), 3.92 (d, 2H, 11-H), 1.55 (s, 1H, 12-H), 
1.41 (m, 2H, 13-H, 13’-H), 1.09-0.73 (m, 6H, 14-H, 14’-H, 15-H), 0.37 (m, 2H, 13-H, 
13’-H).  
13C-NMR (75 MHz, CD2Cl2):  (ppm) = 138.01 (C-2, C-5), 137.32 (C-6, C-6’), 132.41 
(C-8, C-8’), 128.62 (C-7, C-7’), 118.78 (C-10, C-10’), 112.00 (C-9, C-9’), 110.36 (C-3, 
C-4), 52.38 (C-11), 39.42 (C-12), 30.09 (C-13, C-13’), 25.94 (C-15), 25.39 (C-14, C-
14’). 
FT-IR (solid): ṽ (cm-1) = 2922, 2226, 1604, 1490, 1179, 836, 771.  










Synthesis of 1-(cyclohexylmethyl)-2,5-dimethyl-1H-pyrrole (36e) 
 
The reaction mixture was stirred at room temperature for 10 minutes and worked-up 
according to the general procedure. The product was obtained as a brown oil (375 mg, 
1.97 mmol, 98% yield).  
1H-NMR (300 MHz, CD2Cl2): δ [ppm]  = 5.68 (s, 2H, 3-H, 4-H), 3.54 (d, 2H, J = 7.14 Hz, 
7-H), 2.18 (s, 6H, 6-H, 6’-H), 1.80-1.55 (m, 6H, C-8, C-9, C-9’, C-10, C-10’, C-11), 1.30-
1.11 (m, 3H, C-10, C-10’, C-11), 1.06-0.88 (m, 2H, C-9, C-9’). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm]  = 127.6 (C-2, C-5), 104.9 (C-3, C-4), 49.8 (C-7), 
39.5 (C-8), 31.0 (C-9, C-9’), 26.5 (C-11), 26.0 (C-10, C-10‘), 12.6 (C-6, C-6‘).  
FT-IR (solid): ṽ (cm-1) = 2919, 2848, 1511, 1446, 1403, 1353, 1291, 1018, 966, 738. 
















Synthesis of 4,4'-(1-cyclohexyl-1H-pyrrole-2,5-diyl)dibenzonitrile (35f) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc 4:1, Rf = 0.61) 
was performed. The product was obtained as a light yellow solid (537 mg, 1.53 mmol, 
76% yield).  
m.p.: 189 °C;  
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.72 (d, J = 8.43 Hz, 4H, 8-H, 8’-H), 7.55 (d, 
2H J = 8.43 Hz, 7-H, 7’-H), 6.24 (s, 2H, 3-H, 4-H), 3.93 (tt, 1H, J = 3.33 Hz, J = 
12.15 Hz, 11-H), 1.85 (d, 2H, J = 12.27 Hz, 12-H, 12’-H), 1.70-1.41 (m, 5H, 12-H, 12’-
H, 13-H, 13’-H, 14-H), 1.17-0.99 (m, 2H, (13-H, 13’-H), 0.89-0.69 (m, 1H, 14-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 139.3 (C-2, C-5), 136.3 (C-6, C-6’), 131.9 (C-8, 
C-8’), 130.4 (C-7, C-7’), 118.8 (C-10), 111.9 (C-3, C-4), 110.8 (C-9, C-9‘), 59.5 (C-11), 
34.6 (C-12, C-12‘), 26.4 (C-13, C-13‘), 25.1 (C-14). 
FT-IR (solid): ṽ (cm-1) = 2923, 2857, 2222, 1603, 1489, 1451, 1410, 1397, 1376, 1320, 
1265, 1225, 1198, 1177, 1110, 1017, 843, 833, 770, 692. 












Synthesis of 1-cyclohexyl-2,5-dimethyl-1H-pyrrole (36f) 
 
The reaction mixture was stirred at room temperature for 10 minutes and worked-up 
according to the general procedure. The product was obtained as a yellow solid 
(340 mg, 1.92 mmol, 96% yield). 
m.p.: 56 °C.  
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 5.64 (s, 2H, 3-H, 4-H), 3.99-3.79 (m, 1H, 7-H), 
2.26 (s, 6H, 6-H, 6’-H), 1.98-1.67 (m, 7H, 8-H, 8’-H, 9-H, 9’-H, 10-H), 1.49-1.14 (m, 3H, 
9-H, 9’-H, 10-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 127.5 (C-2, C-5), 106.0 (C-3, C-4), 56.3 (C-7), 
32.5 (C-8, C-8‘), 26.6 (C-9, C-9‘), 25.6 (C-10), 14.1 (C-6, C-6‘). 
FT-IR (solid): ṽ (cm-1) = 2927, 2852, 1654, 1446, 1396, 1344, 1293, 1260, 1215, 1188, 
1145, 1057, 1019, 994, 891, 777, 744. 














Synthesis of 4,4'-(1-phenyl-1H-pyrrole-2,5-diyl)dibenzonitrile (35g) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc 6:1, Rf = 0.43) 
was performed. The product was obtained as a yellow solid (421 mg, 1.22 mmol, 61% 
yield).  
m.p.: 192 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.46 (d, 4H, J = 8.52 Hz, 8-H, 8’-H), 7.41-7.30 
(m, 3H, 13-H, 13’-H, 14-H), 7.14 (d, 2H, J = 8.52 Hz, 7-H, 7’-H), 7.06 (d, 2H, J = 
7.86 Hz, 12-H, 12’-H), 6.63 (s, 2H, 3-H, 4-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 138.0 (C-2, C-5), 137.1 (C-6, C-6‘), 135.3 (C-
11), 131.8 (C-8, C-8‘), 129.4 (C-13, C-13‘), 128.7 (C-12, C-12‘), 128.6 (C-7, C-7‘), 
128.4 (C-14), 118.8 (C-10, C-10‘), 112.2 (C-3, C-4), 109.7 (C-9, C-9‘). 
FT-IR (solid): ṽ (cm-1) = 2361, 2222, 1599, 1491, 1428, 1346, 1179, 842, 778, 698.  














Synthesis of 2,5-dimethyl-1-phenyl-1H-pyrrole (36g) 
 
The reaction mixture was stirred at room temperature for 15 minutes and worked-up 
according to the general procedure. The product was obtained as a yellow solid 
(308 mg, 1.80 mmol, 90% yield).  
m.p.: 51 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.51-7.36 (m, 3H, 9-H, 9’-H, 10-H), 7.25-7.16 
(m, 2H, 8-H, 8’-H), 5.83 (s, 2H, 3-H, 4-H), 2.00 (s, 6H, 6-H, 6’-H).  
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 139.1 (C-7), 128.9 (C-9, C-9’), 128.4 (C-2, C-
5), 128.3 (C-10), 127.51 (C-8, C-8’), 105.7 (C-3, C-4), 12.7 (C-6, C-6’). 
FT-IR (solid): ṽ (cm-1) = 2920, 1596, 1495, 1401, 1318, 1067, 1037, 1006, 772, 746, 
716, 684. 















Synthesis of 4,4'-(1-(4-hydroxyphenyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (35h) 
 
The reaction mixture was refluxed for 2 days in an atmosphere of argon, was protected 
from sunlight and was worked-up according to the general procedure. For purification 
column chromatography (n-hexane/EtOAc 3:1, Rf = 0.54) was performed. The product 
was obtained as a yellow solid (296 mg, 0.82 mmol, 41% yield).  
m.p.: 195 °C. 
1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 9.86 (2, 1H, OH), 7.68 (d, 2H, J = 8.58 Hz, 
8-H, 8’-H), 7.23 (d, 2H, J = 8.58 Hz, 7-H, 7’-H), 6.99 (d, 2H, J = 8.70 Hz, 12-H, 12’-H), 
6.75-6.73 (m, 4H, 3-H, 4-H, 13-H, 13’-H). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 157.8 (C-14), 137.4 (C-2, C-5), 135.7 (C-6, 
C-6’), 132.5 (C-8, C-8’), 130.3 (C-12, C-12’), 129.3 (C-11), 128.7 (C-7, C-7’), 119.3 (C-
10, C-10’), 116.5 (C-13, C-13’), 112.6 (C-3, C-4), 109.1 (C-9, C-9’). 
FT-IR (solid): ṽ (cm-1) = 3335, 2922, 2237, 2222, 1596, 1515, 1259, 1220, 1014, 836, 
797, 781, 656. 












Synthesis of 4-(2,5-dimethyl-1H-pyrrol-1-yl)phenol (36h) 
 
The reaction mixture was refluxed for 15 minutes and worked-up according to the 
general procedure. The product was obtained as a yellow solid (329 mg, 1.76 mmol, 
88% yield).  
m.p.: 103 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.07 (d, 2H, J = 8.7 Hz, 8-H, 8’-H), 6.91 (d, 2H, 
J = 8.7 Hz, 9-H, 9’-H), 5.81 (s, 2H, 3-H, 4-H), 5.16 (s, 1H, OH), 1.99 (s, 6H, 6-H, 6’-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] =155.1 (C-10), 131.9 (C-7), 129.5 (C-8, C-8’), 
128.7 (C-2, C-5), 115.6 (C-9, C-9’), 105.3 (C-3, C-4), 12.6 (C-6, C-6’). 
FT-IR (solid): ṽ (cm-1) = 3242, 1512, 1440, 1408, 1217, 1095, 999, 838, 820, 751. 















Synthesis of 2,5-dimethyl-1-(4-nitrophenyl)-1H-pyrrole (36i) 
 
The reaction mixture was refluxed for 15 minutes and worked-up according to the 
general procedure. The product was obtained as a brown solid (389 mg, 1.80 mmol, 
90% yield).  
m.p.: 143 °C.  
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 8.33 (d, 2H, J = 6 Hz, 9-H, 9’-H), 7.39 (d, 2H, J 
= 6 Hz, 8-H, 8’-H), 5.91 (s, 2h; 3-H, 4-H), 2.06 (s, 6H, 6-H, 6’-H).  
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 128.9 (C-9, C-9’), 128.4 (C-2, C-5), 124.4 (C-8, 
C-8’), 107.3 (C-3, C-4), 12.8 (C-6, C-6’). 
FT-IR (solid): ṽ (cm-1) = 1594, 1516, 1490, 1396, 1335, 1223, 1094, 1000, 853, 776, 
764, 718, 689. 














Synthesis of 4,4'-(1-(2-(diethylamino)ethyl)-1H-pyrrole-2,5-diyl)dibenzonitrile 
(44) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (DCM/MeOH 99:1, Rf = 0.38) was 
performed. The product was obtained as yellow crystals (370 mg, 1.00 mmol, 54% 
yield).  
m.p.: 135 °C. 
1H-NMR (300 MHz, CDCl3):  (ppm) = 7.73 (d, 4H, J = 8.25 Hz, 8-H, 8’-H), 7.60 (d, 4H, 
J = 8.25 Hz, 7-H, 7’-H), 6.39 (s, 2H, 3-H, 4-H), 4.14 (t, 2H, J = 7.05 Hz, 11-H), 2.13-
1.99 (m, 6H, 12-H, 13-H, 13’-H), 6.05 (t, 6H, J = 7.13 Hz, 14-H, 14’-H). 
13C-NMR (75 MHz, CD2Cl2):  (ppm) = 137.93 (C-2, C-5), 136.65 (C-6, C-6’), 132.42 
(C-8, C-8’), 129.01 (C-7, C-7’), 118.82 (C-10, C-10’), 111.91 (C-9, C-9’), 110.41 (C-3, 
C-4), 52.40 (C-12), 47.29 (C-13, C-13’), 44.57 (C-11), 11.43 (C-14, C-14’). 
FT-IR (solid): ṽ (cm-1) = 2970, 2956, 2225, 1738, 1603, 1382, 1215, 838, 779. 












Synthesis of 4,4'-(1-(3,4,5-trimethoxybenzyl)-1H-pyrrole-2,5-diyl)dibenzonitrile 
(45) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (hexane/EtOAc 2:1, Rf = 0.34) was 
performed. The product was obtained as an orange solid (227.1 mg, 0.51 mmol 40% 
yield).  
m.p.: 163 °C. 
1H-NMR (300 MHz, CDCl3):  (ppm) = 7.65 (d, 4H, J = 8.5 Hz, 8-H, 8’-H), 7.47 (d, 4H, 
J = 8.5 Hz, 7-H, 7’-H), 6.49 (s, 2H, C-3, C-4), 5.82 (s, 2H, C-13, C-13’), 5.15 (2, 2H, C-
11), 3.77 (s, 3H, 17-H), 3.63 (s, 6H, 16-H). 
13C-NMR (75 MHz, CDCl3):  (ppm) = 153.48 (C-14), 137.46 (C-2, C-5), 136.88 (C-6, 
C-6’), 133.57 (C-15), 132.42 (C-8, C-8’), 128.93 (C-7, C-7’), 118.66 (C-10, C-10’), 
112.40 (C-9, C-9’), 110.74 (C-3, C-4), 106.73 (C-12), 102.62 (C-13, C-13’), 60.86 (C-
16), 55.94 (C-17), 49.29 (C-11). 
FT-IR (solid): ṽ (cm-1) = 2969, 2358, 2228, 1739, 1597, 1455, 1328, 1232, 1123, 1016, 
845, 787. 














The reaction mixture was refluxed for 3 days and worked-up according to the general 
procedure. For purification column chromatography (hexane/EtOAc 2:1, Rf = 0.56) was 
performed. The product was obtained as an orange solid (100.4 mg, 0.25 mmol, 36% 
yield, heavily contaminated with grease).  
m.p.: 168 °C. 
1H-NMR (300 MHz, CDCl3):  (ppm) = 7.62 (d, 4H, J = 8.40 Hz, 8-H, 8’-H), 7.46 (d, 4H, 
J = 8.40 Hz, 7-H, 7’-H), 6.58 (d, 1H, J = 8.43 Hz, 13-H), 6.48 (s, 2H, 3H, 4-H), 6.11-
6.09 (m, 2H, 16-H, 17-H), 5.90 (s, 2H, 18-H), 5.13 (s, 2H, 11-H). 
13C-NMR (300 MHz, CDCl3):  (ppm) = 148.16 (C-14), 146.92 (C-15), 137.40 (C-2, C-
5), 136.64 (C-6, C-6’), 132.37 (C-8, C-8’), 131.82 (C-12), 128.89 (C-7, C-7’), 118.87 
(C-9, C-9’), 118.77 (C-16), 112.29 (C-10, C-10’), 110.67 (C-17), 108.32 (C-13), 105.95 
(C-3, C-4), 101.17 (C-18), 49.03 (C-11). 
FT-IR (solid): ṽ (cm-1) = 2963, 1738, 1258, 1085, 1012, 786. 















4,4'-(1-(2-Aminoethyl)-1H-pyrrole-2,5-diyl)dibenzonitrile (47a) (197 mg, 
0.63 mmol, 1 equiv.) and 3,4,5-trimethoxybenzaldehyde (47b) (155 mg, 0.79 mmol, 
1.25 equiv.) were dissolved in methanol (40 mL) and NaBH3CN (80 mg, 1.27 mmol, 2 
equiv.) was slowly added to the reaction mixture. It was stirred for 3 days and then 
conc. HCl was added until pH 2 was reached. The resulting solution was basified to 
pH 12 with NaOH and the solvents were removed under reduced pressure. The 
resulting orange residue was purified by column chromatography (DCM, Rf = 0.20). 
The product was obtained as a yellow, viscous oil that was heavily contaminated with 
both educts. The product was used for the next reaction step without further 
purification. 













Synthesis of 1,4-bis(4-Bromophenyl)butane-1,4-dione (50) 
 
ZnCl2 (5.11 g, 37.5 mmol, 2 equiv.), Et3N (4.0 mL, 28.1 mmol, 1.5 equiv.) and absolute 
ethanol (1.72 mL, 28.1 mmol, 1.5 equiv.) were suspended in anhydrous toluene 
(50 mL) under an atmosphere of argon. The reaction mixture was stirred for 
60 minutes. Then, 1-(4-bromophenyl)ethan-1-one (48) (5.56 g, 28.1 mmol, 1.5 equiv.) 
and 2-bromo-1-(4-bromophenyl)ethan-1-one (49) (5.17 g, 17.8 mmol, 1 equiv.) was 
added and the resulting suspension was stirred for 7 days at room temperature. The 
reaction mixture was washed with 10% H2SO4 (50 mL) and a saturated solution of 
NaHCO3 (50 mL). The aqueous phase was extracted with EtOAc (2 x 50 mL) and the 
combined organic phases were dried over Na2SO4. The solvent was evaporated under 
reduced pressure. The residue was recrystallized from EtOAc (ca. 100 mL) and the 
product was obtained as a colorless crystalline solid (4.98 g, 12.7 mmol, 71% yield).  
m.p.: 289 °C. 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 7.95 (d, 4H, J = 8.85 Hz, 3-H, 3’-H, 7-H, 7’-
H), 7.76 (d, 4H, J = 8.85 Hz, 4-H, 4’-H, 6-H, 6’-H), 3.39 (2, 4H, 8-H, 8’-H).  
13C-NMR could not be measured due to its low solubility in common organic solvents. 
FT-IR (solid): ṽ (cm-1) = 2896, 1667, 1583, 1568, 1482, 1406, 1389, 1279, 1189, 1104, 
1071, 977, 742, 783, 760, 658.  









Synthesis of 2,5-bis(4-bromophenyl)-1-(cyclohexylmethyl)-1H-pyrrole (51) 
 
1,4-Bis(4-bromophenyl)butane-1,4-dione (50) (3 g, 7.62 mmol, 1 equiv.) was dissolved 
in HFIP (20 mL) and methylcyclohexylamine (34e) (1.29 g,  11.43 mmol, 1.5 equiv.) 
was added slowly. The resulting mixture was refluxed for 3 days after which the 
solvents were evaporated. The residue was dissolved in DCM (50 mL) and was 
washed with water and brine (20 mL each), dried over anhydrous MgSO4 and the 
solvent was evaporated. The residue was purified with column chromatography 
(Hexane/Ethyl acetate 8:1, Rf = 0.82). The product was obtained as an off-white solid 
(2.80 g, 5.95 mmol, 78% yield). 
m.p.: 153 °C. 
1H-NMR (300 MHz, DCM-d2):  (ppm) = 7.55 (d, 4H, J = 8.43 Hz, 7-H, 7’-H), 7.33 (d, 
4H, J = 8.43 Hz, 8-H, 8’-H), 6.23 (s, 2H, 3-H, 4-H), 3.89 (d, 2H, J = 7.32 Hz, 10-H), 
1.41 (m, 3H, 13-H, 13-H, 14-H), 1.1-0.96 (m, 3H, 11-H, 12’-H, 12’-H), 0.93-0.75 (m, 
3H, 13’-H, 13’-H, 14-H), 0.50-0.30 (m, 2H, 12-H, 12-H).  
13C-NMR (75 MHz, DCM-d2):  (ppm) = 136.62 (C-2, C-5), 133.19 (C-6, C-6‘), 131.62 
(C-8, C-8‘), 130.18 (C-7, C-7‘), 120.63 (C-9, C-9‘), 109.98 (C-3, C-4), 51.81 (C-10), 
39.05 (C-11), 30.03 (C-12), 26.07 (C-14), 25.44 (C-13). 
FT-IR (solid): ṽ (cm-1) = 2970, 1738, 1365, 1228, 1217. 









Synthesis of 2,5-bis(4-bromophenyl)-1-(3,3-dimethylbutyl)-1H-pyrrole (52) 
 
1,4-Bis(4-bromophenyl)butane-1,4-dione (50) (3 g, 7.62 mmol, 1 equiv.) was dissolved 
in HFIP (20 mL) and 3,3-dimethylbutan-1-amine (34c) (1.16 g,  11.43 mmol, 
1.5 equiv.) was added slowly. The resulting mixture was refluxed for 3 days after which 
the solvents were evaporated. The residue was dissolved in DCM (50 mL) and was 
washed with water and brine (20 mL each), dried over anhydrous MgSO4 and the 
solvent was evaporated. The residue was purified with column chromatography 
(Hexane/Ethyl acetate 8:1, Rf = 0.86). The product was obtained as a white solid 
(1.52 g, 3.31 mmol, 43% yield). 
m.p.: 175 – 186 °C. 
1H-NMR (300 MHz, DCM-d2):  (ppm) = 7.56 (d, 4H, J = 8.37 Hz, 7-H, 7’-H), 7.33 (d, 
4H, J = 8.37 Hz, 8-H, 8’-H), 6.23 (s, 2H, 3-H, 4-H), 4.07-3.97 (m, 2H, 10-H), 1.12-1.02 
(m, 2H, 11-H), 0.58 (s, 9H, 13-H). 
13C-NMR (75 MHz, DCM-d2):  (ppm) = 135.24 (C-2, C-5), 132.88 (C-6, C-6‘), 131.53 
(C-8, C-8‘), 130.47 (C-7, C-7‘), 120.92 (C-9, C-9‘), 109.95 (C-3, C-4), 43.87 (C-11), 
41.89 (C-10), 29.37 (C-12), 28.48 (C-13). 
FT-IR (solid): ṽ (cm-1) = 2957, 1666, 1477, 1120, 1007, 822, 769. 









Synthesis of 2,5-bis(4-bromophenyl)-1-(4,4,4-trifluorobutyl)-1H-pyrrole (53)
 
1,4-Bis(4-bromophenyl)butane-1,4-dione (50) (3 g, 7.62 mmol, 1 equiv.) was dissolved 
in HFIP (20 mL) and 4,4,4-trifluorobutan-1-amine (34d) (1.45 g,  11.43 mmol, 
1.5 equiv.) was added slowly. The resulting mixture was refluxed for 3 days after which 
the solvents were evaporated. The residue was dissolved in DCM (50 mL) and was 
washed with water and brine (20 mL each), dried over anhydrous MgSO4 and the 
solvent was evaporated. The residue was purified with column chromatography 
(Hexane/Ethyl acetate 8:1, Rf = 0.75). The product was obtained as an off-white solid 
(2.25 g, 4.64 mmol, 61% yield). 
m.p.: 184 °C. 
1H-NMR (300 MHz, DCM-d2):  (ppm) = 7.58 (d, 2H, J = 8.34 Hz, 7-H, 7’-H), 7.33 (d, 
2H, J = 8.34 MHz, 8-H, 8’-H), 6.29 (s, 2H, 3-H, 4-H), 4.13 (t, 2H, J = 6.48 Hz, 10-H), 
1.56-1.32 (m, 4H, 11-H, 12-H). 
13C-NMR (75 MHz, DCM-d2):  (ppm) = 136.10 (C-2, C-5), 132.43 (C-6, C-6‘), 131.85 
(C-8, C-8‘), 130.18 (C-7, C-7‘), 126.61 (C-13), 121.19 (C-9, C-9‘), 110.61 (C-3, C-4), 
44.00 (C-10), 30.06 (C-12), 22.98 (C-11). 
19F-NMR (262 MHz, DCM-d2):  (ppm) = -66.90 (s, CF3). 
FT-IR (solid): ṽ (cm-1) = 2969, 1738, 1366, 1229, 1217, 1126, 1010, 830, 781. 









Synthesis of 1-benzyl-2,5-diphenyl-1H-pyrrole (69) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc 9:1, Rf = 0.76) 
was performed. The product was obtained as colorless crystals (381 mg, 1.23 mmol, 
62% yield).  
m.p.: 131 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.42-7.23 (m, 10H, 7-H, 7’-H, 8-H, 8’-H, 9-H, 
9’-H), 7.14-7.05 (m, 3H, 13-H, 13’-H, 14-H), 6.63-6.58 (m, 2H, 12-H, 12’-H), 6.35 (s, 
2H, 3-H, 4-H), 5.28 (s, 2H, 10-H).  
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 139.2 (C-11), 136.9 (C-2, C-5), 133.7 (C-6, C-
6’), 128.9 (C-8, C-8’), 128.3 (C-7, C-7’), 128.2 (C-13, C-13’), 127.0 (C-9, C-9’), 126.7 
(C-14), 125.8 (C-12, C-12’), 109.8 (C-3, C-4), 48.6 (C-10).  
FT-IR (solid): ṽ (cm-1) = 2357, 1599, 1480, 1448, 1360, 1321, 1024, 752, 731, 699, 
663. 












Synthesis of 1-benzyl-2,5-di-p-tolyl-1H-pyrrole (70) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc 19:1, Rf = 0.72) 
was performed. The product was obtained as colorless crystals (550 mg, 1.64 mmol, 
82% yield).  
m.p.: 144 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.25 (d, 4H, J = 8.1 Hz, 7-H, 7’-H), 7.17-7.07 
(m, 7H, 8-H, 8’-H, 14-H, 14’-H, 15-H), 6.64-6.60 (m, 2H, 13-H, 13’-H), 6.28 (2, 2H, 3-
H, 4-H), 5.24 (s, 2H, 11-H), 2.34 (s, 6H, 10-H, 10’-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 139.5 (C-11), 136.8 (C-2, C-5), 136.5 (C-9, C-
9’), 130.8 (C-6, C-6’), 129.0 (C-7, C-7’), 128.8 (C-8, C-8’), 128.2 (C-14, C-14’), 126.7 
(C-15), 125.7 (C-13, C-13’), 109.4 (C-3, C-4), 48.4 (C-11), 20.8 (C-10, C-10’).  
FT-IR (solid): ṽ (cm-1) = 2967, 2357, 2340, 1736, 1436, 1365, 1216. 












Synthesis of 1-benzyl-2,5-bis(4-bromophenyl)-1H-pyrrole (71) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc 8:1, Rf = 0.56) 
was performed. The product was obtained as colorless crystals (735 mg, 1.58 mmol, 
79% yield).  
m.p.: 174 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.46 (d, 4H, J = 8.46 Hz, 7-H, 7’-H), 7.24 (d, 
4H, J = 8.46 Hz, 8-H, 8’-H), 7.17-7.08 (m, 3H, 13-H, 13’-H, 14-H), 6.64-6.57 (m, 2H, 
12-H, 12’-H), 6.35 (s, 2H, 3-H, 4-H), 5.20 (s, 2H, 10-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 138.8 (C-11), 136.0 (C-2, C-5), 132.5 (C-6, C-
6’), 131.5 (C-7, C-7’), 130.4 (C-8, C-8‘), 128.4 (C-13, C-13‘), 127.0 (C-14), 125.7 (C-
12, C-12‘), 121.0 (C-9, C-9‘), 110.3 (C-3, C-4), 48.7 (C-10). 
FT-IR (solid): ṽ (cm-1) =2962, 2031, 1477, 1409, 1358, 1322, 1259, 1097, 1068, 1008, 
820, 776, 762, 715. 












Synthesis of 1-benzyl-2,5-bis(4-nitrophenyl)-1H-pyrrole (72) 
 
The reaction mixture was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc 6:1, Rf = 0.43) 
was performed. The product was obtained as a brown solid (528 mg, 1.32 mmol, 
66% yield).  
m.p.: 139 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 8.20 (d, 4H, J = 8.88 Hz, 8-H, 8’-H), 7.56 (d, 
4H, J = 8.88 Hz, 7-H, 7’-H), 7.17-7.10 (m, 3H, 13-H, 13’-H, 14-H), 6.67-6.61 (m, 2H, 
12-H, 12’-H), 6.59 (s, 2H, 3-H, 4-H), 5.32 (s, 2H, 10-H, the signal overlaps with the 
solvent residue proton signal). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 146.6 (C-9), 139.3 (C-11), 137.9 (C-6, C-6‘), 
137.0 (C-2, C-5), 128.9 (C-7, C-7‘), 128.6 (C-13, C-13‘), 127.4 (C-14), 125.7 (C-10), 
123.8 (C-8, C-8‘), 112.9 (C-3, C-4), 49.5 (C-10). 
FT-IR (solid): ṽ (cm-1) = 2960, 2921, 2851, 1590, 1508, 1337, 1258, 1012, 792, 750, 
697, 678.  











Synthesis of 1-benzyl-2-methyl-5-phenyl-1H-pyrrole (73) 
 
The reaction was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (Hexane/EtOAc, 20:1, Rf = 0.46) 
was performed. The product was obtained as a slightly yellow oil (175 mg, 1.42 mmol, 
71% yield).  
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.35-7.19 (m, 9H, 7-H, 7’-H, 8-H, 8’-H, 9-H, 13-
H, 13’-H, 14-H), 6.89 (d, 2H, J = 8.19 Hz, 12-H, 12’-H), 6.18 (d, 1H, J = 3.45 Hz, 3-H), 
6.01 (dd, 1H, J = 3.45 Hz, J = 0.84 Hz, 4-H), 5.15 (s, 2H, 10-H), 2.14 (s, 3H, 15-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 139.1 (C-2), 134.4 (C-11), 133.9 (C-6), 130.5 
(C-5), 128.6 (C-8), 128.5 (C-9), 128.3 (C-7), 126.9 (C-14), 126.5 (C-12), 125.6 (C-13), 
108.0 (C-3), 107.2 (C-4), 47.5 (C-10), 12.3 (C-15). 
FT-IR (solid): ṽ (cm-1) = 2914, 1601, 1512, 1495, 1474, 1452, 1444, 1406, 1354, 1310, 
1073, 1026, 748, 726, 695, 574, 536, 458. 













Synthesis of 1-benzyl-2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrole (74) 
 
The reaction was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc, 20:1, Rf = 0.64) 
was performed. The product was obtained as an off-white solid (232 mg, 1.58 mmol, 
79% yield).  
m.p.: 87.9 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.33-7.14 (m, 7H, C-8, C-13, C-13’, C-14, C-
14’, C-15), 6.89 (d, 2H, J = 6.84 Hz, 7-H, 7‘-H), 6.16 (d, 1H, J = 3.45 Hz, 3-H), 6.00 
(dd, 1H, J = 3.45 Hz, J = 0.78 Hz, 4-H), 5.12 (s, 2H, 11-H), 2.45 (s, 3H, 10-H), 2.13 (s, 
3H, 16-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 139.1 (C-2), 130. 7 (C-5), 130.3 (C-12), 128.8 
(C-14), 128.6 (C-7), 126.9 (C-15), 126.4 (C-13), 125.8 (C-8), 125.4 (C-6), 107.9 (C-3), 
107.2 (C-4), 47.5 (C-11), 15.5 (C-10), 12.3 (C-16). 
FT-IR (solid): ṽ (cm-1) = 2917, 1510, 1496, 1434, 1414, 1356, 1311, 1105, 1029, 818, 
760, 727, 694. 











Synthesis of 1-benzyl-2-methyl-5-(4-(methylsulfonyl)phenyl)-1H-pyrrole (75) 
 
The reaction was refluxed for 2 days and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc, 2:1, Rf = 0.55) 
was performed. The product was obtained as a yellow solid (254 mg, 1.56 mmol, 
78% yield).  
m.p.: 140.4 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.80 (d, 2H, J = 8.31 Hz, 7-H, 7’-H), 7.46 (d, 
2H, J = 8.31 Hz, 8-H, 8’-H), 7.35-7.21 (m, 3H, 14-H, 14’-H, 15-H), 6.91 (d, 2H, J = 
7.29 Hz, 13-H, 13’-H), 6.36 (d, 1H, J = 3.57 Hz, 3-H), 6.08 (d, 1H, J = 3.57 Hz, 4-H), 
5.19 (s, 2H, 11-H), 3.00 (s, 3H, 10-H), 2.17 (s, 3H, 16-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 139.1 (C-2), 138.5 (C-9), 137.9 (C-6), 132.9 (C-
12), 132.5 (C-5), 128.8 (C-14, C-14’), 128.3 (C-8, C-8’), 127.5 (C-78, C-7’), 127.2 (C-
15), 125.5 (C-13, C-13’), 110.3 (C-3), 108.1 (C-4), 47.8 (C-11), 44.4 (C-10), 12.3 (C-
16). 
FT-IR (solid): ṽ (cm-1) = 2922, 1593, 1316, 1302, 1147, 964, 776, 761, 738, 726, 697. 











Synthesis of 1-benzyl-2,3,5-triphenyl-1H-pyrrole (76) 
 
The reaction was refluxed for 3 days and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc, 10:1, Rf = 0.63) 
was performed. The product was obtained as a white solid (285 mg, 1.48 mmol, 74% 
yield).  
m.p.: 167.5 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] 7.55-7.00 (m, 18H, 7-H, 7’-H, 8-H, 8’-H, 9-H, 11-
H, 11’-H, 12-H, 12’-H, 13-H, 15-H, 15’-H, 16-H, 16’-H, 17-H, 21-H, 21’-H, 22-H), 6.66-
6.61 (m, 2H, 20-H, 20’-H), 6.57 (s, 1H, 4-H), 5.13 (s, 2H, 18-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 139.1 (C-2), 136.3 (C-10), 135.6 (C-19), 133.5 
(C-6), 133.1 (C-14), 132.4 (C-5), 131.3 (C-8, C-8’), 129.0 (C-12, C-12’), 128.4 (C-16, 
C-16’), 128.4 (C-7, C-7’), 128.1 (C-15, C-15’), 128.0 (C-21, C-21’), 127.7 (C-9), 127.6 
(C-11, C-11’), 127.1 (C-13), 126.7 (C-17), 125.9 (C-20, C-20’), 125.2 (C-22), 123.3 (C-
3), 109.6 (C-4), 48.3 (C-18). 
FT-IR (solid): ṽ (cm-1) = 1600, 1450, 1341, 805, 766, 750, 740, 695. 










Synthesis of ethyl 1-benzyl-5-(4-bromophenyl)-2-phenyl-1H-pyrrole-3-
carboxylate (77) 
 
The reaction was refluxed for 3 days and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc, 10:1, Rf = 0.30) 
was performed. The product was obtained as a colorless oil (377 mg, 1.64 mmol,  
82% yield).  
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.47 (d, 2H, J = 8.55 Hz, 14-H, 14’-H), 7.40-
7.20 (m, 7H, 7-H, 7’-H, 8-H, 8’-H, 9-H, 15-H, 15’-H), 7.19-7.07 (m, 3H, 20-H, 20’-H, 21-
H), 6.79 (s, 1H, 4-H), 6.66-6.57 (m, 2H, 19-H, 19’-H), 5.05 (s, 2H, 17-H), 4.10 (q, 2H, 
J = 7.12 Hz, 11-H), 1.12 (t, 3H, J = 7.12 Hz, 12-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 164.2 (C-10), 140.2 (C-13), 138.0 (C-18), 133.8 
(C-6), 132.0 (C-2), 131.7 (C-5), 131.6 (C-14, C-14’), 130.8 (C-7, C-7’, C-8, C-8’), 128.3 
(C-20, C-20’), 128.3 (C-9), 127.7 (C-15, C-15’), 127.1 (C-21), 125.7 (C-19, C-19’), 
121.7 (C3), 114.4 (C-4), 111.2 (C-16), 59.4 (C-11), 48.5 (C-17), 13.9 (C-12).  
FT-IR (solid): ṽ (cm-1) = 1712, 1474, 1454, 1413, 1267, 1176, 1100, 1073, 1035, 984, 
836, 823, 778, 759, 736, 720, 706, 696. 









Synthesis of 1-benzyl-2,3,4,5-tetramethyl-1H-pyrrole (78) 
 
The reaction was stirred for 5 minutes and worked-up according to the general 
procedure. For purification column chromatography (n-hexane/EtOAc, 10:1, Rf = 0.85) 
was performed. The product was obtained as a reddish oil (175 mg, 1.64 mmol, 82% 
yield).  
1H-NMR (300 MHz,CD2Cl2): δ [ppm] = 7.32-7.19 (m, 3H, 9-H, 9’-H, 10-H), 6.88 (d, 2H, 
J = 6.9 Hz, 8-H, 8’-H), 4.96 (s, 2H, 6-H), 2.03 (s, 6H, 11-H, 11’-H), 1.94 (s, 6H, 12-H, 
12’-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 139.6 (C-7), 128.5 (C-9, C-9’), 126.7 (C-2, C-
5), 125.8 (C-8, C-8’), 122.3 (C-10), 113.0 (C-3, C-4), 46.7 (C-6), 9.5 (C-11, C-11’), 9.2 
(C-12, C-12’). 
FT-IR (solid): ṽ (cm-1) = 2916, 2857, 1643, 1495, 1453, 1393, 1351, 1215, 1190, 1101, 
1029, 729, 695. 
















The reaction mixture was heated for 3 days in a pressure tube at 95 °C. Afterwards, 
the reaction mixture was diluted with iPrOH and acetone (1:1, ca. 15 mL) and cooled 
to 0 °C. The precipitated solid was isolated by filtration, washed with cold water to 
remove trace solvents, and dried under vacuum to afford the desired product. The 
product was obtained as a yellow crystalline solid (344 mg, 0.68 mmol, 34% yield).  
m.p.: 219 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.37-6.84 (m, 19, H, 6-H, 6’-H, 7-H, 7’-H, 10-
H, 10’-H, 11-H, 11’-H, 12-H, 15-H, 15’-H, 16-H, 16’-H, 17-H, 22-H, 22’-H, 23-H, 23’-H, 
24-H), 5.09 (s, 2H, 20-H), 3.24 (sept, 1H, 18-H), 1.36 (d, 6H, J = 6.81 Hz, 19-H, 19’-
H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 160.68 (C-14), 141.31 (C-4), 138.53 (C-9), 
138.47 (C-14), 134.83 (C-21), 133.17 (C-7, C-7’), 130.46 (C-11, C-11’), 129.34 (C-1), 
128.63 (C-6, C-6’), 128.29 (C-10, C-10’), 128.04 (C-5), 127.20 (C-12), 126.54 (C-17), 
125.52 (C-23, C-23’), 123.47 (C-22, C-22’), 121.80 (C-2), 119.46 (C-16, C-16’), 
116.12 (C-3), 115.16 (C-24), 114.87 (C-15, C-15’), 47.91 (C-20), 26.63 (C-18), 21.13 
(C-19, C-19’). 
19F-NMR (282 MHz, CD2Cl2): δ [ppm] = -114.44. 
FT-IR (solid): ṽ (cm-1) =3403, 2962, 1661, 1595, 1563, 1525, 1496, 1437, 1309, 
1242, 1217, 1154, 845, 752, 736, 693. 





General procedure for the synthesis of 2,5-substituted Furans or Thiophenes: The 1,4-
diketone (2 mmol) was dissolved in 4-10 mL 1,1,1,3,3,3-hexafluoroisopropanol at 
ambient temperature. Hydrochloric acid (catalytic amounts) for furans or Lawessons’s 
reagent (3.5 mmol) for thiophenes was added slowly and the mixture was stirred for 
the indicated time under reflux conditions. The reaction mixture was allowed to cool to 
room temperature and the solvent was removed. The residue was dissolved in an 
appropriate solvent and the insoluble solids were removed by filtration. The organic 
phase was dried over MgSO4 and the solvent was removed under reduced pressure. 






















Synthesis of 4,4'-(furan-2,5-diyl)dibenzonitrile (80) 
 
The reaction was refluxed for 2 h and worked-up according to the general procedure. 
For purification, the crude product was recrystallized from THF. The product was 
obtained as a yellow solid (238 mg, 0.88 mmol, 88% yield).  
m.p.: 292.1 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.86 (d, 4H, J = 8.7 Hz, 6-H, 6-H, 6’-H, 6’-H), 
7.72 (d, 4H, J = 8.7 Hz, 7-H, 7-H, 7’-H, 7’-H), 6.99 (s, 2H, 2-H, 3-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 152.8 (C-1, C-4), 133.8 (C-5, C-5’), 132.7 (7-C, 
7-C, 7’-C, 7’-C), 124.1 (6-C, 6-C, 6’-C, 6’-C), 118.7 (9-C, 9’-C), 110.9 (8-C, 8’-C), 110.7 
(2-C, 3-C). 
FT-IR (solid): ṽ (cm-1) = 3352, 2222, 1605, 842, 792, 664. 














Synthesis of 2,5-diphenylfuran (81) 
 
The reaction was refluxed for 3 h and worked-up according to the general procedure. 
For purification column chromatography (n-hexane/EtOAc, 10:1, Rf = 0.85) was 
performed. The product was obtained as a white solid (176 mg, 0.80 mmol, 80% yield).  
m.p.: 91 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.79 (d, 4H, J = 7.29 Hz, 6-H, 6’-H), 7.45 (t, 4H, 
J = 7.29 Hz, 7-H, 7’-H), 7.31 (7, 2H, J = 7.29 Hz, 8-H, 8’-H), 6.80 (s, 2H, 2-H, 3-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 155.3 (C-1, C-4), 130.7 (C-5, C-5’), 128.7 (C-7, 
C-7’), 127.4 (C-8, C-8’), 123.6 (C-6, C-6’), 107.3 (C-2, C-3). 
FT-IR (solid): ṽ (cm-1) = 3039, 1610, 1488, 1480, 1260, 1021, 928, 794, 754, 689, 671.  














Synthesis of 2,5-bis(4-bromophenyl)furan (82) 
 
The reaction was refluxed for 2 h and worked-up according to the general procedure. 
For purification, the crude product was recrystallized from THF. The product was 
obtained as colorless needles (342 mg, 0.91 mmol, 91% yield).  
m.p.: 205.9 °C. 
1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 7.79 (d, 4H, J = 8.58 Hz, 7-H, 7-H, 7’-H, 7’-
H), 7.65 (d, 4H, J = 8.58 Hz, 6-H, 6-H, 6’-H, 6’-H), 7.17 (s, 2H, 2-H, 3-H). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 152.4 (C-1, C-4), 132.3 (C-6, C-6, C-6’, C-
6’), 129.6 (C-5, C-5’), 126.0 (C-7, C-7, C-7’, C-7’), 121.1 (C-8, C-8’), 109.7 (C-2, C-3). 
FT-IR (solid): ṽ (cm-1) = 1471, 1406, 1106, 1072, 1020, 1004, 924, 824, 790, 715, 669. 















Synthesis of 2,5-bis(4-nitrophenyl)furan (83) 
 
The reaction was refluxed for 2 h and worked-up according to the general procedure. 
For purification the crude product was recrystallized from THF. The product was 
obtained as an orange solid (264 mg, 0.85 mmol, 85% yield).  
m.p.: 270.4 °C. 
1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 8.35 (d, 4H, J = 8.85 Hz, 7-H, 7-H, 7’-H, 7’-
H), 8.15 (d, 4H, J = 8.85 Hz, 6-H, 6-H, 6’-H, 6’-H), 7.56 (s, 2H, 2-H, 3-H). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 153.0 (C-1, C-4), 135.7 (C-8, C-8’), 125.1 (C-
7, C-7, C-7’, C-7’), 125.0 (C-6, C-6, C-6’, C-6’), 113.6 (C-5, C-5’), 100.0 (C-2, C-3). 
FT-IR (solid): ṽ (cm-1) = 3117, 1594, 1504, 1485, 1327, 1287, 1105, 1035, 930, 851, 
792, 750, 690. 














Synthesis of 2-methyl-5-phenylfuran (84) 
 
The reaction was refluxed for 6 h and worked-up according to the general procedure. 
For purification column chromatography (n-pentane, Rf = 0.82) was performed. The 
product was obtained as a slightly yellow oil (128 mg, 0.81 mmol, 81% yield).  
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.62 (d, 2H, J = 7.38 Hz, 7-H, 7’-H), 7.36 (t, 2H, 
J = 7.77 Hz, 8-H, 8’-H), 7.22 (t, 1H, J = 7.95 Hz, 9-H), 6.57 (d, 1H, J = 3.20 Hz, 3-H), 
6.08 (d, 1H, J = 3.20 Hz, 2-H), 2.37 (s, 3H, 5-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 152.1 (C-6,), 131.1 (C-4), 128.6 (C-8, C-8’), 
126.7 (C-9), 123.1 (C-7, C-7’), 107.6 (C-2), 105.9 (C-3), 100.0 (C-1), 13.4 (C-5). 
FT-IR (solid): ṽ (cm-1) = 2918, 1667, 1595, 1546, 1488, 1446, 1205, 1065, 1021, 784, 
756, 589, 661. 















Synthesis of 2-methyl-5-(4-(methylthio)phenyl)furan (85) 
 
The reaction was refluxed for 2 h and worked-up according to the general procedure. 
For purification column chromatography (n-hexane/EtOAc, 10:1, Rf = 0.74) was 
performed. The product was obtained as a yellow solid (177 mg, 0.87 mmol, 87% yield.  
m.p.: 81.8 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.55 (d, 2H, J = 8.55 Hz, 6-H, 6’-H), 7.24 (d, 
2H, J = 8.55 Hz, 5-H, 5’-H), 6.52 (d, 1H, J = 3.18 Hz, 2-H), 6.07 (d, 1H, J = 3.18 Hz, 3-
H), 2.49 (s, 3H, 10-H), 2.35 (s, 3H, 9-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 152.0 (C-1), 151. 8 (C-4), 136.9 (C-8), 128.1 
(C-5), 126.6 (C-6, C-6’), 123.6 (C-7, C-7’), 107.7 (C-3), 105.6 (C-2), 15.6 (C-9), 13.4 
(C-10). 
 FT-IR (solid): ṽ (cm-1) = 2912, 2402, 1689, 1553, 1492, 1433, 1073, 1020, 974, 793, 
771. 













Synthesis of 2-methyl-5-(4-(methylsulfonyl)phenyl)furan (86) 
 
The reaction was refluxed for 4 h and worked-up according to the general procedure. 
For purification column chromatography (n-hexane/EtOAc, 4:1, Rf = 0.74) was 
performed. The product was obtained as a white solid (194 mg, 0.82 mmol, 82% yield).  
m.p. (decomposition): 140 °C;  
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.89 (d, 2H, J = 8.61 Hz, 6-H, 6’-H), 7.79 (d, 
2H, J = 8.61 Hz, 7-H, 7’-H), 6.78 (d, 1H, J = 3.29 Hz, 2-H), 6.15 (dd, 1H, J = 3.29 Hz, 
J = 0.87 Hz, 3-H), 3.04 (s, 3H, 9-H), 2.39 (s, 3H, 10-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 154.2 (C-5), 150.3 (C-4), 138.0 (C-8), 135.8 (C-
1), 127.9 (C-6, C-6’), 123.4 (C-7, C-7’), 109.4 (C-2), 108.4 (C-3), 44.5 (C-9), 13.5 (C-
10). 
FT-IR (solid): ṽ (cm-1) = 2919, 1590, 1300, 1279, 1143, 1089, 1026, 835, 796, 775. 













Synthesis of 2,3,5-triphenylfuran (87) 
 
The reaction was refluxed for 4 h and worked-up according to the general procedure. 
For purification column chromatography (n-hexane/EtOAc, 20:1, Rf = 0.79) was 
performed. The product was obtained as colorless crystals (207 mg, 0.70 mmol,  
70% yield).  
m.p.: 95 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.79 (d, 2H, J = 7.71 Hz, 14-H, 14’-H), 7.62 (d, 
2H, J = 7.17 Hz, 6-H, 6’-H), 7.51-7.23 (m, 11H, 7-H, 7’H, 8-H, 10-H, 10’-H, 11-H, 11’-
H, 12-H, 15-H, 15’-H, 16-H), 6.87 (s, 1H, 2-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 152.5 (C-13), 147.9 (C-1), 134.2 (C-9), 131.1 
(C-13), 130.4 (C-5), 128.8 (C-10, C-10’), 128.7 (C-15, C-15’), 128.6 (C-7, C-7’), 127.4 
(C-11, C-11’), 127.6 (C-16), 127.6 (C-8), 127.3 (C-12), 126.1 (C-6, C-6’), 124.6 (C-3), 
123.7 (C-14, C-14’), 109.5 (C-2). 
FT-IR (solid): ṽ (cm-1) = 2922, 2360, 1487, 1143, 950, 804, 766, 753, 687, 568. 












Synthesis of ethyl 5-(4-bromophenyl)-2-phenylfuran-3-carboxylate (88) 
 
The reaction was refluxed for 4 h and worked-up according to the general procedure. 
For purification column chromatography (n-hexane/EtOAc, 3:1, Rf = 0.88) was 
performed. The product was obtained as a colorless liquid (315 mg, 0.85 mmol, 
85% yield).  
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 8.06 (d, 2H, J = 8.34 Hz, 13-H, 13’-H), 7.64 (d, 
2H, J = 8.58 Hz, 6-H, 6’-H), 7.57 (d, 2H, J = 8.58 Hz, 7-H, 7’-H), 7.52-7.39 (m, 3H, 14-
H, 14’-H, 15-H), 7.13 (s, 1H, 2-H), 4.31 (q, 2H, J = 7.11 Hz, 10-H), 1.35 (t, 3H, J = 
7.11 Hz, 11-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 163.1 (C-9), 156.5 (C-12), 151.3 (C-5), 132.0 
(C-7, C-7’), 129.6 (C-1), 129.4 (C-15), 128.8 (C-4), 128.3 (C-13, C-13’), 128.1 (C-14, 
C-14’), 125.4 (C-6, C-6’), 121.8 (C-8), 116.1 (C-3), 108.5 (C-2), 60.7 (C-10), 14.0 (C-
11). 
FT-IR (solid): ṽ (cm-1) = 2973, 2360, 1271, 1479, 1267, 1238, 1157, 1094, 1071, 825, 
813, 776, 753, 683. 










Synthesis of 5-(4-fluorophenyl)-2-isopropyl-N,4-diphenylfuran-3-carboxamide 
(89) 
 
The reaction was refluxed for 14 h and worked-up according to the general procedure. 
For purification column chromatography (n-hexane/EtOAc, 4:1, Rf = 0.62) was 
performed. The product was obtained as a brown solid (219 mg, 0.55 mmol,  
55% yield).  
m.p.: 160 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.38-7.21 (m, 8H, 11-H, 11’-H, 12-H, 15-H, 15’-
H, 16-H, 16’-H, 17-H ), 7.21-7.12 (m, 2H, 10-H, 10’-H), 6.89 (m, 2H, 6-H, 6’-H), 6.72 
(m, 2H, 7-H, 7’-H), 2.43 (sept, 1H, J = 6.78 Hz, 18-H), 1.01 (d, 6H, J = 6.78 Hz, 19-H, 
19’-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 186.04 (C-4), 168.82 (C-13), 163.38 (C-8), 
160.10 (C-1), 135.09 (C-14), 134.79 (C-9), 132.06 (C-6, C-6’), 130.77 (C-11, C-11’), 
130.02 (C-15), 128.65 (C-16, C-16’), 128.10 (C-10, C-10’), 127.40 (C-15, C-15’), 
127.33 (C-12), 127.10 (C-17), 116.55 (C-2), 114.60 (C-7, C-7’), 105.05 (C-3), 30.88 
(C-18), 18.95 (C-19, C-19’). 
19F-NMR (282 MHz, CD2Cl2): δ [ppm] = -114.49. 
FT-IR (solid): ṽ (cm-1) = 2965, 1592, 1504, 1489, 1222, 1156, 1074, 845, 740, 704, 
687. 






Synthesis of 2,5-diphenylthiophene (90) 
 
1,4-Diphenylbutane-1,4-dione (59) (200.2 mg, 0.84 mmol, 1 equiv.) and Lawesson’s 
Reagent (564.5 mg, 1.26 mmol, 3 equiv.) were dissolved in 1,1,1,3,3,3-
hexafluoroisopropanol (6 mL) in an atmosphere of argon. The reaction mixture was 
refluxed for 18 hours. The solvent was evaporated and the yellow residue was purified 
with column chromatography (n-hexane/EtOAc 25:1, Rf = 0.6). The 1H-NMR spectrum 
revealed a mixture of the product and the corresponding furan in a ratio of 4:1. 139.0 
mg, 70% yield. After recrystallization from hexane the product was obtained as white 
crystals. 29.5 mg, 15% yield. A furan impurification of 2 % was detected by 1H-NMR 
spectroscopy.  
m.p.: 151.7 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.66 (d, 4H, J = 7.26 Hz, 7-H, 7’-H), 7.41 (t, 4H, 
J = 7.26 Hz, 8-H, 8’-H), 7.37-7.25 (m, 4H, 3-H, 4-H, 9-H, 9’-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 143.5 (C-2, C-5), 134.2 (C-6, C-6’), 128.9 (C-8, 
C-8’), 127.6 (C-9, C-9’), 125.5 (C-7, C-7’), 124.1 (C-3, C-4). 
FT-IR (solid): ṽ (cm-1) = 2158, 1453, 939, 902, 803, 746, 682. 










Synthesis of 2,5-bis(4-Bromophenyl)thiophene (91) 
 
1,4-bis(4-Bromo-phenyl)butane-1,4-dione (50) (402.3 mg, 1.0 mmol, 1 equiv.) and 
Lawesson’s Reagent (636.2 mg, 1.5 mmol, 3 equiv.) were dissolved in 1,1,1,3,3,3-
hexafluoroisopropanol  (6 mL) in an atmosphere of argon. The reaction mixture was 
refluxed for 18 hours. The solvent was evaporated and the yellow residue was purified 
with column chromatography (n-hexane/EtOAc 25:1, Rf = 0.55). The product was 
obtained as a white white solid (328.5 mg, 0.83 mmol, 83 % yield).  
m.p.: 206.5 °C;  
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.52 (s, 8H, 7-H, 7’-H, 8-H, 8’-H), 7.32 (s, 2H, 
3-H, 4-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 142.59 (C-2, C-5), 133.1 (C-6, C-6’), 132.0 (C-
8, C-8’), 127.0 (C-7, C-7’), 124.6 (C-3, C-4), 121.4 (C-9, C-9’). 
FT-IR (solid): ṽ (cm-1) = 3076, 1446, 1400, 1118, 934, 825, 794. 












Synthesis of 2,5-bis(4-Nitrophenyl)thiophene (92) 
 
1,4-bis(4-Nitrophenyl)-butane-1,4-dione (61) (330 mg, 1.0 mmol, 1 equiv.) and 
Lawesson’s Reagent (622.6 mg, 1.5 mmol, 3 equiv.) were dissolved in 1,1,1,3,3,3-
hexafluoroisopropanol  (6 mL) in an atmosphere of argon. The reaction mixture was 
refluxed for 8 hours. The solvent was evaporated and the yellow residue was refluxed 
in saturated sodium carbonate solution (20 mL) for 14 h. The suspension was then 
extracted with dichloromethane (3 × 30 mL). The combined organic layers were 
washed with saturated sodium carbonate solution (30 mL) and brine (30 mL). After 
drying over magnesium sulfate and evaporation of the solvent the product was 
obtained as a highly hygroscopic orange solid (270 mg, 0.82 mmol, 82% yield).  
m.p. (decomposition): 257.0 °C. 
1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 8.28 (d, 4H, J = 8.89 Hz, 8-H, 8’-H), 7.83 (d, 
4H, J = 8.91 Hz, 7-H, 7’-H), 7.57 (s, 2H, 3-H, 4-H). 
13C-NMR could not be measured due to its low solubility in common organic solvents. 
FT-IR (solid): ṽ (cm-1) = 1587, 1506, 1335, 1278, 1107, 846, 796, 746, 682. 










Synthesis of 2-Methyl-5-(4-(methylthio)phenyl)thiophene (93) 
 
1-(4-(Methylthio)phenyl)pentane-1,4-dione (62) (223.7 mg, 1.0 mmol, 1 equiv.) and 
Lawesson’s Reagent (638.2 mg, 1.5 mmol, 3 equiv.) were dissolved in 1,1,1,3,3,3-
hexafluoroisopropanol  (6 mL) in an atmosphere of argon. The reaction mixture was 
refluxed for 20 hours. The solvent was evaporated and the yellow residue was purified 
with column chromatography (n-hexane/EtOAc 25:1, Rf = 0.65). The product was 
obtained as a light yellow solid (161.0 mg, 0.73 mmol, 73 % yield).  
m.p.: 117.7 °C. 
 1H-NMR (300 MHz, CD2Cl2): δ [ppm] = 7.47 (d, 2 H, J = 8.37, 7-H, 7’-H), 7.23 (d, 2 H, 
J = 8.34 Hz, 8-H, 8’-H), 7.09 (d, 2H, J = 3.51 Hz, 4-H), 6.73 (d, 2 H, J = 3.48 Hz, 3-H), 
2.49 (s, 6 H, 11-H, 12-H). 
13C-NMR (75 MHz, CD2Cl2): δ [ppm] = 141.9 (C-9), 140.0 (C-5), 137.9 (C-2), 132.1 (C-
6), 127.3 (C8), 126.8 (C-4), 126.2 (C-7), 123.2 (C-3), 16.2 (C-11), 15.7 (C-12). 
FT-IR (solid): ṽ (cm-1) = 2915, 1497, 1404, 1095, 944, 815, 796. 











Synthesis of 2,3,5-Triphenylthiophene (94) 
 
1,2,4-Triphenylbutane-1,4-dione (65) (317.2 mg, 1.0 mmol, 1 equiv.) and Lawesson’s 
Reagent (609.4 mg, 1.5 mmol, 3 equiv.) were dissolved in 1,1,1,3,3,3-
hexafluoroisopropanol (9 mL) in an atmosphere of argon. The reaction mixture was 
refluxed for 14 hours. The solvent was evaporated and the yellow residue purified with 
column chromatography (n-hexane/EtOAc 25:1, Rf = 0.7). The 1H-NMR spectrum 
showed a mixture of the product and the corresponding furan in a ratio of 1:1. 
Recrystallization from n-hexane had no effect on the purity. The mixture was obtained 
as slightly yellow crystals (300.1 mg, 0.91 mmol, 91% yield).  















6.1.2.3 Syntheses for chapter 4.3 
 
Synthesis of 1,3-bis(4-bromophenyl)propan-2-one (98) 
 
DCC (0.5 g, 2.42 mmol, 0.6 equiv.) and DMAP (148 mg, 1.21 mmol, 0.3 equiv.) were 
dissolved in anhydrous DCM (20 mL) under an atmosphere of argon. 4-
Bromophenylacetic acid (96) (1.73 g, 8.07 mmol, 2 equiv.) dissolved in anhydrous 
DCM (25 mL) was added slowly to the reaction mixture which turned orange and gas 
evolution was observed. The reaction mixture was stirred overnight. The precipitated 
DCU was removed by filtration through Celite, the filter cake was washed with MeCN 
(50 mL), and afterwards the solvents were removed from the combined organic 
phases. The yellow residue was dissolved in EtOAc (50 mL) and it was washed with 
1 M HCl (50 mL) to remove DMAP, then with a saturated solution of NaHCO3 (50 mL) 
to remove 4-Bromophenylacetic acid, then with a saturated solution of NaCl (50 mL) 
and the solvents were removed. The yellow residue was recrystallized from EtOH to 
give the desired product as slightly yellow needles (1.07 g, 2.92 mmol, 72% yield). 
m.p.: 115 °C. 
1H-NMR (300 MHz, CDCl3):  (ppm) = 7.44 (d, 4H, J = 8.36 Hz, 5-H, 5’-H), 7.01 (d, 4H, 
J = 8.36 Hz, 4-H, 4’-H), 3.68 (s, 4H. 2-H, 2’-H). 
13C-NMR (300 MHz, CDCl3):  (ppm) = 204.23 (C-1), 132.59 (C-3, C-3’), 131.86 (C-5, 
C-5’), 131.17 (C-4, C-4’), 121.27 (C-6, C-6’), 48.47 (C-2, C-2’). 
FT-IR (solid): ṽ (cm-1) = 2970, 2359, 1738, 1712, 1506, 1471, 1413, 1365, 1336, 1216, 
1052, 768, 688. 





Synthesis of 1,3-bis(4-bromophenyl)propan-2-one (99) 
 
DCC (1.57 g, 2.42 mmol, 0.6 equiv.) and DMAP (466 mg, 1.21 mmol, 0.3 equiv.) were 
dissolved in anhydrous DCM (40 mL) under an atmosphere of argon. 4-
Bromophenylacetic acid (96) (2.05 g, 12.7 mmol, 2 equiv.) dissolved in anhydrous 
DCM (30 mL) was added slowly to the reaction mixture which turned orange and gas 
evolution was observed. The reaction mixture was stirred overnight. The precipitated 
DCU was removed by filtration through Celite, the filter cake was washed with MeCN 
(80 mL), and afterwards the solvents were removed from the combined organic 
phases. The yellow residue was dissolved in EtOAc (80 mL) and it was washed with 
1 M HCl (60 mL) to remove DMAP, then with a saturated solution of NaHCO3 (60 mL) 
to remove 4-Bromophenylacetic acid, then with a saturated solution of NaCl (60 mL) 
and the solvents were removed. The yellow residue was recrystallized from EtOH to 
give the desired product as slightly yellow needles (1.51 g, 9.4 mmol, 74% yield). 
m.p.: 148 °C. 
1H-NMR (300 MHz, CDCl3):  (ppm) = 7.64 (d, 4H, J = 8.13 Hz, 5-H, 5’-H), 7.29 (d, 4H, 
J = 8.13 Hz, 4-H, 4’-H), 3.87 (s, 4H, 2-H, 2’-H). 
13C-NMR (300 MHz, CDCl3):  (ppm) = 202.30 (C-1), 138.57 (C-3, C-3’), 132.48 (C-5, 
C-5’), 130.36 (C-4, C-4’), 118.53 (C-7, C-7’), 111.44 (C-6, C-6’), 49.21 (C-2, C-2’). 
FT-IR (solid): ṽ (cm-1) = 2927, 2357, 2223, 1712, 1605, 1338, 1057, 848, 807. 







Synthesis of 1,3-diphenylpropan-2-amine (100) 
 
1,3-Diphenylacetone (95) (1 g, 4.76 mmol, 1 equiv.) was dissolved in a mixture of 
MeOH and THF (5:1, 45 mL) and NH4OAc (6.70 g, 48 mmol, 10 equiv.) was added at 
once. The reaction mixture was stirred until all solids were dissolved, then NaBH3CN 
(1.04 g, 16.7 mmol, 3.5 equiv.) was added in small portions over the course of 3 days. 
Afterwards, concentrated HCl was added to the reaction mixture until the vigorous 
evolution of HCN and H2 ceased (HCN gas was bubbled through a solution of 13% 
NaOCl to convert it to the non-toxic NaOCN), the pH of the suspension was 1-2. All 
solvents were removed under reduced pressure and the off-white residue was 
suspended in a mixture of DCM and water (both 60 mL). The white precipitate was 
filtered off, this was the insoluble hydrochloride salt of the product. The solid was 
recrystallized from a mixture of iPrOH and EtOAc (1:1, ca. 25 mL). The product was 
obtained as a white solid (613 mg, 2.90 mmol, 61% yield). 
m.p.: 197 °C (as the hydrochloride salt). 
1H-NMR (300 MHz, DCM-d2):  (ppm) = 7.38-7.18 (m, 10H, 4-H, 5-H, 6-H), 3.32 (m, 
1H, 1-H), 2.92-2.83 (m, 2H, 2-H, 2’-H), 2.64-2.54 (m, 2H, 2-H, 2’-H), 1.27 (br s, 2H, 
NH2).  
13C-NMR (300 MHz, DCM-d2):  (ppm) = 139.42 (C-3), 129.25 (C-5), 128.46 (C-4), 
126.27 (C-6), 54.17 (C-1), 44.20 (C-2). 
FT-IR (solid): ṽ (cm-1) = 3409, 2962, 2359, 1738, 1453, 1366, 1217, 1054, 1032, 754, 
701. 






Synthesis of 1,3-bis(4-bromophenyl)propan-2-amine (101) 
 
1,3-Bis(4-bromophenyl)propan-2-one (98) (3 g, 8.20 mmol, 1 equiv.) was dissolved in 
a mixture of MeOH and THF (5:1, 200 mL) and NH4OAc (6.32 g, 82 mmol, 10 equiv.) 
was added at once. The reaction mixture was stirred until all solids were dissolved, 
then NaBH3CN (1.8 g, 28.7 mmol, 3.5 equiv.) was added in small portions over the 
course of 3 days. Afterwards, concentrated HCl was added to the reaction mixture until 
the vigorous evolution of HCN and H2 ceased (HCN gas was bubbled through a 
solution of 13% NaOCl to convert it to the non-toxic NaOCN), the pH of the suspension 
was 1-2. All solvents were removed under reduced pressure and the off-white residue 
was suspended in a mixture of DCM and water (both 150 mL). The white precipitate 
was filtered off, this was the insoluble hydrochloride salt of the product. In order to 
produce the free base, the dried powder was suspended in a mixture of DCM and a 
saturated aqueous solution of K2CO3 (both 50 mL) and the mixture was stirred until all 
solids dissolved in the organic phase. The aqueous phase was extracted with DCM  
(2 x 20 mL) and the combined organic phases were dried over Na2SO4. Removal of 
the solvent gave the product as a colorless oil (2.29 g, 6.24 mmol, 76% yield). 
The transformation of the hydrochloride salt into the free base is critical for the success 
of the following reaction because the in situ formation of the free base gives rise to 
chloride-bromide exchange prior to a nucleophilic substitution.  
1H-NMR (300 MHz, DCM-d2):  (ppm) = 7.45 (d, 4H, J = 8.36 Hz, 5-H, 5’-H), 7.10 (d, 
4H, J = 8-36 Hz, 4-H, 4’-H), 3.26 (m, 1H, 1-H), 2.86-2.72 (m, 2H, 2-H, 2’-H), 2.62–2.47 
(m, 2H, 2-H, 2’-H), 1.64 (s, 2H, NH2). 
13C-NMR (75 MHz, DCM-d2):  (ppm) = 137.93 (C-3, C-3‘), 131.63 (C-5, C-5‘), 130.97 
(C-4, C-4‘), 120.33 (C-6, C-6‘), 53.94 (C-1), 43.26 (C-2, C-2‘). 
FT-IR (solid): ṽ (cm-1) = 2970, 2359, 1735, 1365, 1215, 786, 668. 




Synthesis of N-(2-(benzyloxy)ethyl)-1,3-bis(4-bromophenyl)propan-2-amine 
(103) 
 
1,3-Bis(4-bromophenyl)propan-2-amine (101) (203 mg, 0.55 mmol, 1 equiv.) was 
dissolved in 15 mL MeCN. To this solution were added K2CO3 (190 mg, 1.38 mmol, 
2.5 equiv.) and ((2-bromoethoxy)methyl)benzene (296 mg, 1.38 mmol, 2.5 equiv.). 
The reaction mixture was refluxed for 48 h and was then cooled to room temperature. 
The solids were removed by filtration and the reaction mixture was diluted with toluene 
(20 mL). The organic phase was washed with water (20 mL), brine (20 mL) and was 
dried over MgSO4 and then the solvents were evaporated. The residue was purified by 
column chromatography (hexane/EtOAc 10:1 → EtOAc, Rf = 0.47). The product was 
obtained as a yellow oil (192 mg, 0.38 mmol, 69%). 
1H-NMR (300 MHz, CD2Cl2):  (ppm) = 7.43 – 7.24 (7H, m, 5-H, 5’-H, 12-H, 13-H), 
7.24-7.16 (m, 2H, 11-H), 7.07 (4H, d, J = 8.4 Hz, 4-H, 4’-H), 4.38 (s, 2H, 9-H), 3.49 (t, 
2H, J = 5.2 Hz, 8-H), 3.02 (m, 1H, 1-H), 2.78 (t, 2H, J = 5.2 Hz, 7-H), 2.62 (t, 4H, J = 
6.48 Hz, 2-H, 2’-H).  
13C-NMR (75 MHz, CD2Cl2):  (ppm) = 139.01 (C-3, C-3‘), 138.96 (C-10), 131.68 (C-
4, C-4‘), 131.60 (C-5, C-5‘), 128.68 (C-12), 127.87 (C-11), 127.85 (C-13), 120.20 (C-
6, C-6‘), 73.21 (C-9), 70.29 (C-8), 60.59 (C-1), 47.12 (C-7), 40.24 (C-2, C-2‘). 
FT-IR (solid): ṽ (cm-1) = 3032, 2926, 2843, 1647, 1491, 1401, 1114, 1043, 1008, 745, 
696, 458. 







Synthesis of 4-(Carboxymethyl)benzoic acid (106) 
 
4-(Cyanomethyl)benzonitrile (105) (20 g, 140.8 mmol, 1 equiv.) was dissolved in 
ethanol (150 mL) and a solution of KOH (36 g, 642.9 mmol, 4.6 equiv.) in water (150 
mL) was added. The reaction mixture was refluxed overnight and afterwards ethanol 
was removed under reduced pressure. The aqueous phase was washed with DCM (2 
x 50 mL) and was then acidified to pH 1 with concentrated HCl. The precipitated solid 
was filtered and dried. The product was obtained as an off-white solid (27 g, quant.) 
that was slightly contaminated with organic salts originating from neutralization of the 
alkaline aqueous phase. 
m.p.: 230 °C. 
1H-NMR (300 MHz, D2O + NaOD):  (ppm) = 7.65 (d, 2H, J = 8.22 Hz, 3-H, 3’-H), 7.16 
(d, 2H, J = 8.22 Hz, 4-H, 4’-H), 4.31 (s, 2H. 6-H). 
13C-NMR (75 MHz, D2O + NaOD):  (ppm) = 180.51 (C-7), 175.54 (C-1), 140.41 (C-5), 
134.08 (C-2), 128.98 (C-3, C-3’), 128.84 (C-4, C-4’). 
FT-IR (solid): ṽ (cm-1) = 2980, 1677, 1427, 1256, 1100, 1016, 934, 881, 730. 










Synthesis of Ethyl 4-(2-ethoxy-2-oxoethyl)benzoate (107) 
 
4-(Carboxymethyl)benzoic acid (106) (27 g, contaminated with a small amount of 
inorganic salts) was suspended in EtOH (300 mL) and 10 mL of conc. H2SO4 was 
added slowly. The reaction mixture was refluxed overnight and afterwards ethanol was 
removed under reduced pressure. The oily residue was dissolved in a mixture of sat. 
NaHCO3 solution (200 mL) and DCM (100 mL), the organic phase was separated. The 
aqueous phase was extracted with DCM (3 x 30 mL) and the combined organic phases 
were washed with water (100 mL) and dried over MgSO4. The solvent was removed, 
and the oily residue was analyzed by means of TLC. Product formation was confirmed, 
alongside the formation of both mono-esterificated products and educt. Separation of 
this large amount of material (21.1 g) by column chromatography was deemed 















Synthesis of 2-(4-(Ethoxycarbonyl)phenyl)acetic acid (108) 
 
Ethyl 4-(2-ethoxy-2-oxoethyl)benzoate (107) (21.1 g, crude product) was dissolved in 
a mixture of THF/H2O/EtOH (150 mL / 150 mL / 50 mL) and LiOH*H2O (4.01 g,  
approx. 1.2 equiv.) was added. The resulting solution was stirred at room temperature 
overnight, after which THF and EtOH were removed under reduced pressure. The 
aqueous phase was washed with EtOAc (2 x 100 mL) and afterwards it was acidified 
to pH 1 with conc. HCl. The precipitated solid was isolated by filtration and dried under 
reduced pressure. The product was obtained as an off-white solid (17.05 g, 
81.94 mmol). 
m.p.: 100 °C. 
1H-NMR (300 MHz, CD2Cl2):  (ppm) = 8.00 (d, 2H, J = 8.15 Hz, 3-H, 3’-H), 7.37 (d, 
2H, J = 8.15 Hz, 4-H, 4’-H), 4.35 (q, 2H, J = 7.09 Hz, 8-H), 3.74 (s, 2H, 6-H), 1.37 (t, 
3H, J = 7.09 Hz, 9-H). 
13C-NMR (75 MHz, CD2Cl2):  (ppm) = 176.33 (C-7), 166.10 (C-1), 138.43 (C-5), 
129.68 (C-2), 129.61 (C-3, C-3‘), 129.47 (C-4, C-4‘), 60.98 (C-8), 40.65 (C-6), 14.06 
(C-9). 
FT-IR (solid): ṽ (cm-1) = 2980, 1691, 1408, 1270, 1170, 1099, 762, 712. 









Synthesis of Diethyl 4,4'-(2-oxopropane-1,3-diyl)dibenzoate (109) 
 
2-(4-(Ethoxycarbonyl)phenyl)acetic acid (108) (11.55 g, 55.5 mmol, 2 equiv.) and 
DMAP (2.03 g, 16.7 mmol, 0.3 equiv.) were dissolved in anhydrous DCM (70 mL) 
under an atmosphere of argon. DCC (6.89 g, 33.3 mmol, 0.6 equiv.) dissolved in 
anhydrous DCM (100 mL) was added to the reaction mixture and the resulting 
suspension was stirred overnight. The precipitated DCU was removed by filtration over 
Celite, the filter cake was washed with MeCN (200 mL). The solvents were removed, 
and the residue was dissolved in a mixture of hexane/EtOAc (100 mL / 100 mL). The 
organic phase was washed with 1 M HCl to remove DMAP (80 mL), saturated aqueous 
NaHCO3-solution (80 mL) and brine (100 mL) and was dried over MgSO4. The solvents 
were removed under reduced pressure and the residue was recrystallized from EtOH. 
The product was obtained as slightly yellow crystals (4.5 g, 12.7 mmol, 46% yield). 
m.p.: > 200 °C (decomposition). 
1H-NMR (300 MHz, CD2Cl2):  (ppm) = 7.98 (d, 4H, J = 8.16 Hz, 5-H, 5’-H), 7.24 (d, 
4H, J = 8.16 Hz, 4-H, 4’-H), 4.34 (q, 4H, J = 7.11 Hz, 8-H, 8’-H), 3.83 (s, 4H, 2-H), 1.37 
(t, 6H, J = 7.11 Hz, 9-H). 
13C-NMR (75 MHz, CD2Cl2):  (ppm) = 204.09 (C-1), 166.50 (C-7, C-7‘), 139.39 (C-3, 
C-3‘), 130.06 (C-5, C-5‘), 130.03 (C-4, C-4‘), 129.91 (C-6, C-6‘), 61.34 (C-8, C-8‘), 
49.54 (C-2, C-2’), 14.50 (C-9, C-9’). 
FT-IR (solid): ṽ (cm-1) = 2991, 1704, 1610, 1276, 1178, 1102, 1051, 1021, 859, 746, 
714. 







Synthesis of 4,4'-(2-Aminopropane-1,3-diyl)dibenzoic acid (111) 
 
Diethyl 4,4'-(2-aminopropane-1,3-diyl)dibenzoate (110) (0.25 g, 0.71 mmol, 1 equiv.) 
was dissolved in a mixture of EtOH/H2O (1:1, 10 mL). KOH (142 mg, 3.55 mmol, 
5 equiv.) was added and the reaction mixture was heated to reflux overnight. After 
cooling to room temperature, the solvents were removed in vacuo. The residue was 
taken up in H2O (10 mL) and the solution was acidified to pH 1 with conc, HCl. The 
precipitated solid was filtered, washed with water until acid-free and dried in vacuo. 
The product was obtained as a white solid (106 mg, 0.36 mmol, 50 % yield). 
m.p.: > 290 °C (decomposition). 
1H-NMR (300 MHz, CD2Cl2):  (ppm) = 8.27 (br s, 3H, NH3+), 7.87 (d, 4H, J = 8.1 Hz, 
5-H, 5’-H), 7.38 (d, 4H, J = 8.1 Hz, 4-H, 4’-H), 3.73 (m, 1H, 1-H, overlaps with residual 
water), 3.14-2.81 (m, 4H, 2-H, 2’-H, overlaps with residual water). 
13C-NMR (75 MHz, CD2Cl2):  (ppm) = 167.63 (C-7), 141.93 (C-3), 130.10 (C-5), 
130.03 (C-4), 129.83 (C-6), 52.99 (C-1), 39.28 (C-2). 
FT-IR (solid): ṽ (cm-1) = 2913, 1695, 1604, 1382, 1230, 1184, 1119, 750, 694. 












Synthesis of 2,2'-((1,3-bis(4-chlorophenyl)propan-2-yl)azanediyl)bis(ethan-1-ol) 
(114) 
 
Tetrahydro-7aH-oxazolo[2,3-b]oxazole (113) (691 mg, 6.00 mmol, 1 equiv.) was 
dissolved in anhydrous Et2O (50 mL) under an atmosphere of argon. With vigorous 
stirring a solution of (4-chlorobenzyl)magnesium chloride (112) (50 mL, 0.25 M in Et2O, 
12.5 mmol, 2.1 equiv.) was added dropwise to the reaction mixture, which was stirred 
for 12 h at room temperature. Afterwards it was diluted with sat. NH4Cl-solution (50 mL) 
and the organic phase was isolated. The aqueous phase was extracted with Et2O (2 x 
30 mL), the combined organic phases were washed with water (30 mL), brine (30 mL) 
and were dried over MgSO4. The solvent was removed under reduced pressure and 
the residue was purified with column chromatography (hexane/EtOAc 1:1, Rf = 0.1). 
The product was obtained as a yellow solid (757 mg, 2.06 mmol, 34% yield). 
m.p.: 120 °C. 
1H-NMR (300 MHz, CDCl3):  (ppm) = 7.27 (d, 4H, J = 8.42 Hz, 5-H, 5’-H), 7.11 (d, 4H, 
J = 8.42 Hz, 4-H, 4’-H), 3.40 (t, 4H, J = 5.36 Hz, 8-H, 8’-H), 3.01 (quint, 1H, J = 7.2 Hz, 
1-H), 2.90-2.52 (m, 8H, 2-H, 2’-H, 7-H, 7’-H), 1.77 (s, 2H, NH2). 
13C-NMR (75 MHz, CDCl3):  (ppm) = 138.92 (C-3), 131.71 (C-6), 130.49 (C-4), 128.47 
(C-5), 65.58 (C-1), 59.97 (C-8), 51.51 (C-7), 35.80 (C-2). 
FT-IR (solid): ṽ (cm-1) = 3447, 2925, 23410, 1734, 1489, 1407, 1086, 1066, 1012, 837, 
802, 738, 510, 438. 








Synthesis of bis(2-mercaptoethyl)ammonium chloride (117) 
 
Bis(2-chloroethyl)ammonium chloride (2.0 g, 11.3 mmol, 1 equiv.) and 
triphenylmethanethiol (6.79 g, 24.6 mmol, 2.18 equiv.) were dissolved in anhydrous 
DMF (10 mL) under an atmosphere of argon. DBU (6 mL, 38.7 mmol, 3.4 equiv.) was 
dissolved in anhydrous DMF (6 mL) and the solution was added to the reaction mixture. 
Afterwards it was heated at 100 °C for 1 h. After cooling to room temperature the 
reaction mixture was poured into water (500 mL). The resulting solid was filtered off 
and dissolved in EtOAc (100 mL). The organic phase was washed with water 
(2 x 50 mL) and dried over MgSO4. The solvent was removed in vacuo and the 
resulting yellow solid was washed with boiling EtOH. The product was obtained as a 
white solid (4.98 g, 8.02 mmol, 71% yield) and was used directly for the next reaction 
step. 
Bis(2-(tritylthio)ethyl)amine (1.01 g, 1.63 mmol, 1 equiv.) was dissolved in DCM 
(5 mL). The reaction mixture was cooled to 0 °C and TFA (5 mL) was added dropwise. 
Afterwards, Et3SiH (0.54 mL, 3.38 mL, 2 equiv.) was added and the reaction mixture 
was stirred for 24 h at room temperature. The solvent was removed in vacuo and the 
residue was coevaporated with toluene (2 x 10 mL). The residue was dissolved in 
water (25 mL) and the aqueous phase was washed with toluene (20 mL). The organic 
phase was reextracted with water (10 mL) and the combined aqueous phases were 
acidified to pH 1 with conc. HCl. The solvent was removed in vacuo and the 
hydrochloride salt of the product was obtained as a white solid (141 mg, 0.82 mmol, 
50% yield). 
m.p.: 155 °C. 
1H-NMR (300 MHz, DMSO-d6):  (ppm) = 8.98 (br s, 2H, NH2+), 3.19-3.03 (m, 4H, 1-
H, 1‘-H), 2.95 (t, 2H, J = 8.30 Hz, SH), 2.83-2.70 (m, 4H, 2-H, 2‘-H). 
13C-NMR (75 MHz, DMSO-d6):  (ppm) = 49.77 (C-1, C-1‘), 20.14 (C-2, C-2‘). 
HR-MS (ESI): m/z calculated for C4H10NS2 [M+H]+ 136.0249; observed 136.0250 (note 




6.1.2.4 Syntheses for chapter 4.4 
 
Synthesis of Di-para-bimethyl-octafluoro-1,1’-biphenyl (120) 
 
Perfluoro-1,1'-biphenyl (119) (2.95 g, 8.8 mmol, 1 equiv.) was dissolved in anhydrous 
THF (12 mL) under an atmosphere of argon. The reaction mixture was cooled to 0 °C 
and a solution of methyllithium (6.2 mL, 3.3 M in DEM, 19.2 mmol, 2.2 equiv.) was 
added dropwise in a fashion that the vigorous reaction was kept minimal. The resulting 
purple solution was stirred at room temperature for 2 h and then diluted with EtOAc 
(15 mL). The organic phase was washed with water (2 x 15 mL) and brine (15 mL) and 
was dried over MgSO4. The solvent was removed under reduced pressure and the 
residue was purified by column chromatography (7:1 hexane/EtOAc, Rf = 0.69). The 
product was obtained as a white solid (1.14 g, 3.5 mmol, 39% yield). 
m.p.: 141 °C. 
1H-NMR (300 MHz, CDCl3):  (ppm) = 2.36 (t, 6H, J = 2.16 Hz, 1-H, 1’-H). 
19F-NMR (282.4 MHz, CDCl3):  (ppm) = -140.27 (m, 4F, 3-F, 3’-F), -142.89 (m, 4F, 4-
F, 4’-F). 










Synthesis of Di-para-bibromomethyl-octafluoro-1,1’-biphenyl (121) 
 
Di-para-bimethyl-octafluoro-1,1’-biphenyl (120) (1.14 g, 3.5 mmol, 1 equiv.) was 
dissolved in CCl4 (10 mL) and NBS (1.32 g, 7.4 mmol, 2.1 equiv.) was added at once. 
The resulting reaction mixture was refluxed for 24 h. Afterwards, it was diluted with 
EtOAc (50 mL) and the organic phase was washed with water (2 x 20 mL) and brine 
(20 mL) and dried over MgSO4. The solvents were removed under reduced pressure 
and the residue was purified by column chromatography (hexane, Rf = 0.46). The 
product was obtained as a white, crystalline solid (1.24 g, 2.56 mmol, 73% yield). 
m.p.: 148 °C. 
1H-NMR (300 MHz, CDCl3):  (ppm) = 4.58 (s, 4H, 1-H, 1’-H). 














6.2 Biological methods 
6.2.1 Materials 
a) Chemicals 
All commercially available chemicals for biological or analytical purposes were used 
without further purification if not stated otherwise. Anhydrous solvents were supplied 
by AcrosOrganics (Thermo Fischer scientific brand) and were stored in the original 
package over molecular sieves under an atmosphere of argon. 
 
b) Enzymes 
DNase I     AppliChem GmbH 
Lysozyme     AppliChem GmbH 
Phusion polymerase    Thermo Fischer scientific 
 
c) Plasmids 
pET303C-hSOD1wt   donated by Prof. Samar Hasnain, University 
   of Liverpool 
 
d) Bacterial strains 
E. coli BL21 (DE3)    Invitrogen TM 
E. coli Bl21 StarTM    Invitrogen TM 
E. coli XL1 blue    Stratagene 
 
e) Kits and associated solutions 
dNTP mix (10 mM)    Thermo Fischer scientific 
NucleoSpinTM Plasmid Kit   Macherey Nagel 
NucleoSpinTM Gel/PCR clean up  Macherey Nagel 




Gel Filtration standard   BioRad laboratories GmbH 
PierceTM unstained protein   Thermo Fischer scientific 
Molecular weight marker  
Gene Rule DNA ladder mix  Thermo Fischer scientific 
DNA loading dye (x6)   Thermo Fischer scientific 
SOD assay kit (19160 -1kt - f)  Sigma Aldrich Chemie GmbH 
 
f) Crystallization screens 
AdditiveScreenTM HR-418   Hampton Reasearch Corp. 
The AmSO4 suite    QIAGEN 
Classic Lite     QIAGEN 
Classics     QIAGEN 
Classic II     QIAGEN 
Compass     QIAGEN 
Index      Hampton Research 
MBclass     QIAGEN 
MBclass II     QIAGEN 
PACT      QIAGEN 
PEGs      QIAGEN 
pHCLear     QIAGEN 
Protein Complex    QIAGEN 









LB medium – yeast extract (0.5% w/v), tryptone (1% w/v), NaCl (0.5% w/v) 
LB agar plates – yeast extract (0.5% w/v), tryptone (1% w/v), NaCl (0.5% w/v),  
   Agar (2% w/v) 
 
h) Mutagenesis primers 
hSOD1A4V Fwd  5`-GCGACGAAGGTCGTGTGCGTG-3` 
hSOD1A4V Rew  CACGCACACGACCTTCGTCGC 
hSOD1C6F Fwd  GACGAAGGCCGTGTTCGTGCTGAAGG 
hSOD1C6F Rew  CCTTCAGCACGAACACGGCCTTCGTC 
hSOD1D90A Fwd  CAATGTGACTGCTGCCAAAGATGGTGTGG 
hSOD1D90A Rew  CCACACCATCTTTGGCAGCAGTCACATTG 
hSOD1G93C Fwd  CTGACAAAGATTGCGTGGCCGATGTGT 
hSOD1G93C Rew  ACACATCGGCCACGCAATCTTTGTCAG 
 
i) Sequencing primers 
T7 promotor 5'-TAATACGACTCACTATAGGG-3' 
5’ – GCGACGAAGGTCGTGTGCGTG– 3’ 




Fluoromax 4 spectrofluorometer  BRUKER 
NanoDropOne    Thermo Fischer scientific 
Spectrofluorometer FP-8500  JASCO GmbH 




X-Ray BeamLine P14   EMBL Hamburg 
Arium®proVF     Sartorius AG   
C1000 thermal cycler    BioRad Laboratories GmbH   
CFX96™ Optical Reaction Module  BioRad Laboratories GmbH 
Thermocycler TProfessional  Biometra   
pH-electrode Minitrode Hamilton   Mettler Toledo GmbH 
pH-electrode     Mettler Toledo GmbH   
Monolith NT.115Pico    NanoTemper Technologies GmbH 
Melting point meter (M5000)   A. KRÜSS Optronic GmbH   
 
b) Cell culture and cell disruption 
Biofermenter, Biostat    C Sartorius AG   
Incubation shaker, Unitron   Infors AG   
Microfluidizer, M-110S    Microfluidics   
Multifuge 1S-R     Thermo Fischer scientific 
 
c) Centrifuges and lab rotors 
Avanti™ HP-30I     Beckman Coulter GmbH   
Rotor JA-10      Beckman Coulter GmbH   
Rotor JA-30.50 Ti     Beckman Coulter GmbH   
Avanti™ J-20XPI     Beckman Coulter GmbH   
Rotor JLA-8.1000     Beckman Coulter GmbH   
Rotor SW40 Ti     Beckman Coulter GmbH   
Rotor SW60 class GH   Beckman Coulter GmbH   
OptimaTM L-90K Ultracentrifuge  Beckman Coulter GmbH   
Eppendorf 5810R     Eppendorf AG   
Rotor A-4-81     Eppendorf AG   
Mikro 200      Hettich GmbH & Co. KG   
Rotor 2424 B     Hettich GmbH & Co. KG   
Universal 320R     Hettich GmbH & Co. KG   




Rotor 1617 A     Hettich GmbH & Co. KG  
Rotor 1620 A     Hettich GmbH & Co. KG  
 
d) Liquid chromatography 
Fractogel® EMD TMAE 650 (S)   Merck KGaA   
ÄKTAprime plus     GE Healthcare Europe   
ÄKTApurifier     GE Healthcare Europe  
HiPrep™ 26/10 desalting (50 mL)  GE Healthcare Europe   
HiTrap™ 26/10 desalting (5 mL)   GE Healthcare Europe   
Superdex™ 200 HiLoad™ 16/60   GE Healthcare Europe   
Superdex™ 75 10/300 GL    GE Healthcare Europe   
Superdex™ 200 10/300 GL   GE Healthcare Europe   
Superdex® 200 Increase 10/300 GL GE Healthcare Europe   
Superloop (10 mL, 50 mL, 150 mL)  GE Healthcare Europe  
 
6.2.3 Molecular biology protocols 
6.2.3.1 Plasmid transformation 
The plasmid pET303C-hSOD1wt was donated by Prof. Samar Hasnain from the 
University of Liverpool. This plasmid was introduced into competent cells of different 
strains: the multiplication of the plasmid was performed with the XL1-Blue strain, 
recombinant protein expression was done with BL21 (DE3) and BL21 StarTM (DE3) 
strains.  
The commercially available competent cells (50 µg) were thawed on ice for 15 min and 
1 ng of plasmid was added. The components were mixed by flicking. The obtained 
cells were incubated on ice for 25 minutes. Afterwards, the cells were exposed to a 
heat shock (42 °C, 20 s), followed by subsequent incubation on ice for 5 min.[137] To 
the cells was then added 1 mL SOC medium preheated to 37 °C. The obtained cell 
suspension was incubated at 37 °C, 800 rpm for 70 min to induce cell growth.  
After that, the cells were placed onto LB-agar plates that were pretreated with 




6.2.3.2 Plasmid DNA isolation 
Single colonies of the aforementioned transformed cells were manually picked and 
incubated with LB medium (6 x 10 mL) pretreated with carbenicillin (100 µg/mL) 
overnight at 37 °C, 200 rpm. The optical density (OD600) was followed throughout the 
growing process. When OD600 = 3 – 3.5 could be observed, cells were harvested by 
centrifugation at 4 °C, 9000 rpm, 5 min. The obtained pellet was used for subsequent 
plasmid isolation following a protocol from MachereyNagel using the NucleoSpinTM 
Plasmid kit. 
 
6.2.3.3 Determination of DNA concentration 
The concentration of the processed DNA c was calculated using the Beer-Lambert law 
according to the following equation 
A260  = c * d *  
With A260: absorbance measured at 260 nm using a NanoDrop OneTM device,  
: 50 ng/µl*cm, d: 1cm. 
 
6.2.3.4 DNA sequencing 
The sequencing of the obtained plasmids was performed by GATC Biotech AG using 
the primers mentioned in section 6.2.1 i. 
 
6.2.3.5 PCR (Polymerase Chain Reaction) 
The employed PCR conditions consisted of the QuickChange protocol (Strategene), 
which was adapted for the Phusion® DNA-polymerase. The used mutagenesis primers 
are listed in section 6.2.1 h. The template DNA with the unmodified sequence was then 
digested by the addition of 5 equivalents of restriction enzyme (DpnI), followed by 
incubation at 37 °C overnight. The digestion suspension was then inactivated by 





6.2.3.6 Horizontal agarose gel electrophoresis 
The obtained DNA samples were mixed with DNA loading dye (6x) and loaded onto 
agarose gels (1% agarose containing 1x TAE buffer [40 mM Tris, 20 mM acetic acid, 
1 mM EDTA, pH 7.0]). Gel staining was performed with ethidium bromide (2 µg/mL) 
for 15 min, followed by visualization with UV-light. The separated DNA fragments were 
compared with a 1kb DNA ladder dye to visualize the size of the purified fractions. 
 
6.2.4 Protein expression 
6.2.4.1 hSOD1 wt and mutant expression 
The following protocol was used for the expression of the wild type as well as of all 
mentioned mutants: 
200 mL of sterilized LB medium (10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl) 
containing 100 µg/mL carbenicillin was inoculated with two to three colonies of E. coli 
Bl21 StarTM (DE3), holding the desired plasmid. This preculture was incubated 
overnight at 37 °C, 200 rpm. The preculture was then aliquoted and centrifuged at 
10 °C, 9000 rpm for 15 min. The supernatant was discarded and the pellet was 
resuspended in 4 mL of fresh LB medium per 50 mL preculture. The obtained main 
cultures were incubated at 37 °C, 200 rpm. The protein expression was induced by 
addition of IPTG (200 mM, 2 mL) and ZnSO4 (500 mM, 1 mL) after OD600 was  
0.6 – 0.8. Afterwards the cells were incubated overnight at 25 °C, 200 rpm. Successful 
expression of the desired protein was verified with SDS-page analysis. The obtained 
cells were harvested by centrifugation at 4 °C, 4800 rpm, 20 min. The cell pellets were 
suspended in approx. 5 – 10 mL buffer A per aliquot, transferred to 50 mL falcon tubes 
and centrifuged at 4 °C, 400 rpm, 20 min. The resulting cell pellets were frozen at  
-78 °C for long-term storage and at -20 °C for short-term storage. 
6.2.4.2 hSOD1 Purification  
The used purification protocol was obtained by Dr. Michael Capper from the University 
of Liverpool and was optimized by Lisa-Marie Funk. The cell pellets (each approx. 10 g) 
were suspended in 4 mL/g loading buffer A (20 mM Tris, pH 8.0) and the suspension 




amount of lysozyme were added subsequently. The resulting suspension was stirred 
at 0 °C for 45 min. A microfluidizer device was used to achieve lysis of the cells in 3 to 
5 cycles at 1034 bar each. Afterwards the cell suspension was centrifuged at 10 °C, 
75.000 x g, 30 min. The supernatant was dialyzed against buffer A (2 L, 20 mM Tris, 
pH 8.0) for 16 h at 4 °C. The resulting solution was centrifuged at 10 °C, 75.000 g, 
20 min. The supernatant was loaded onto a TMAE column equilibrated with buffer A. 
The loaded column was washed with buffer A until no traces of unbound protein were 
visible in the flow-through. Elution was performed using buffer B (20 mM Tris, 500 mM 
NaCl, pH 8.0) with a gradient of 20% in 150 mL. After elution if the desired protein the 
column was washed with 100% buffer B to remove any traces of bound proteins from 
the column. The success of the purification was verified by SDS-page analysis. The 
resulting fractions containing pure protein were combined and concentrated using a 
Corning-Spin-X UF micro concentrator. The resulting protein was stored at – 78 °C for 
long-term storage or used immediately. 
 
6.2.4.3 SDS-page analysis 
Stacking gel: 5% acrylamide, 125 mM Tris, 0.1% (w/v) SDS, pH 6.8. 
Separating gel: 15% acrylamide, 375 mM Tris, 0.1% (w/v) SDS, pH 8.0. 
Samples were mixed with sample buffer (0.1 M Tris, 25% (v/v) glycerol, 2% (w/v) SDS, 
0.02% (w/v) bromophenol blue, 2.5% -mercaptoethanol, pH 6.8) and incubated at  
95 °C for 5 min. SDS-page analysis was conducted at 35 mA, 150 W, 300 V for 30 min 
or until no further elution could be observed. Afterwards, the gels were stained with 
staining solution (0.25% (w/v) Coomassie Brilliant Blue G250, 30% (v/v) ethanol, 6% 
acetic acid) for 5 min at room temperature. Excess dye was removed by washing the 
stained gels with destaining solution (30% (v/v) ethanol, 10% (v/v) acetic acid). 
 
6.2.4.4 Determination of protein concentration 
The Beer-Lambert law was used to measure the absorbance of tryptophan at 280 nm 
on a NanoDrop One™ device. The molecular weight of hSOD1 was approx. 




alternative method using a standard Bradford-protocol gave the same results during 
the course of this work.[138] Since the Bradford approach was more time consuming the 
spectroscopic method was primarily used.  
 
6.2.4.5 Cofactor reconstitution 
The purified protein (see 6.2.4.2) was dialyzed against 2 L buffer D1 (100 mM sodium 
acetate, 5 mM EDTA, pH 3.8) at 4 °C for 16 h to remove zinc ions that were added 
during the purification process. Afterwards, the protein was dialyzed against 2 L buffer 
D2 (100 mM sodium acetate, 150 mM NaCl, pH 3.8) at 4 °C for 4 h. The protein was 
then incubated with 10 mM CuSO4 for 15 min, followed by incubation with 10 mM 
ZnSO4 for 15 min. The resulting holo-enzyme was desalted using a HiPrep 26/10 
desalting column. Used buffers included Tris buffer (20 mM Tris, pH 8.0) for 
crystallization, SP buffer (50 mM sodium phosphate, pH 7.4) and HEPES buffer 
(100 mM HEPES, 150 mM NaCl, pH 7.4) for biophysical analysis and assays. 
 
6.2.4.6 Activity assays 
A SOD1 activity assay kit from Sigma Aldrich was used to measure the catalytic activity 
in this thesis. 220 µL of sample mixture were prepared by mixing 200 µL of WST 
working solution with 20 µL of buffer containing the desired sample (protein, ligands or 
nothing for blank measurements). The resulting sample mixture was incubated for 
2 min at 25 °C. Afterwards, 40 µL of xanthine oxidase were added and the initiated 
reaction was analyzed spectroscopically over the course of 2 minutes. The absorbance 
of the sample was recorded at 440 nm in triplicates and the measured value were 
plotted against time. The slope of the resulting curve was calculated in the 0-50 s 
period and the inhibition of SOD1 samples was calculated in % following the equation 
𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%) =  
𝑠𝑙𝑜𝑝𝑒 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙) − 𝑠𝑙𝑜𝑝𝑒 (𝑠𝑎𝑚𝑝𝑙𝑒)
𝑠𝑙𝑜𝑝𝑒 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 
6.2.4.7 Size exclusion chromatography (SEC) 
A Superdex Increase 200 10/300 GL column was used to run size exclusion 




buffer (50 mM, pH 7.4), afterwards, the sample was loaded onto the column (150 µL 
hSOD1 solution, 0.1 – 0.5 mg/mL). The used flow rate was 0.5 mL/min and the 
purification was performed at 4 °C. A commercially available gel-filtration standard 
(BioRad laboratories) was used to acquire a calibration curve for the molecular weight 
of the fractions obtained from the experiment. The partition coefficient Kav was 
calculated using the following equation 




With Ve as the elution volume, Vc as the geometric column volume and V0 as the empty 
column volume. The obtained values for the partition coefficient were plotted against 
the molecular weight that resulted from the standard, using a logarithmic scale for the 
abscissa. 
 
6.2.4.8 X-ray crystallography 
The used protein was thawed on ice and centrifuged for at 4 °c, 13.000 x g for 15 min. 
afterwards, protein stock solutions were prepared using a concentration range of 5-
20 mg/mL in Tris buffer (20 mM Tris, pH 8). After that, 500 µL of well solution was 
prepared (18-22 % (w/v) PEG-8000, 0.2 M ammonium sulfate, 0.1 M HEPES, pH 6.5). 
The hanging-drop diffusion method was chosen for screening the optimal conditions 
for crystal growth, two drops were used per well, filled with a mixture of 2 µL protein 
stock solution and 2 µL well solution. The resulting crystal plate was stored at -20 °C 
for 3-10 days, after which crystal growth could be observed. Crystals that were suitable 
for X-Ray analysis were picked and incubated with 50% (w/v) PEG-8000 in cryo-
protecting solution (20% DMSO, 0.2 M ammonium sulfate, 0.1 M MES, 1 mM ZnSO4, 
1 mM CuSO4), increasing the amount of PEG-8000 in steps of 5% over the course of 
1-4 min depending on the quality of the crystal. The resulting crystals were then soaked 
with solutions of the desired ligands for a short period of time (1 – 10 min). 
Diffraction data of all obtained crystals were measured at the P14 BeamLine at DESY 




6.3 Biophysical assays 
6.3.1 UV/VIS and fluorescence measurements 
Absorption and Emission spectra were recorded on a JASCO V-750 UV/VIS-
Spectrophotometer and a JASCO FP-8500 Fluorescence Spectrometer using the 
following device settings:  





Measurement range 750 – 190 nm 650 – 200 nm 
Data interval 0.5 nm 0.5 nm 
Scan speed 200 nm/s 200 nm/s 
Bandwidth 2.0 nm 5 nm 
Response 0.24 s 0.2 s 
Sensitivity N/A Very low 
Temperature 25 °C 25 °C 
   
The concentration of the ligands was kept at a consistent value of 40 µM to ensure the 
possibility of a rational comparison between them. Before each UV/VIS measurement, 
a baseline was recorded using the same buffer and/or solvent mixture as for the 
upcoming measurement.  
 
 
6.3.2 Fluorescence Anisotropy 
Anisotropy measurements were performed using a FluoroMax® (Horiba) device and 
the corresponding software FluorEssenceTM (Horiba). The measurements were done 
using the following protocol: 
1. Samples were prepared in the following way: The final concentration of the 
respective ligand was set to 40 µm by dilution of the stock solution with 
phosphate buffer (50 mM sodium phosphate, pH 7.4). The final concentration 




stock solution with phosphate buffer (50 mM sodium phosphate, pH 7.4). The 
necessary amounts of protein stock solution, ligand stock solution and buffer 
were pipetted and mixed by pipetting 
2. The samples were incubated for 2.5 h at room temperature. 
3. The samples were centrifuged at room temperature, 10.000 x g, 2 min 
4. The samples were loaded into a cuvette and the anisotropy was measured 
against a “single point” at 20 °C. The “single point” was defined by the 
absorption and emission maxima of the respective ligand.  
5. Each data point consisted of up to ten individual measurements that were 
performed until the relative error was smaller than 5% or all 10 measurements 
were done. The mean value of all performed measurements was given as the 
result of each data point. 
6. A series of triplicates of data points was measured for each sample. 
7. The sample with 0 µM protein was used as a blank. 
8. Analysis of the data was done with Origin. 
 
6.3.3 Microscale thermophoresis (MST) 
The chosen labelling strategy ensured that the protein was fluorescent to allow 
fluorescence analysis of the protein-ligand complex under MST conditions. The 
labelling was based on the reaction of an active NHS-ester group from the dye with 
primary amines from the protein at neutral pH, resulting in an amide bond. SOD1 offers 
11 lysine residues for the reaction with the NHS-ester in each monomer compared to 
only one N terminus of the AA chain that would also be able to react with said ester. In 
turn, it was concluded that the majority of the dye was bound away from the dimer 
interface and from the binding cavity of interest, so no interactions between dye and 
ligands were assumed. 
The fully reconstituted protein was prepared according to section 6.2.4.5 and was 
diluted with phosphate buffer to a concentration of 200 µM. The used NHS-dye (2nd 
generation red NHS dye from the Monolith labelling kit by NanoTemper) was dissolved 
in DMSO, the final concentration was 600 µM. The protein and the dye were mixed by 




of light. Afterwards, unreacted dye was removed with SEC (according to section 
6.2.4.7), employing a Superdex 200 10/300 GL column.  
The degree of labelling (DOL) was calculated using the following equation 




The concentration of the dye was calculated using the Beer-Lambert equation similar 
to section 6.2.3.3 with dye = 195.000 M-1cm-1. The concentration of the protein was 
calculated using the following equation 
𝑐(𝑝𝑟𝑜𝑡𝑒𝑖𝑛) =  
𝐴280 − (𝐴650 ∗ 𝑐𝑓650)
𝑒(𝑝𝑟𝑜𝑡𝑒𝑖𝑛) ∗ 𝑑
 
A280: absorbance at 280 nm, A650: absorbance at 650 nm, cf650: 0.04 (dye-dependent 
correction factor),  (protein): extinction factor of the protein (10.800 M-1cm-1), d: path 
length of the instrument (1 cm). The calculated DOL ranged from 0.3 to 1.1 in different 
labelling implementations. 
The labelling was performed by Viktoria Mrđen Debono. 
 
MST measurements were performed using the following protocol: 
1. The labelled protein concentration was adjusted to 10 nM with assay buffer 
(50 mM phosphate buffer, 0.05% Tween-20). 
2. The ligand was used with the highest possible concentration, ranging from 10 
to 40 mM in phosphate buffer ( 50 mM sodium phosphate, pH 7.4) depending 
on the substrate. A dilution series was prepared in a way that the concentration 
was halved after each iteration, starting with 20 µL of ligand and diluting with 10 
µL of buffer each time. A total number of 16 samples were prepared. 
3. 10 µL of the protein stock were added to each of the 16 ligand solutions and 
were mixed by pipetting. 
4. The samples were incubated for 2.5 h at room temperature in the absence of 
light. 
5. The samples were centrifuged at room temperature, 10.000 x g, 2 min. 





7. The measurements were done using a Monolith NT.115 Pico instrument using 
varying LED power and MST power at 22 °C. 
8. Analysis of the MST data was done using the provided MO. Affinity Analysis 
Software version 2.3 (NanoTemper). 
 
6.3.4 Isothermal Titration Calorimetry (ITC) 
ITC measurements were done using the following protocol on a MicroCal PEAQ-ITC 
instrument (Malvern): 
1. The protein was reconstituted in HEPES buffer (100 mM HEPES, 150 mM NaCl, 
pH 7.4) or phosphate buffer (50 mM sodium phosphate, pH 7.4) depending on 
the substrate. The ligands were dissolved in the appropriate buffer at the highest 
concentration possible, ranging from 10 to 40 mM.  Protein and ligand stocks 
were degassed prior to use for 2 min using a stream of nitrogen. 
2. The measurement cell was flushed with ligand stock (50 – 200 µL). 
3. The sample was loaded onto a syringe with a concentration of 10 nM in the 
respective buffer. 
4. The sample was titrated against hSOD1 wt (175 µM) with a rate of 1 µL/min. 
5. Analysis of the obtained data was done using the provided software. 
 
All ITC measurements and analyses were done by Lisa-Marie Funk. 
 
6.4 Protein structure and ligand structure preparation for in silico 
screening 
 
The crystal structure that was used in this thesis was obtained from the RCSB Protein 
Data Bank with the ID 2C9U. The file was opened with Pymol and prepared for in silico 
studies by removing water molecules, phosphate anions and by adding charges 
wherever necessary. Moreover, the amino acid chain was investigated in order to 
validate its integrity. The file was opened with Chimera and saved as either a PDB or 




The corresponding ligand structures were prepared in ChemDraw3D (v 15.1) and 
saved as either a PDB or mol2 file, depending on the used docking program. 
Molecular docking was performed with two different programs: AutoDockVina and the 
open source platform swissdock.ch. In AutoDockVina, the whole protein was chosen 
as the receptor, the ligand was assumed rigid with non-rotatable bonds except for 
those of functional groups. All other parameters were set to default. Docking with 
swissdock.ch was performed by following the instructions on the respective website 
and required no special treatment of files or other parameters. Instead, all necessary 
files had to be uploaded onto the website or could be directly connected via the RCSB 
Protein Data Bank in case for proteins. 
The obtained ligands were then ranked according to their docking score (typically given 
in negative Gibbs free energy, kcal/mol or kJ/mol) that resulted from the used scoring 
functions. Since the resulting docking poses from both approaches were largely 
indistinguishable, swissdock.ch was chosen as the main platform for screening large 
amounts of ligands since it was more suitable for this approach. It is assumed that 
predicting docking poses is far more reliable than predicting binding affinities of protein-
ligand complexes. Therefore, docking poses were treated as the decisive criteria for 
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Figure 8-1. Biorad standard curve for SEC. 

















































































































































































































































































































































































































































































































































































































































































































































































The shown spectrum is the crude spectrum after extraction. The approximate yields were 
calculated by comparing the backbone signal of the Furan (6.87 ppm) to the entire aromatic 
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